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ABBREVIATIONS
AA Arachidonic acid
ADP Adenosine diphosphate
AMP Adenosine monophosphate
ANOVA Analysis of variance
APH Antepartum haemorrhage
ATP Adenosine triphosphate
/?-TG Beta-thromboglobulin
+-1CN(0(J Intracellular free calcium ions
cpm Counts per minute
CTG Cardiotocograph
cyclic AMP Cyclic adenosine 3',5'-monophosphate
cyclic GMP Cyclic guanosine 3',5'-monophosphate
DAG Diacylglycerol
DIC Disseminated intravascular coagulation
dpm Disintegrations per minute
e c50 Concentration of an agonist giving half maximal response
EDRF Endothelium derived relaxing factor
EDTA Ethylene diamine tetra-acetic acid
ELISA Enzyme linked immunosorbent assay
FDP Fibrin(ogen) degradation products
FPA Fibrinopeptide A
G protein Guanine nucleotide binding protein
GDP Guanosine diphosphate
Gi Inhibitory G protein
Gw Alpha subunit of inhibitory G protein
Gjjr Beta/gamma subunit of inhibitory G protein
G. Stimulatory G protein
GTP Guanosine triphosphate
Hb Haemoglobin
HCI Hydrochloric acid
HELLP Haemolysis elevated liver enzymes and low platelets
12-HETE 12-hydroxyeicosatetraenoic acid
HP Healthy pregnant group
12-HPETE 12-hydroperoxyeicosatetraenoic acid
5-HT 5-hydroxytryptamine
IP3 Inositol trisphosphate
ITP Immune thrombocytopenia
Kd Dissociation constant of an antagonist
mmHg Millimetres of mercury
MPV Mean platelet volume
NECA 5-N-ethylcarboxyaminoadenosine
NP Non pregnant women
PAF Platelet activating factor
PAI Plasminogen activator inhibitor
PCV Packed cell volume
PDE Phosphodiesterase
PDGF Platelet derived growth factor
PDW Platelet distribution width
pf4 Platelet factor 4
p g d 2 Prostaglandin D2
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PGE, Prostaglandin E1
p g e 2 Prostaglandin E2
PGF1ff Prostaglandin F1c
p g g 2 Prostaglandin G2
p g h 2 Prostaglandin H2
p g i2 Prostacyclin
PI Phosphatidylinositol
PIH Pregnancy induced hypertension
PIP2 Phosphatidylinositol bisphosphate
PLC Phospholipase C
PPP Platelet poor plasma
PRP Platelet rich plasma
RP Pregnant women at risk of pre-eclampsia
SAFP Serum alphafetoprotein
SEM Standard error of the mean
SIN-1 3-morpholinosydnonimine
SVD Spontaneous vaginal delivery
TCA Trichloroacetic acid
TOP Termination of pregnancy
TSI Thromboxane synthetase inhibitor
t x a 2 Thromboxane A2
t x b 2 Thromboxane B2
U/S Ultrasound scan
VASP Vasodilator stimulated phosphoprotein
WBC White cell count
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SUMMARY
Platelet activation in vivo is a feature of normal pregnancy and occurs to 
a greater degree in pre-eclampsia, a hypertensive disorder of pregnancy. 
Furthermore, there is increasing evidence that platelet activation plays a key role 
in the pathophysiology of pre-eclampsia. Increased platelet reactivity in vitro has 
been previously reported in healthy pregnancy, but variable results have been 
obtained by different investigators conducting in vitro studies of platelet reactivity 
in pre-eclampsia.
Platelet behaviour is controlled by a complex interaction of regulatory 
mechanisms, some of which promote and some of which inhibit platelet 
activation. Prostaglandins are involved in both stimulatory and inhibitory regulatory 
pathways. This thesis has examined platelet responses to inhibitory and pro- 
aggregatory prostaglandins in healthy pregnancy and pre-eclampsia, with an 
emphasis on the effects on platelets of inhibitory prostanoids.
These studies have shown that during healthy pregnancy, platelets were 
less sensitive, compared with those from non pregnant women, to the inhibitory 
effects in vitro of a wide range of prostaglandins including prostacyclin, 
prostaglandin D2 and prostaglandin E,. This was associated with a reduction in 
accumulation in platelets of the inhibitory second messenger cyclic AMP, in 
response to these agents. The data presented are consistent with a reduction in 
platelet adenylate cyclase activity during healthy pregnancy. Longitudinal studies 
suggested changes in platelet cyclic AMP responses occurred early in the first 
trimester of pregnancy.
Platelets from primigravid women with established pre-eclampsia showed 
reductions both in platelet sensitivity to the inhibitory effects of prostaglandins
17
and in platelet cyclic AMP accumulation, of a similar degree to those demonstrated 
in platelets from healthy pregnant women. On the other hand, women with a 
previous history of pre-eclampsia, when studied longitudinally during a subsequent 
pregnancy, showed a more marked loss of platelet sensitivity to such 
prostaglandins, and this was accompanied by lower stimulated cyclic AMP levels 
compared with those in platelets from healthy pregnant women studied in parallel.
In contrast with the loss of sensitivity to inhibitory prostaglandins, platelet 
aggregation was increased during healthy pregnancy, compared with that in non 
pregnant women, in response to an agonist at the thromboxane receptor 
(U46619). This was not due to enhanced endogenous thromboxane synthesis, as 
differences were maintained between pregnant and non pregnant women in the 
extent of U46619 induced aggregation in blood incubated with aspirin in vitro. 
Furthermore, platelet thromboxane B2 production was not increased during 
pregnancy, when measured either following spontaneous clotting of whole blood 
in vitro or in response to arachidonic acid in platelet rich plasma.
It was therefore concluded that enhanced sensitivity of platelets to thromboxane 
is likely to contribute to increased reactivity of platelets in vitro, during pregnancy, 
particularly in response to weak agonists.
The simultaneous reduction in platelet responses to inhibitory 
prostaglandins and increase in platelet sensitivity to pro-aggregatory 
prostaglandins are likely to interact to play a substantial role in platelet activation 
in vivo in healthy pregnancy. Further platelet activation in vivo in pre-eclampsia is 
readily explicable by the well established changes in balance of in vivo 
biosynthesis of pro-aggregatory and inhibitory prostanoids in pregnancy induced 
hypertension, on the background of physiological, pregnancy associated, 
alterations in responses to these prostaglandins which have been demonstrated
18
in this thesis, intrinsic differences in platelet behaviour in women at risk of pre­
eclampsia, may, however, also promote in vivo platelet activation in this condition.
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INTRODUCTION
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CHAPTER 1 
INTRODUCTION
1. GENERAL INTRODUCTION.
Pregnancy is associated with a physiological hypercoagulable state, of 
which platelet activation in vivo is one feature.1'2'3,4,5 The changes in the 
haemostatic system during pregnancy are appropriate for the limitation of blood 
loss at parturition, but they may also contribute to the aetiology of a number of 
complications of pregnancy such as thromboembolism, disseminated intravascular 
coagulation and pre-eclampsia. There is evidence in particular for a role for 
platelets in the pathophysiology of pre-eclampsia.
The regulation of platelet behaviour is complex and is governed by a large 
number of interacting factors. Prostaglandins make an important contribution to 
the mechanisms controlling platelet behaviour, either as agents which promote or 
those which inhibit platelet activation. This thesis is concerned with changes in 
platelet responses to prostaglandins in normal and hypertensive pregnancy. The 
introductory chapter describes the normal mechanisms and regulation of platelet 
function and on this background provides a review of the literature on platelet 
behaviour in normal pregnancy and in pre-eclampsia.
2. NORMAL MECHANISMS OF PLATELET ACTIVATION 
2.1. Platelet Production and Morphology
Platelets are anucleate blood cells whose function is in primary 
haemostasis. Activated platelets form a plug at sites of vascular injury, thus 
limiting blood loss. In the resting state platelets have the shape of biconvex
21
discs6,7 with a diameter of 2-4um6. Platelets are produced by fragmentation of the 
cytoplasm of megakaryocytes, large polyploid cells found in bone marrow. The 
process of platelet formation from megakaryocytes may either occur in the 
marrow sinusoids8 or megakaryocytes may leave the marrow to enter the blood 
stream and platelet production subsequently occurs in the pulmonary circulation9. 
The mechanisms involved in the control of platelet production from 
megakaryocytes are only beginning to be understood, and are likely to involve 
megakaryocyte colony stimulating activity and "thrombopoiesis" stimulating 
activity of a number of haemopoietic growth factors8.
Platelets circulate in the blood for 9-11 days10 and during that time freely 
exchange between the general circulation and the splenic circulation. At any given 
time, approximately one third of platelets are found in the spleen11. The normal 
range for the peripheral blood platelet count is 150-400 x 109/l. At the end of their 
lifespan platelets are destroyed by the reticuloendothelial system.
The platelet has been shown to have four distinct ultrastructural regions 
revealed by electron microscopy : the peripheral zone, the sol-gel zone, the 
organelle zone, and the membrane systems6,7. Important components of the 
peripheral zone are the surface membrane glycoproteins, many of which act as 
receptors for various agents involved in platelet activation12,13, and the 
phospholipid bilayer of the surface membrane which has a role in accelerating 
blood coagulation14 and also contains transmembrane proteins including adenylate 
cyclase15,16. The sol-gel zone comprises the cytoplasmic matrix of the platelet and 
contains a system of microtubules and microfilaments involved in platelet 
contractile processes which play a role in platelet activation responses such as 
shape change and secretion6,7. Actin is the most important contractile protein in 
platelets and platelet activation is associated with polymerisation of monomeric
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G-actin to F-actin17,18. The organelle zone contains mitochondria, and the storage 
granules. Three types of storage granules can be identified in platelets: the alpha 
granules, dense granules, and the lysosomes18,20. Release of the contents of 
storage granules is a key feature of platelet activation responses and will be 
discussed in detail later. The internal membrane systems in platelets consist of the 
surface-connected canalicular system and the dense tubular system7. The former 
represents complex invaginations of the surface membrane into the interior of the 
cell and can be externalised, possibly exposing active sites when platelets are 
stimulated6. The open canalicular system also serves as a conduit for the contents 
of the secretory granules to the external medium7, as granule membranes fuse 
with this surface-connected membrane when a release reaction is initiated. The 
dense tubular system is analogous to the sarcoplasmic reticulum in smooth 
muscle7,21. It acts as the major storage site for intracellular calcium. Mobilisation 
of calcium from the dense tubular system to the cytosol is a key mechanism in 
stimulus response coupling in platelets22.
2.2 Basic Physiology of Platelet Plug Formation In Vivo.
When the integrity of vascular endothelium is breached, platelets adhere 
to components of the exposed subendothelium including collagen23. This process 
is facilitated by von Willebrand factor, particularly at high vessel wall shear rates24. 
Von Willebrand factor, is a multimeric protein synthesised by endothelial cells25 
and circulates in association with the coagulation factor, factor VIII. Von 
Willebrand factor binds to the subendothelial collagen and to glycoprotein lb on 
the platelet surface26 thus promoting adhesion. Recently, major advances in the 
understanding of the molecular basis of the platelet adhesive process have been 
made. It has become clear that a wide variety of adhesive proteins are involved 
in supporting platelet attachment to extracellular matrix and these are associated
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with distinct receptors on the platelet membrane. These receptors most commonly 
belong to the integrin family, consisting of proteins with a heterodimeric structure 
with alpha and beta subunits27. These include the fibrinogen receptor, glycoprotein 
llb-llla, the collagen receptor, glycoprotein la-lla, and the fibronectin receptor, 
glycoprotein Ic-lla. Fibronectin is found in the extracellular matrix of the vessel 
wall,in plasma, and in platelet alpha granules, and probably facilitates platelet 
spreading over the subendothelium28. Some integrins such as glycoprotein llb-llla 
can act as receptors for more than one type of adhesive protein. Furthermore, not 
all platelet receptors for adhesive proteins belong to the integrin family. Exceptions 
are glycoprotein Ib-IX, the receptor for von Willebrand factor, and glycoprotein lllb- 
IV27, the receptor for thrombospondin, a protein found in the endothelial basement 
membrane and platelet alpha granules.
Adherent platelets change shape from discs to spheres with pseudopods 
and then spread out over the exposed subendothelium23. The activated platelets 
then release the contents of their storage granules and aggregate together building 
up a haemostatic plug at the site of vascular injury23. The pseudopods formed 
during shape change facilitate platelet-platelet contact and the released granule 
contents such as adenosine diphosphate (ADP) and 5-hydroxytryptamine (5-HT) 
recruit further activated platelets19,20. Fibrinogen plays a key role in platelet 
aggregation20,29,30 as it forms a bridge between adjacent platelets by binding to 
receptors on glycoprotein llb-llla, which are exposed on platelet activation.27,31,32,33 
Platelet activation during formation of a haemostatic plug is also accompanied by 
the synthesis of the unstable prostanoid thromboxane A2 by platelets.34,35 This in 
itself is a powerful platelet activator and vasoconstrictor, thus providing another 
positive feedback mechanism for further platelet aggregation.20,34,35,38
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The coagulation cascade becomes activated at sites of vascular injury as 
a result of contact activation and release of tissue thromboplastin. This results in 
the production of thrombin which, in addition to catalysing the conversion of 
fibrinogen to fibrin, is a powerful platelet activating substance.20 Further 
interactions between platelets and the coagulation cascade occur, as platelets 
provide a phospholipid surface for localisation and acceleration of many of the 
reactions in the coagulation system such as the initiation of the intrinsic 
pathway,37 the conversion of Factor X to Xa by Factor IX.38 and the conversion of 
prothrombin to thrombin by Factor X ..14,39 The latter is sometimes referred to as 
platelet prothrombinase activity.14 Ultimately the platelet plug is stabilised by 
cross-linked fibrin, the end product of the coagulation cascade.
In vivo, a large number of interacting factors are simultaneously involved 
in promoting platelet activation and responses of platelets occur in concert with 
one another. Many of the details of individual platelet responses and of the effects 
of individual platelet agonists have been elucidated from in vitro studies where it 
is possible to focus on particular aspects of platelet behaviour or upon particular 
stimuli. These advantages are to some extent offset by the disadvantages of 
studying platelet behaviour in an unphysiological environment. Nevertheless the 
bulk of current knowledge of the mechanisms of platelet responses has been 
gleaned from such in vitro studies. Platelet behaviour in vitro has been investigated 
in platelet rich plasma (PRP), washed platelet suspensions and in whole blood.
2 .3  Aspects of Platelet Behaviour In Vitro.
Platelet activation responses in vitro in suspensions of platelets are similar 
to those in vivo and consist of shape change, aggregation, secretion, and 
thromboxane synthesis.20,40 The responses elicited depend upon the nature of the 
agonist and upon its concentration.15,20,40,41,42 All platelet agonists act on specific
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receptors on the platelet membrane to initiate the platelet activation process.40 In 
some cases these receptors have been identified whilst in others their nature 
remains obscure. Agonists of physiological relevance which can be used to 
activate platelets in vitro are ADP, collagen, thrombin, adrenaline, 5-HT, platelet 
activating factor (PAF) and prostaglandins. Thromboxane A2 is the key 
prostaglandin involved in platelet activation in vivo,34,35 36 but this is too unstable 
for in vitro use. Thromboxane mediated platelet behaviour may be studied in vitro 
by using the endoperoxide analogue 9 ,1 1-dideoxy-11 a,9o-epoxymethano- 
prostaglandin F2ff (U46619), which is thought to act at the same receptor as 
thromboxane.40 Alternatively, exogenous arachidonic acid, the substrate for 
thromboxane synthesis,34,35,36 can be added to platelets in vitro to produce 
thromboxane dependent platelet responses. Substances which activate platelets 
can be categorised as weak or strong agonists.20,43,44 ADP, adrenaline and PAF are 
weak agonists, whereas thrombin and high concentrations of collagen act as 
strong agonists.20,43,44
Platelet shape change is seen with all physiological agonists except 
adrenaline.20,45 Shape change occurs independently of extracellular calcium,20 
requires the weakest stimulus and is the response most resistant to inhibition.44 
Shape change is detected in vitro in platelet rich plasma or washed platelet 
preparations by an increase in optical density of the suspension.20,40
Platelet aggregation is dependent on the binding of fibrinogen to 
platelets.29,30 Fibrinogen receptors become exposed on activated platelets 40,46 by 
induction of a conformational change in the glycoprotein llb/llla complex.33,40 
Monoclonal antibodies, for example PAC-1, have been described which bind to 
glycoprotein llb-llla only when platelets have been activated.47 These are a useful 
tool for assessment of fibrinogen receptor exposure. Following the initial
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description of the central role of fibrinogen in ADP induced aggregation,29'30 it was 
unclear whether released ADP was responsible for mediating platelet aggregation 
in response to other agonists. Subsequently, most physiological agonists have 
been shown to be capable of inducing fibrinogen receptor exposure40,4849,50 but 
some controversy remains about whether collagen is capable of doing this directly, 
or whether collagen induced aggregation is a consequence of thromboxane A2 
synthesis and ADP release.41,48 Fibrinogen binding to its receptor and therefore 
aggregation are dependent upon extracellular calcium.30 Aggregation is also 
dependent on close contact between platelets which can be achieved in vitro by 
stirring the platelet suspension.30 Aggregation in vitro can be monitored by 
following reductions in optical density of platelet rich plasma or washed platelet 
suspensions as aggregation proceeds.51 Platelet aggregation in whole blood can 
be monitored either by counting single platelets in small aliquots of blood52,53 or 
by measuring changes in electrical impedance.54
Platelet aggregation in vitro may be reversible (primary) or irreversible 
depending on the strength and concentration of the agonist.20,40,42,43,44 Weak 
agonists may elicit primary aggregation at low concentrations, and then at higher 
concentrations a second wave of aggregation (secondary aggregation) occurs 
which is irreversible and associated with a release reaction and with the synthesis 
of thromboxane A2.20,40,43,44 Secondary, but not primary aggregation in response 
to weak agonists can be inhibited by preventing thromboxane synthesis with drugs 
such as aspirin. Strong agonists can elicit a full irreversible aggregation response 
which is not thromboxane dependent.20,40,43,44
As a weak agonist, ADP at low concentrations produces primary 
aggregation in PRP, followed by secondary aggregation if the concentration of 
ADP is increased.42,48 The secondary wave of aggregation in response to ADP in
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PRP is thought, however, to be an artefact induced by the unphysiologicaliy low 
calcium concentrations in plasma anticoagulated with citrate.55 Platelet 
aggregation in response to collagen in vitro occurs in a single phase after an initial 
lag period and is irreversible.43,56 At low concentrations of collagen, the 
aggregation response is thromboxane dependent, but at higher concentrations can 
occur even when thromboxane synthesis is inhibited. As adrenaline induces little 
or no platelet aggregation in PRP anticoagulated with the thrombin inhibitor 
hirudin,57 there has been controversy as to whether adrenaline can itself cause 
platelet aggregation or whether it merely synergises with other agonists, such as 
trace amounts of thrombin in citrated PRP. Evidence has emerged, however,for a 
direct effect of adrenaline, mediated by alpha2 receptor stimulation.20,40,50,58 
Aggregation in response to the addition of exogenous arachidonic acid in vitro 
occurs in a single phase and is irreversible.59 By contrast, prostaglandin 
endoperoxides and agonists at the thromboxane receptor available for in vitro use 
are of intermediate potency and induce reversible aggregation when present at low 
concentrations, the response becoming irreversible when their concentration is 
increased.59 Thrombin is the strongest platelet agonist and induces irreversible 
platelet aggregation.20,40,43,44 Thrombin binds to high and low affinity sites on the 
platelet membrane,20,40 but it has been difficult to show which of these sites is the 
functional thrombin receptor. Recently, a functional platelet thrombin receptor has 
been cloned and it has been shown that the proteolytic effects of thrombin are 
necessary for activation of its receptor.60,61 Aggregation studies in vitro using 
thrombin require the preparation of washed platelets to remove fibrinogen so that 
fibrin formation does not interfere with the measurement of aggregation.56
Platelet secretion or the release of contents of storage granules can be 
divided into three phases.19,20 The strength of stimulus required for alpha granule
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release is less than that required for dense granule release which in turn is less 
than the stimulus required for lysosomal release.20 Alpha granule release results 
in the secretion of platelet specific proteins such as platelet factor 4, ft- 
thromboglobulin and platelet derived growth factor, together with coagulation 
factors such as factor V, and fibrinogen and proteins involved in cell adhesion 
such as von Willebrand factor, fibronectin and thrombospondin.20 Platelet factor 
4 has a high affinity for heparin62 and heparan sulphate on endothelial cells. 
Platelet factor 4 may have a role in vivo in preventing the inactivation of thrombin 
by antithrombin III, which is greatly accelerated by endothelial heparan sulphate.63 
The biological effects of /?-thromboglobulin are less well characterised but it has 
been shown to bind to endothelial cells and inhibit prostacyclin production64 and 
to have chemotactic activity for fibroblasts.65 Platelet derived growth factor is 
mitogenic for smooth muscle cells6667 and may be involved in the smooth muscle 
proliferation seen in atheromatous lesions.67 Alpha granule release also results in 
the appearance of the alpha granule membrane protein, GMP-140, on the surface 
membrane of the platelet.66 GMP-140 is an adhesion molecule of the selectin 
family which acts as a receptor for neutrophils and monocytes, thus facilitating 
white cell/platelet interaction.68 Measurement of plasma platelet factor 4 and ft- 
thromboglobulin levels by radioimmunoassay can provide a useful marker of 
platelet alpha granule release in vivo, provided blood is taken under conditions 
which minimise platelet activation during venepuncture and subsequent handling 
in vitro.56
Platelet dense granules contain calcium ions, adenosine triphosphate (ATP), 
ADP, pyrophosphate and 5-HT.19,20 ADP and 5-HT are themselves platelet agonists 
contributing to positive feedback loops promoting further platelet activation. Dense 
granule contents in general do not exchange with nucleotides or calcium in the
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cytoplasm or in the plasma,20 but there is an active transport system which allows 
uptake of 5-HT from plasma across the plasma membrane and dense granule 
membranes.69,70 Dense granule release can be measured easily in vitro either by 
labelling the dense granules with radioactive 5-HT which is subsequently released 
upon platelet stimulation69 or by continuous monitoring of chemiluminescence 
using the luciferin-luciferase reaction which measures ATP release during platelet 
activation.20
All physiological agonists are capable of stimulating alpha granule and 
dense granule release but in the case of weak agonists this occurs in an 
aggregation dependent manner and is also dependent on thromboxane 
synthesis.43,44 If aggregation or thromboxane synthesis is blocked, no release 
reaction takes place. In the case of strong agonists the release reaction can be 
triggered independently of aggregation and thromboxane synthesis.43,44,71 
The third category of secretory granules in platelets, the lysosomes, contain acid 
hydrolase enzymes, the function of which is unclear, but they may have a role in 
clearing of platelet thrombi, heparin inactivation and possibly anti-inflammatory 
mechanisms.20 Lysosomal secretion only occurs when platelets are stimulated with 
the strongest agonists, and even then release is incomplete.20,44
2 .4  Arachidonic Acid Liberation: The Synthesis and Role o f Platelet 
Prostaglandins.
When platelets become activated, various pro-aggregatory prostanoids are 
synthesised by the activated platelets, the most important of which is 
thromboxane A2 which was first identified by Hamberg in 1975.34,36,36 All 
physiological agonists are capable of initiating thromboxane synthesis in vitro but 
the extent of this varies with the strength and concentration of the agonist.16,41,66 
The substrate from which prostaglandins are synthesised is arachidonic acid, a 20-
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carbon fatty acid, derived from linoleic acid. Unless added exogenously in vitro, 
all of the arachidonic acid utilised by platelets for prostaglandin synthesis is 
released by hydrolysis from platelet membrane phospholipids.35,36,72 At least two 
pathways are involved in arachidonic acid liberation, in the first, free arachidonic 
acid is produced mainly from phosphatidylcholine and phophatidylethanolamine, 
by the action of phospholipase A2 72,73,74 In the second pathway, phospholipase C 
acts specifically on phosphatidylinositol resulting in diacylglycerol production.75 
Free arachidonic acid is then liberated from diacylglycerol by diglyceride lipase.76 
Free arachidonic acid is metabolised via two main pathways: the cyclooxygenase 
pathway and the lipoxygenase pathway.35,36 This is illustrated in Figure 1.1. In 
activated platelets the cyclooxygenase pathway is of greater importance.
Cyclooxygenase itself catalyses the conversion of arachidonic acid to the 
cyclic endoperoxides prostaglandin G2 (PGG2) and prostaglandin H2 (PGH2).77 
PGG2 and PGH2 are normally rapidly converted by thromboxane synthetase to 
thromboxane A2.34,78 Malondialdehyde and 12-hydroxyheptadecatrienoic acid are 
formed as byproducts of this reaction.34 As discussed above, thromboxane 
synthesis represents an important positive feedback mechanism in platelets and 
plays a key role in platelet responses to weak agonists.20 In addition to its pro- 
aggregatory effects on platelets, thromboxane A2 is also a potent 
vasoconstrictor.35,36,78 In vivo, it appears to exert its effects on platelets and 
vascular tissue by local rather than systemic action.79 Thromboxane A 2 is 
extremely unstable, having a half life of 30 seconds in aqueous solution, and 
spontaneously hydrolyses to thromboxane Ba.34,78 In vivo, it is further metabolised 
giving rise to 2,3 dinor-thromboxane B280 and 1 1-dehydro-TXB281, which are 
excreted by the kidney and may be measured in the urine.82 Measurement of these 
metabolites in urine by gas chromatography-mass spectrometry (GCMS) is the
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Figure 1.1
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most accurate means of assessing thromboxane biosynthesis in vivo, as plasma 
measurements of thromboxane B2 are subject to artefact as a result of 
thromboxane formation from platelet activation during venepuncture and sample 
handling.82 Measurement of serum thromboxane B2 levels, however, represents a 
useful method of assessing platelet thromboxane production during spontaneous 
clotting of whole blood in vitro.58,83
Although the intermediates PGG2 and PGH2 are usually very quickly 
metabolised to thromboxane A2, these prostaglandins are themselves pro- 
aggregatory84 and probably act at the same platelet receptor as thromboxane.85 
The normal route of metabolism of the cyclic endoperoxides is via thromboxane 
synthetase, but PGG2 and PGH2 can also be converted to other prostaglandins 
such as PGE2, PGD2 and PGF2<f.35,38 These prostaglandins are formed only in small 
amounts under normal circumstances, but their effects on platelet behaviour are 
worthy of consideration. PGD2 inhibits platelet activation and may serve as a 
negative feedback mechanism to limit platelet activation.88 PGE2 at low 
concentrations can synergise with other agonists to promote platelet 
activation,87,88,89 whilst at higher concentrations it is inhibitory.89,90
The lipoxygenase pathway involves the conversion of arachidonic acid to 
12-hydroperoxyeicosotetraenoic (12-HPETE)and 12-hydroxyeicosotetraenoic acid 
(12-HETE).35,79 12-HETE has chemotactic activity for neutrophils,79 and there is 
evidence that lipoxygenase products can inhibit platelet aggregation in vitro.91 It 
is unlikely, however, on the basis of current evidence, that these agents have a 
major role in the regulation of haemostasis.
2.5 Stimulus Response Coupling Mechanisms in Platelet Activation.
As in many cell types, cytosolic calcium ions and the products of 
breakdown of inositol phospholipids act as important stimulatory second
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messengers in platelets , linking receptor occupancy with an agonist to platelet 
responses such as shape change, aggregation, secretion, and thromboxane 
synthesis.
Intracellular Free Calcium
Evidence for the role of calcium ions as intracellular messengers has been 
derived from studies showing that calcium ionophores such as A 23187 can 
activate platelets,82,93 giving rise to responses very similar to those observed with 
physiological agonists. Permeabilised platelets can also be activated by addition 
of extracellular calcium in concentrations in the micromolar range,84,95 and 
intracellular calcium antagonists, for example some local anaesthetics, have been 
shown to inhibit platelet activation induced by calcium ionophore or thrombin.80 
Furthermore, in experiments using intracellular calcium probes such as the 
fluorescent dyes quin-2, and fura-2 or the chemiluminescent photoprotein, 
aequorin, an increase in intracellular free calcium can be demonstrated upon 
platelet stimulation by a wide range of physiological agonists.97,88,99 In many 
tissues, calcium flux across the plasma membrane plays a role in the increase in 
cytosolic calcium observed upon excitation of the cell. As platelets can become 
activated in the absence of extracellular calcium,100 it was proposed that calcium 
was mobilised from intracellular storage sites to increase cytosolic free calcium in 
response to a stimulus. Large amounts of calcium are sequestered by the dense 
tubular system in resting platelets101 and the membranes of the dense tubular 
system contain a calcium-ATPase pump.102,103 The dense tubular system has 
therefore been considered to be the major source of stimulus induced increases 
in cytosolic calcium in platelets. Furthermore, it has been shown that inositol 
trisphosphate which is released from membrane phospholipids following 
stimulation of platelets by physiological agonists, is capable of releasing calcium
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from isolated calcium transporting internal platelet membranes.22,104 At least for 
some agonists, however, an influx of calcium across the plasma membrane via 
receptor operated calcium channels appears to contribute to the increase in 
cytosolic calcium observed upon platelet activation.41,106 This is especially relevant 
to ADP induced platelet activation.100,107 Platelets do not appear to possess voltage 
operated calcium channels.41,108
There have been several attempts to correlate concentrations of 
intracellular free calcium with platelet responses using calcium ionophore treated 
platelets97 and permeabilised platelets.95 Such studies show that shape change 
requires a lesser rise in intracellular free calcium than aggregation and secretion, 
and phosphatidylserine exposure leading to prothrombinase activity requires the 
greatest rise in cytosolic calcium. Studies with quin-2, fura-2 and aequorin in 
platelets stimulated with physiological agonists have indicated, however, that 
responses predicted by the rise in intracellular free calcium following stimulation 
do not completely correlate with the actual platelet responses elicited by the 
agonist.41,95,97 Part of the explanation of this lies in the fact that aequorin may be 
measuring localised calcium transients, and quin-2 may itself quench larger 
increments in intracellular free calcium,109,110 but some observations cannot be 
accounted for in this way. For example stimulation of platelets with collagen, in 
the presence of cyclooxygenase inhibitors, results in a negligible rise in intracellular 
free calcium, measured with fura-2,111 but collagen is a strong agonist capable of 
eliciting all platelet responses including lysosomal release and prothrombinase 
activity.20 By contrast, calcium signals measured by aqueorin in response to 
collagen could account for all the observed platelet responses to collagen,41,110 but 
predicted and observed responses for other agonists such as ADP, on the basis 
of aqueorin data, fail to correlate.41 All the data can only be reconciled by the
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involvement of other second messenger systems in the signalling of platelet 
responses to agonists. ADP, thrombin, and thromboxane analogues are good 
mobilisers of calcium, whereas collagen and adrenaline are poor calcium 
mobilisers.41,110
Various targets for cytosolic calcium which are of relevance to the 
execution of platelet responses have been identified. Platelets have been shown 
to contain calmodulin,112 a calcium binding protein which in many tissues mediates 
calcium regulation of cellular responses. In platelets calmodulin has been shown 
to regulate the activity of myosin light chain kinase.113 Moreover, phosphorylation 
of a 20 Kilodalton (20K) protein114 subsequently identified as the light chain of 
myosin occurs during platelet activation with physiological agonists.115 
Contractility of actomyosin is dependent on myosin phosphorylation,110 therefore 
calcium dependent activation of myosin light chain kinase ultimately elicits 
contractile processes in the platelet which may be linked with responses such as 
shape change and secretion.114,115 The enzyme phospholipase A2 represents 
another target for cytosolic calcium.74,117 Activation of this enzyme by calcium 
results in the liberation of arachidonic acid from membrane phospholipids and 
ultimately prostaglandin synthesis.74 
Phosphoinositide Metabolism.
As has been shown above, stimulus response coupling in platelets cannot 
be entirely explained by intracellular calcium transients. There is substantial 
evidence that platelet activation by many physiological agonists is accompanied 
by an increased turnover of membrane phosphatidylinositol,75,98,118'119 together 
with the inositol polyphosphates, phosphatidylinositol 4-phosphate and 
phosphatidylinositol 4,5-bisphosphate (PIP2).120,121 Hydrolysis of these 
phospholipids is catalysed by the enzyme phospholipase C yielding diacylglycerol
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and inositol phosphate, inositol bisphosphate or inositol trisphosphate (Figure 
1.2).41'44'75121 The cycle is completed by the actions of diacylglycerol kinase and 
two transferases, regenerating phosphatidylinositol which can in turn undergo 
phosphorylation rendering the inositol polyphosphates.44,121 Time course studies 
in thrombin stimulated platelets have shown that phospholipase C induced 
hydrolysis of PIP2 is the initial event in this cycle and is closely coupled to receptor 
occupancy.120 PIP2 hydrolysis is linked to receptor occupancy by a putative G 
protein "Gp".122 This G protein has not been isolated but evidence for its existence 
comes from studies showing that addition to permeabilised platelets of GTP 
analogues, which bind to G proteins, and convert them to their active state, can 
induce metabolism of polyphosphoinositides,123 and potentiate platelet responses 
such as 5~HT secretion.124 The diacylglycerol generated acts as a second 
messenger by activating protein kinase C125 which in turn phosphorylates a 40  
kilodalton (40K) regulatory intracellular protein.40,125,126 Protein kinase C also 
requires calcium for activation but diacylglycerol greatly reduces the calcium 
threshold at which the enzyme will become activated.40,44,125,127 Evidence for the 
role of diacylglycerol and of protein kinase C in platelet activation comes from the 
observations that addition to platelet suspensions of exogenous analogues of 
diacylglycerol or of phorbol esters which activate protein kinase C directly, can 
elicit platelet responses such as aggregation and secretion.127 Whilst 
phosphorylation of the 40K protein, the substrate for protein kinase C, has been 
consistently observed upon platelet activation by physiological agonists such as 
thrombin,114,125 its ultimate function and its relevance to particular platelet 
responses remain uncertain. Phosphorylation of the 40K protein has been 
associated with platelet secretion114 but other studies have found the correlation 
of the two events to be incomplete.128
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Inositol trisphosphate (IP3) generated by the metabolism of inositol 
phospholipids also has a role as a second messenger in platelets. Inositol 
trisphosphate acts as link between receptor activation and calcium mobilisation. 
Inositol trisphosphate has been shown to cause dose dependent release of calcium 
from calcium transporting membrane vesicles derived from platelets.22,104 The 
membrane vesicles prepared in these experiments had the biochemical 
composition of dense tubular system membranes. Furthermore, IP3 binding sites 
which have the characteristics of receptors have been demonstrated on highly 
purified platelet intracellular membranes.129 There is recent evidence, however, for 
the existence of an IP3 insensitive intracellular calcium pool130
Different agonists display differing abilities to activate phospholipase C. 
Thrombin,75,120 thromboxane,98 platelet activating factor119 and vasopressin118 have 
all been shown to increase diacylglycerol and IP3 formation in platelets, whereas 
the levels of these second messengers are little affected by ADP41,131 and 
adrenaline.40,41 Some very recent studies suggest that thromboxane A2 may 
activate phospholipase C via a G protein distinct from "Gp".132 If thromboxane 
synthesis is suppressed, platelet stimulation with collagen results in phosphatidate 
formation111 but there is little IP3 formation. Hydrolysis of phosphatidylcholine 
seems to provide some of the diacylglycerol formed after platelet stimulation with 
collagen.111 A phospholipase D, which probably hydrolyses phosphatidylcholine 
has been identified in platelets133,134 and it is possible that the collagen receptor 
is coupled to this.
As has been discussed above, adrenaline is a poor calcium mobiliser and 
also does not seem to be coupled to activation of phospholipase C.111 The 
mechanism of platelet activation by adrenaline therefore remains difficult to
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explain. Alpha2 adrenoreceptors are linked to a G protein (G) whose activation 
inhibits adenylate cyclase/35 the enzyme responsible for the synthesis of cyclic 
AMP, an inhibitory second messenger in platelets.130 Whilst a reduction in the 
basal level of cyclic AMP has not itself been shown to cause platelet activation,137 
reduction in elevated levels of cyclic AMP can antagonise the effects of platelet 
inhibitors acting via this second messenger.138 It is conceivable that the coupling 
of adrenaline to G( is involved in an as yet undefined manner in the mechanism of 
adrenaline induced platelet activation, and may be more important in vivo than in 
vitro. The role of cyclic AMP as an inhibitory second messenger and the control 
of adenylate cyclase will be discussed in detail in subsequent sections of this 
chapter.
3 . PATHOLOGICAL PLATELET AC TIVATIO N
In vivo, platelet plug formation is normally limited to an extent appropriate 
to securing haemostasis by protective mechanisms in which vascular endothelium 
has a major role to play. When platelet activation occurs inappropriately thrombus 
formation may occur resulting in pathological sequelae. Circumstances which 
contribute to thrombus formation are, as first described by Virschow in 1856:139 
1) damage to the vessel wall, which may lead to failure of normal endothelial 
function, 2) an abnormal pattern of blood flow, which may itself result from vessel 
wall damage, and 3) abnormalities of the blood itself, including changes in 
platelets and coagulation factors. Clearly any shift in the balance between factors 
which promote platelet activation and those which limit it could lead to a pro- 
thrombotic state. Platelets have been particularly implicated in arterial thrombosis, 
as thrombi forming in the fast flow conditions found in arteries are rich in platelets 
and leucocytes, whereas red cells and fibrin are predominant components of
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venous thrombi.140 Arterial thrombi are also generally associated with disease in 
the vessel wall.141 Platelet activation has therefore been implicated in a variety of 
clinical conditions in which arterial thrombosis plays a part, such as myocardial 
infarction, ischaemic stroke, transient ischaemic attacks, and occlusion of vascular 
grafts.141 Furthermore, platelets have also been implicated in the development of 
atherosclerosis, and several possible mechanisms have been proposed. One 
hypothesis67,142 suggests that endothelial injury or dysfunction results in adherence 
of platelets and monocytes to the vessel wall. Adherent platelets release platelet 
derived growth factor which is a mitogen for smooth muscle. Ultimately, intimal 
thickening and atherosclerosis develop. Pathological platelet activation has also 
been implicated in the development of other clinical conditions in which vascular 
occlusion is a feature, for example the microvascular complications of diabetes,143 
migraine,144 and pre-eclampsia.145 The role of platelets in pre-eclampsia is 
discussed in detail in a subsequent section of the introduction. It is relevant here 
to review the normal physiological mechanisms which limit platelet activation. 
Some pharmacological means of inhibiting platelet behaviour, aimed at preventing 
pathological platelet activation and thrombosis will then be described.
4 .INHIBITION OF PLATELET ACTIVATION:
THE PHYSIOLOGICAL ROLE OF ENDOTHELIUM.
4.1 General Aspects of Endothelial Function.
In intact blood vessels platelet activation is normally prevented by the 
endothelium. This is partly because the endothelium forms a physical barrier from 
the thrombogenic surface of the underlying basement membrane, and the negative 
charge on both endothelial cells and platelets makes them mutually repulsive.146 
The endothelium, however, plays a much more active role in the regulation of
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platelet activity by the synthesis and release of some very powerful platelet 
inhibitory substances. These consist of inhibitory prostaglandins and endothelium 
derived relaxing factor. Furthermore, endothelium is capable of promoting 
catabolism of ADP and also contributes to the inactivation of thrombin. Each of 
these functions will be considered in turn.
4.2 Synthesis of Prostaglandins which Reoulate Platelet Behaviour
The ability of vascular tissue to generate an unstable prostaglandin product 
which was a potent inhibitor of platelet aggregation was first described by 
Moncada et al in 1976.147 This was later identified as prostacyclin.148 Prostacyclin 
is synthesised by endothelial cells from arachidonic acid by a pathway identical to 
that for thromboxane synthesis in platelets except for the final step in which the 
enzyme prostacyclin synthetase catalyses the conversion of cyclic endoperoxides 
to prostacyclin (PGI2).35,147 Prostacyclin is the most potent known platelet 
inhibitory agent35,38 and is also a powerful vasodilator.149 It is unstable in vitro147 
and, both in vitro and in vivo is rapidly broken down by non enzymatic hydrolysis 
to 6-ketoprostaglandinFl4F (PGF1<r).148 In vivo, further metabolism by enzymatic 
degradation takes place resulting in the excretion of 2,3 dinor-6-ketoPGF1<r and 
6 ,1 5-diketo-13,14 dihydro-2,3 dinor PGF,,.150 Prostacyclin is thought to act 
locally, as circulating levels are too low to have biological activity.151,152 It is 
capable of inhibiting all platelet responses, irrespective of the inducing agonist,20,44 
but is less efficient as an inhibitor of adhesion than of other aspects of platelet 
behaviour.153 Prostacyclin synthesis by endothelial cells is stimulated by thrombin, 
bradykinin, changes in shear stress, and products derived from activated platelets 
such as ADP and ATP.154 Furthermore PGG2 and PGH2 released from activated 
platelets may be utilised by the endothelium for prostacyclin synthesis.38,155 The 
stimulation of prostacyclin synthesis by substances from activated platelets
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provides a means of limiting thrombus formation. A rise in intracellular free 
calcium in the endothelial cell is the main second messenger driving prostacyclin 
synthesis.166 Prostacyclin release is subject to rapid homologous desensitisation, 
even in the continued presence of the stimulating agonist.157
It has been proposed that an imbalance between the pro-aggregatory and 
vasoconstrictor effects of thromboxane and the anti-aggregatory vasodilator 
effects of prostacyclin may be a key factor predisposing to pathological platelet 
activation and thrombosis.35,30 Furthermore, some evidence of such an imbalance 
has been found in conditions associated with thrombosis such as diabetes,35,141 
hyperlipidaemia141 and cigarette smoking,36 and in pregnancy induced 
hypertension.168,169,160 The subject of thromboxane/prostacyclin imbalance in 
hypertensive pregnancy is discussed in detail in a subsequent section of this 
chapter. On the other hand, increased excretion of urinary metabolites of both 
thromboxane and prostacyclin have been described in other conditions associated 
with platelet activation such as severe atherosclerosis and unstable angina.161,162 
The increase in prostacyclin synthesis may represent a compensatory response by 
vascular tissue to platelet activation.
Whilst prostacyclin is the major prostaglandin synthesised by the 
endothelium of large and medium sized blood vessels, PGE2 is the main metabolite 
of arachidonic acid in microvascular endothelium.163,164 Unlike prostacyclin, PGE2 
at low concentrations potentiates platelet aggregation induced by other agonists, 
whilst at high concentrations inhibits platelet behaviour in response to a wide 
range of agonists.87,88,89,90
The prostaglandins produced by endothelial cells and indeed PGD2 produced 
by platelets themselves, act as inhibitors of platelet behaviour by increasing the 
levels of the inhibitory second messenger cyclic AMP in platelets.185,166 The
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inhibitory prostaglandins act on specific surface receptors which are linked to 
stimulation of adenylate cyclase, the enzyme which catalyses the synthesis of 
cyclic AMP from ATP.188 As cyclic AMP is capable of inhibiting most platelet 
responses at the level of intracellular signal processing, the inhibitory effects of 
agents which act via cyclic AMP are not agonist specific.44
4 .3  Endothelium Derived Relaxing Factor.
Endothelium produces a highly labile agent with powerful vasodilator 
activity which became known as endothelium derived relaxing factor (EDRF)187 and 
was subsequently identified as nitric oxide.188 EDRF inhibits platelet behaviour in 
response to a wide range of agonists,189,170,171 and unlike prostacyclin, is 
moderately active as an inhibitor of platelet adhesion.172 Like prostacyclin, EDRF, 
as a highly labile agent, is likely to exert its effects on platelets and blood vessels 
at a local level.173,174 EDRF is synthesised from L-arginine by the soluble enzyme 
nitric oxide synthetase.175 The activity of nitric oxide as an inhibitor of platelet 
behaviour and as a vasodilator is prolonged by superoxide dismutase and is 
inhibited by haemoglobin to which nitric oxide binds.189,171,174 EDRF synthesis in 
endothelium is stimulated by acetylcholine,187 substance p,173-176-177 shear stress 
on the endothelium,173 and factors released during thrombus formation such as 
ATP, ADP, 5-HT, and thrombin.173,178,177 This again could act as a negative 
feedback mechanism limiting thrombus extension. EDRF acts as an inhibitor of 
platelet behaviour by raising the level in platelets of cyclic GMP,171,178,179 which like 
cyclic AMP, acts as an inhibitory second messenger in platelets.41,44,180,181 Nitric 
oxide increases cyclic GMP by stimulating the platelet soluble guanylate cyclase, 
the enzyme responsible for the synthesis of cyclic GMP from GTP.171,178,179 The 
inhibitory effects on platelet behaviour of prostacyclin and EDRF are markedly
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synergistic,182 but the exact mechanism of the synergism has not been completely 
elucidated.
4.4 Other Mechanisms Bv Which Endothelium Limits Haemostasis.
ADP and ATP released from platelets and damaged vessel walls are 
catabolized by endothelial ectonucleotidases to yield adenosine.183 Adenosine is 
also capable of acting on specific receptors on the platelet membrane to raise 
platelet cyclic AMP levels and to inhibit platelet behaviour.184 The activity of 
adenosine is limited by its rapid uptake into red cells and endothelial cells.183,185 
Endothelial cells also have a surface protein called thrombomodulin which binds 
thrombin with a high affinity.186 Binding of thrombin to thrombomodulin inhibits 
its ability to cleave fibrinogen and to activate platelets and Factor V. Furthermore, 
thrombin mediated activation of the naturally occurring anticoagulant Protein C is 
greatly accelerated by thrombin binding to thrombomodulin.186,187 Activated Protein 
C then inhibits the activity of Factor V, and Factor VIII, thus limiting thrombin and 
fibrin formation.187
The second anticoagulant, as opposed to antiplatelet, property of 
endothelium resides in the presence of substances on the endothelial surface 
which have heparin like activity and are thus able to accelerate the activity of 
plasma antithrombin III.63 In addition to inhibiting thrombin, antithrombin III has 
activity against Factor X, and other serine protease coagulation factors.188
4.5 Inhibitory Second Messengers in Platelets
Cyclic AMP and cyclic GMP perform the function of inhibitory second 
messengers in platelets.44,136,166 Increased levels of these cyclic nucleotides lead 
to inhibition of most aspects of platelet behaviour. The importance of the cyclic 
nucleotides lies in their key role as mediators of inhibition of platelet behaviour by 
physiologically relevant regulators of haemostasis such as prostacyclin165 and
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other inhibitory prostanoids in the case of cyclic AMP135,138,166,180 and EDRF in the 
case of cyclic GMP.171,178,178 
Cyclic AMP.
The inhibitory effects on platelet behaviour of cyclic AMP and its dibutyryl 
derivative were first described by Marcus and Zucker in 1965.136 Basal levels of 
cyclic AMP in platelets are very low and exert little effect on platelet behaviour.189 
On the other hand only a slight elevation of cyclic AMP is required to obtain a 
marked inhibitory effect.41,138,190 Cyclic AMP is synthesised from ATP by the 
enzyme adenylate cyclase in response to receptor occupation by specific 
ligands.166 The metabolism of cyclic AMP to 5'-AMP is brought about by 
phosphodiesterase enzymes.166
Adenylate cyclase is a high molecular weight transmembrane enzyme16,16,191 
which consists of a catalytic subunit closely associated with two guanine 
nucleotide binding proteins (G proteins): the stimulatory G protein (Ga) and the 
inhibitory G protein (Gj).40,41,44,191 Indirect evidence for the involvement of G 
proteins in the regulation of platelet adenylate cyclase activity came from 
observations that GTP and its analogues could influence adenylate cyclase 
activity.135,166 Binding of a ligand to a receptor linked with G, leads to stimulation 
of adenylate cyclase, whilst occupancy of a receptor linked to Q leads to inhibition 
of the enzyme.136 Both G proteins consist of alpha, beta, and gamma 
subunits.44,122,191 The alpha subunit contains the site which binds to guanine 
nucleotides. In the inactive state the G proteins bind GDP, but when stimulated 
by receptor activation, lose their affinity for GDP and bind GTP tightly. This leads 
to dissociation of the alpha subunit from the other subunits and subsequent 
stimulatory or inhibitory action on the catalytic component of adenylate 
cyclase.40,122
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Substances which have been shown to interact with surface receptors 
leading to stimulation of adenylate cyclase include prostacyclin (PGI2),105 
prostaglandin E, (PGE,),192,193 PGD2,194 PGE2 in high concentrations,90 adenosine,184 
and beta2 adrenergic agonists.193 PGI2, PGE1 and PGE2 share a common receptor 
on the platelet membrane,195,196 whilst PGD2 has a distinct receptor.195,197,198,199 
The catalytic subunit of adenylate cyclase can also be stimulated directly with 
forskolin, a diterpene isolated from plants.200,201 PGI2 is the most potent stimulator 
of adenylate cyclase and gives rise to a more sustained elevation of cyclic AMP 
than that produced by PGE, and PGE2.166 All of the prostaglandins which stimulate 
adenylate cyclase, however, give rise to a rapid increase in cyclic AMP which then 
decreases to a variable extent to reach a plateau.202 Whilst metabolism of cyclic 
AMP by phosphodiesterase contributes to this, there is evidence that this effect 
also results from prostaglandin induced activation of G| via receptors on the 
platelet surface distinct from the prostaglandin receptors linked with G,.202 The 
relative affinity of prostaglandins for receptors linked with G, and those linked with 
Gj varies and for each prostaglandin its effects on adenylate cyclase inhibition are 
both time and concentration dependent.202 There is good evidence that PGE2 at 
low concentrations is capable of reducing platelet cyclic AMP levels raised by 
other adenylate cyclase stimulators, whilst at higher concentrations PGE2 
stimulates the enzyme resulting in an increase in cyclic AMP.88,89,203 A number of 
other agents can inhibit adenylate cyclase by binding to receptors linked to Gj. 
These include many aggregating agents such as ADP,204 adrenaline (acting at the 
alpha2 adrenoreceptor),135 and thrombin.205 Conflicting evidence exists regarding 
the ability of thromboxane A2to inhibit adenylate cyclase.206,207 Reduction in cyclic 
AMP from basal levels by these agents, however, appears ngi to be the 
mechanism by which they induce platelet aggregation.137,138,180,193 Furthermore, in
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the case of ADP, there is evidence that the receptor which mediates inhibition of 
adenylate cyclase is distinct from that mediating aggregation.40208
Platelets contain several subtypes of the phosphodiesterase enzymes which 
breakdown cyclic nucleotides.209,210Type III phosphodiesterase (PDE III) is specific 
for cyclic AMP and is active at low concentrations of the cyclic nucleotide. PDE 
II hydrolyses both cyclic AMP and cyclic GMP and requires higher concentrations 
of cyclic nucleotide for activity, and PDE I preferentially hydrolyses cyclic GMP. 
Cyclic AMP may be raised by drugs which inhibit cyclic AMP 
phosphodiesterase.88,160,192 Inhibition of platelet behaviour occurs as a result of a 
smaller increment in cyclic AMP with phosphodiesterase inhibitors in comparison 
with adenylate cyclase stimulators.44,211,212 Moreover, phosphodiesterase inhibitors 
and adenylate cyclase stimulators have synergistic effects on platelet cyclic AMP 
levels and on inhibition of platelet behaviour.160,192
An increase in cyclic AMP in platelets inhibits most morphological and 
biochemical aspects of platelet behaviour, suggesting that cyclic AMP acts at a 
point in the signal transduction mechanism close to stimulus response coupling. 
Cyclic AMP appears to increase the threshold stimulus required for activation 
rendering platelets more resistant to activation,44 but cyclic AMP is also capable 
of causing platelet disaggregation.44 The exact mechanism of action of cyclic AMP 
has not been fully elucidated but multiple effects have been reported. Cyclic AMP 
has been shown by some to increase calcium re-uptake by platelet internal 
membranes, an effect which would reduce cytosolic calcium,213 but others have 
disputed this effect.214 Inhibition of agonist stimulated phospholipase C activation 
has also been reported.40,75,215 This may result from enhancement by cyclic AMP 
of GTPW activity of the putative G protein "Gp" implicated in receptor- 
phospholipase C coupling thus converting the G protein back to the inactive (Gp-
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GDP) state.124 Another group of investigators have shown that cyclic AMP is 
capable of inhibiting intracellular calcium mobilisation by IP3, an effect distinct 
from enhancement of calcium re-uptake.216 It has also been shown, however, that 
inhibition of platelet responses such as aggregation and release occurs at lower 
cyclic AMP concentrations than those required to inhibit phophoinositol 
breakdown, suggesting that cyclic AMP may additionally act at sites distal to 
phosphoinositol metabolism.190 Inhibition of protein kinase C by cyclic AMP has 
been reported by some,217 but not confirmed by other investigators,218 and cyclic 
AMP dependent phosphorylation and consequent inhibition of myosin light chain 
kinase has been demonstrated.218
Many of the effects of cyclic AMP are dependent on the action of a cyclic 
AMP dependent protein kinase, .referred to as protein kinase A .220 Indeed, 
phosphorylation of a number of intracellular proteins has been demonstrated 
following treatment of platelets with agents which increase cyclic AMP or with 
dibutyryl cyclic AMP. Such proteins include a 22kDa, a 24kDa, a 39kDa and a 
50kDa protein.181,221,222 Some of these proteins have very recently been identified. 
The 24kDa protein is the beta chain of glycoprotein 1 b,223 and the 22kDa protein 
has been identified as rap 1 b, a low molecular weight GTP binding protein224,225 
which shares homology with the product of the ras oncogene. The exact function 
of rap 1 b is only beginning to be elucidated. Some reports have suggested that its 
phosphorylation by protein kinase A may not be involved in the inhibition of 
platelet aggregation and secretion by cyclic AMP.221 By contrast, Lapetina226 has 
suggested that, in thrombin stimulated platelets, rap 1b can bind to another 
platelet protein, rasGAP, which is constitutively associated with phospholipase C. 
Binding of rasGAP to raplb facilitates hydrolysis of membrane inositol 
phospholipids by phospholipase C. Phosphorylation of raplb, by cyclic
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AMP dependent protein kinase, induces dissociation of rap1 b from the membrane 
and therefore inhibits the action of phospholipase C on inositol phospholipids. The 
50kDa protein phosphorylated by protein kinase A has also recently been purified 
and has become known as vasodilator stimulated phosphoprotein (VASP).227 The 
phosphorylation of this protein correlates well with platelet inhibition by cyclic 
nucleotides.228 A simplified scheme of the interaction of cyclic AMP and second 
messenger systems involved in platelet activation is shown in Figure 1.3.
Cyclic GMP.
An increase in the level of cyclic GMP in platelets leads to inhibition of their 
behaviour.40,41,44'178*181'191 Cyclic GMP, like cyclic AMP can inhibit platelet 
responses to a wide range of agonists, and appears to be a better inhibitor of 
platelet adhesion than cyclic AMP.172 Cyclic GMP is synthesised from GTP by the 
action of guanylate cyclase, which is a soluble enzyme found in the platelet 
cytoplasm.179,191 Types I and II phosphodiesterase are capable of hydrolysing cyclic 
GMP.209,210 As discussed above, EDRF stimulates guanylate cyclase, but the 
enzyme may also be stimulated by nitrovasodilators such as sodium 
nitroprusside,178,229 glyceryl trinitrate and 3-morpholinosydnonimine (SIN-1), a 
metabolite of molsidomine.230 It is thought that these compounds stimulate 
guanylate cyclase by releasing nitric oxide.173,178,230 Cyclic GMP levels may also 
be raised by inhibiting the phosphodiesterase enzymes responsible for its 
metabolism, and some compounds exist which are relatively specific for the type 
I phosphodiesterase.210 Platelet aggregation has been reported to increase cyclic 
GMP levels.180,189,231 This may be mediated by contact of platelets with each other 
or a matrix such as collagen 189,231 and may act as a negative feedback 
mechanism. It has recently been shown that platelets themselves possess an
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L-arginine-nitric oxide pathway, and this is likely to be involved in the 
mechanism of aggregation-induced increments in cyclic GMP levels.232,233
Relatively little is known of the mechanisms by which cyclic GMP inhibits 
platelet behaviour but treatment of platelets with sodium nitroprusside or with 8- 
bromo-cyclic GMP has been reported to result in phosphorylation of the VASP 
50kDa protein.40,181,222,227,228 Phosphorylation of VASP by both protein kinase A 
and cyclic GMP dependent protein kinase may be involved in the synergism of 
platelet inhibitors acting via these cyclic nucleotides,228 but other mechanisms may 
also come into play. For example, it has been shown that cyclic AMP 
phosphodiesterase is inhibited by cyclic GMP.234
5.PHARMACOLOGICAL MEANS OF INHIBITING PLATELET BEHAVIOUR.
To date therapeutic agents which have been used clinically as inhibitors of 
platelet behaviour have mainly been targeted at the platelet arachidonic acid- 
thromboxane pathway. Aspirin is the most widely used antiplatelet drug and the 
agent for which there is the most evidence of clinical efficacy in thrombotic 
disease. Benefit of aspirin has been shown in myocardial infarction,235,236 unstable 
angina,236 ischaemic stroke,236 transient ischaemic attacks,236 prevention of 
occlusion of coronary artery bypass grafts237,238 and large trials are currently 
underway in pregnancy induced hypertension. Aspirin inhibits cyclooxygenase, 
preventing endoperoxide production.239,240 This inhibition is irreversible as aspirin 
acetylates cyclooxygenase241 and, platelets, being anucleate, are unable to 
regenerate cyclooxygenase activity. Recovery of prostaglandin production is 
therefore dependent upon production of new platelets from megakaryocytes.242 
It is noteworthy that as an inhibitor of cyclooxygenase aspirin also reduces 
endothelial prostacyclin synthesis. Advantage can be taken of the capacity of the
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endothelium to regenerate cyclooxygenase activity, the relative sensitivities of the 
platelet and endothelial enzymes, and the extensive pre-systemic hydrolysis of 
aspirin to salicylate, to limit the effects of aspirin on prostacyclin synthesis.243,244 
Low doses of aspirin are relatively selective in inhibiting platelet thromboxane 
production whilst sparing prostacyclin production;243 no dose of aspirin, however, 
is completely selective.245
Drugs which inhibit thromboxane synthetase are capable of suppressing 
thromboxane production selectively.246 The main mechanism of action of 
thromboxane synthetase inhibitors, however, is thought to reside in the diversion 
of the metabolism of endoperoxides formed in platelets to give rise to PGD2,PGE2 
and PGF2ff in much larger amounts than would normally be formed.247,248 
Inhibition of platelet behaviour is consequently achieved by stimulation of 
adenylate cyclase by PGD2.247,249 Furthermore, there is evidence that when 
thromboxane synthetase is blocked, PGG2 and PGH2 can be utilised by 
endothelium resulting in enhanced prostacyclin synthesis.250 Despite such 
potentially favourable pharmacological effects, thromboxane synthetase inhibitors 
have given disappointing clinical results.251 One explanation for this may lie in the 
fact that incubation of platelets in vitro with thromboxane synthetase inhibitors 
fails to result in inhibition of platelet aggregation in some individuals.247'249,252 
These individuals have been referred to as non responders and have been shown 
to have platelets which are more sensitive to the pro-aggregatory effects of 
endoperoxides and PGE2.253,254 Moreover, platelets from non responders produce 
less cyclic AMP in the presence of thromboxane synthetase inhibitors and in 
response to PGD2.249,253,254 Poor clinical results with thromboxane synthetase 
inhibitors may also result from their short duration of action.251
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More recently, thromboxane/endoperoxide receptor blockers have been 
developed which also offer the potential advantage over aspirin of specifically 
targeting thromboxane mediated platelet responses, whilst sparing PGI2 
production.251'255,25®’257 These drugs have as yet to be proven superior to aspirin 
in clinical trials in thrombotic disease. There are good theoretical grounds for 
believing that the best method of manipulating the platelet arachidonic acid- 
thromboxane pathway would be the combined use of a thromboxane receptor 
blocker and a thromboxane synthetase inhibitor.257 The receptor blocker would 
overcome the problem of remaining pro-aggregatory activity of endoperoxides with 
thromboxane synthetase inhibitors and the combination would offer the potential 
advantage of enhanced inhibitory prostanoid availability which would not be 
provided by the use of a thromboxane receptor blocker alone.257,258
All of the pharmacological methods of manipulating the platelet 
thromboxane pathway, however, have the drawback that pathways of platelet 
activation which are not thromboxane dependent are unaffected and are able to 
remain active to promote thrombus formation. The use of drugs which increase 
the level of cyclic AMP in platelets can overcome this problem, as cyclic AMP 
renders platelets more resistant to activation by all agonists. Cyclic AMP can be 
increased by the use of an adenylate cyclase stimulator or a phosphodiesterase 
inhibitor.166,192 Prostacyclin itself has been used in some clinical conditions 
associated with platelet activation, and although efficacy was demonstrated in 
Raynaud's phenomenon,259 peripheral arterial disease,260 and cardiopulmonary 
bypass,261 its use was limited by its instability, and a high incidence of adverse 
effects such as flushing and hypotension.262 Furthermore, rebound platelet 
hyperactivity has been described both during infusions and when the drug was 
discontinued.263,264 Stable prostacyclin analogues which can be administered either
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orally or by infusion are currently being evaluated. Phosphodiesterase inhibitors 
inhibit platelet behaviour at lower levels of cyclic AMP than adenylate cyclase 
stimulators44,211,212 and have the potential of synergising with endogenous 
adenylate cyclase stimulators such as prostacyclin.166,192 The existence of 
phosphodiesterase subtypes which are to some extent tissue specific also makes 
this class of drugs an attractive option in antithrombotic therapy.209,210 No 
phosphodiesterase inhibitors with specific effects on platelet cyclic AMP are 
available for clinical use to date. Dipyridamole, which has been used 
therapeutically as an antiplatelet agent for many years, has been shown to have 
activity as a phosphodiesterase inhibitor.265 It is more likely, however, that its main 
antiplatelet effects reside in its ability to inhibit adenosine uptake into cells such 
as red cells and vascular tissue.265 Adenosine therefore becomes more available 
to act on surface platelet receptors linked to stimulation of adenylate cyclase. 
Clinical trials, however, have shown that dipyridamole alone has little efficacy as 
an antithrombotic agent.236,265
Several new approaches to manipulating platelet behaviour, aimed at 
treatment of disease in which platelet activation plays a role, have been developed 
recently and are undergoing evaluation. Specific monoclonal antibodies directed 
at the fibrinogen binding site on glycoprotein llb/llla have become available266 
which offer the possibility of blocking "the final common pathway" of platelet 
aggregation.267 These agents appear to be promising but require more extensive 
clinical evaluation. Potential problems include allergic reactions and bleeding. 
Synthetic peptide analogues containing an 'RGD' (arginine-glycine-asparagine) 
sequence which is found in many adhesion proteins268 have been synthesised. 
These are also capable of competing with fibrinogen for binding to platelets by 
attaching to the appropriate site on glycoprotein llb/llla.269 Ticlopidine is an
55
antiplatelet drug which inhibits platelet aggregation induced by a wide range of 
agonists, probably by impairing fibrinogen binding to platelets.270 Although adverse 
effects such as neutropenia, diarrhoea and skin rashes may limit its use, it has 
recently been shown to compare favourably with aspirin in a large double blind 
randomised trial in ischaemic stroke.271 Finally a thrombin inhibitor, recombinant 
hirudin, has become available which offers the possibility of combined antiplatelet 
and anticoagulant action.272,273 Until these newer agents have undergone extensive 
clinical trials it is likely that aspirin will remain the cornerstone of antiplatelet 
therapy in clinical practice, and any novel antithrombotic treatment should be 
shown to compare favourably with aspirin before being adopted for therapeutic 
use.
6.PLATELET BEHAVIOUR IN NORMAL PREGNANCY.
6.1 General Aspects of Haemostasis During Pregnancy.
The physiological hypercoagulable state which occurs during normal 
pregnancy consists of changes in both platelets and coagulation factors. 
Documented changes in the coagulation system include an increase in factors VII, 
VIII, IX, X and a particularly marked increase in plasma fibrinogen.1,4,6,274 Others 
have noted an increase in high molecular weight fibrin/fibrinogen complexes in 
plasma,275 and some, but not all, investigators have reported a rise in levels of 
fibrinopeptide A ,276 indicating thrombin cleavage of fibrinogen. Deposits of fibrin 
are found in normal placentae, indicating local activation of the coagulation system 
during pregnancy.3
Complex changes in fibrinolysis also occur, including a reduction in plasma 
plasminogen activator activity,277 and an increase in plasminogen activator inhibitor 
(PAD activity, with the appearance of a novel PAI, named PAI ||277'278. The overall
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result is a reduction in fibrinolysis.277 Despite this, FDP and D dimer have been 
shown to be elevated, presumably reflecting activation of coagulation, fibrin 
deposition, and subsequent catabolism.276,277 Studies have given rise to varied 
findings regarding the naturally occurring inhibitors of coagulation in normal 
pregnancy, particularly with regard to antithrombin III. Some authors have reported 
a slight reduction in antithrombin III during normal pregnancy,274 whilst others have 
reported no change.279 Most authors agree, however that levels of Protein S fall 
during pregnancy.280
All of these changes favour a pro-coagulant state, and there is strong 
evidence that platelets also make an important contribution to the physiological 
hypercoagulability of pregnancy. There is evidence of platelet activation in vivo 
during healthy pregnancy and increased platelet reactivity in vitro has also been 
documented. The changes in platelet behaviour which have been described in 
normal pregnancy will now be reviewed in detail.
6.2 Evidence of Platelet Activation in Vivo in Pregnancy.
Evidence of platelet activation in vivo during pregnancy comes from studies 
of platelet indices in peripheral blood, measurement of platelet secretory products 
in plasma, and studies of prostaglandin metabolites in urine.
Platelet Indices in Peripheral Blood in Pregnancy
Since the widespread introduction of multi-parameter automated electronic 
counters in haematology laboratories there have been several studies investigating 
platelet count and indices of platelet size during pregnancy. Some studies have 
reported a reduction in platelet count in late pregnancy281,282,283, whilst others have 
not confirmed this.284,285,288,287 Criteria for patient selection have varied and it was 
not made clear by some authors whether all subjects with complications of 
pregnancy which may lead to a reduction in platelet count had been excluded. The
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authors of one longitudinal study point out that there is a great deal of variation 
between individual patients in the direction of change in their platelet count during 
healthy pregnancy.288 From all of the available evidence it seems reasonable to 
conclude that overall no substantial change in platelet count occurs in normal 
pregnancy.
Reports of changes in mean platelet volume (MPV) and platelet distribution 
width (PDW) during pregnancy are more consistent. Most report an increase in 
both of these indices, indicating the presence of a population of larger platelets in 
the circulation of pregnant women.281286,287 Increases in indices of platelet size 
occur in conditions in which there is peripheral platelet consumption or 
destruction,289 but there is some debate as to whether this is simply because of 
an increase in the proportion of 'young' platelets circulating290 or whether platelet 
size is determined by changes in the pattern of platelet production from 
megakaryocytes.289 Irrespective of the mechanism, the increase in MPV and PDW 
associated with normal pregnancy supports the occurrence of peripheral platelet 
consumption, which could result from platelet activation in the circulation and the 
formation of platelet microthrombi. In normal pregnancy, platelet consumption is 
compensated by increased platelet production by megakaryocytes, resulting in no 
significant change in the peripheral blood platelet count.
Platelet Lifespan
In the light of the above evidence a reduction in platelet lifespan would be 
expected during pregnancy. As radiolabelled platelets cannot be used during 
pregnancy to study platelet lifespan, this has been investigated by following the 
recovery of platelet malondialdehyde production following the administration of a 
single dose of aspirin. Malondialdehyde is formed as a byproduct during 
thromboxane synthesis from cyclic endoperoxides.35 When platelet
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cyclooxygenase is irreversibly inhibited by aspirin, no endoperoxides are available 
for malondialdehyde synthesis until a new population of platelets enter the 
circulation. The recovery of platelet malondialdehyde synthesis is therefore a 
reflection of platelet lifespan. Such studies of platelet lifespan have, however, 
revealed only small non significant reductions during pregnancy.291,292 It is possible 
that the administration of even a single dose of aspirin, by inhibiting platelet 
activation, prolongs platelet lifespan and therefore masks any pregnancy 
associated reduction which may be evident if it were possible to make 
measurements by another method.
Beta-thromboolobulin and Platelet Factor 4
A number of studies have shown higher plasma levels of the platelet alpha 
granule protein ^-thromboglobulin 0?~TG) in third trimester pregnant women 
compared with non pregnant controls.292,293,294,295 This supports the occurrence 
of platelet activation in vivo during the later stages of pregnancy. Interestingly, 
Douglas et al showed, in a study measuring platelet release products and 
fibrinopeptide A, that the increased levels of fi-TG  in pregnancy were not 
associated with increased thrombin generation.293 This implies that the platelet 
activation which occurs in vivo in pregnancy is not thrombin dependent. 0-TG  is 
cleared from plasma by the kidney, therefore alterations in plasma levels can occur 
as a result of changes in renal function.290 Reduced clearance, however, could not 
explain the findings in pregnancy as the glomerular filtration rate increases in 
pregnant women.297 Furthermore, a study measuring both £-thromboglobulin and 
platelet factor 4, an alpha granule protein whose rapid clearance from plasma is 
by binding to endothelium rather than by renal excretion,290 showed that the level 
of both proteins increased in parallel in plasma in third trimester healthy pregnant 
subjects.294
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6 .3  Prostaglandin Biosynthesis and Platelet Activation in Vivo Purina
Pregnancy.
Reproductive tissues synthesise a variety of prostaglandins and this 
increases during pregnancy.298'289 The placenta is a major site for prostaglandin 
synthesis during pregnancy. In vitro, placental tissues are capable of generating 
PGE2, PGD2, PGFj,, and probably thromboxane a 2,298'299'300 but prostacyclin is the 
major placental eicosanoid product.298 Many studies have shown that 
prostaglandin biosynthesis in vivo is increased in pregnant compared with non 
pregnant women. Historically, increased PGE2 and PGF^ formation were first to 
be described.298 The exact physiological role of these prostanoids in pregnancy is 
not known, but it has been reported that PGE2, whilst itself capable of constricting 
human umbilical vessels,301 blunts the vasoconstrictor effects of angiotensin II on 
isolated umbilical arteries.302 It is also thought that PGE2 and PGF^ play a role in 
induction of labour.298,303,304 As described in the previous section, PGE2 can either 
activate or inhibit platelets87,88,89,90 and the relationship of the changes in PGE2 
biosynthesis to platelet activation in vivo during pregnancy has not been studied. 
Prostacyclin and thromboxane biosynthesis have subsequently also been shown 
to increase during healthy pregnancy.298 Plasma levels of derivatives of these 
prostaglandins have been shown by some298-305.3oe,307 not a||3oo,308 stu(jjes to
be elevated. More significantly, studies measuring urinary metabolites of 
thromboxane and prostacyclin, which give a more reliable indication of in vivo 
synthesis, have confirmed increased production of both PGI2 and TXA2 during 
pregnancy.180,309,310 Excretion of the prostacyclin metabolite 2,3-dinor-6-keto-PGF1# 
increases 6-10 fold in normal pregnancy.298,310 Increased prostacyclin synthesis is 
present during the first trimester and persists throughout gestation.100 There is
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some evidence that the placenta is the main source of this increased prostacyclin 
production.298
Urinary excretion of the thromboxane metabolites 2,3-dinor-thromboxane 
B2 and 11 -dehydro-thromboxane B2 rise markedly earlier than 20 weeks gestation 
in healthy pregnancy and remain elevated throughout the gestational period.309 
There is good evidence that platelets are the source of increased thromboxane 
biosynthesis in pregnancy. Following treatment of pregnant subjects with doses 
of aspirin sufficient to cause 97%  inhibition of platelet thromboxane production 
ex vivo, whilst preserving cyclooxygenase dependent prostaglandin synthesis by 
other tissues, Fitzgerald showed that urinary 2,3,dinor-thromboxane B2 was 
almost completely suppressed and its recovery parallelled the recovery of platelet 
thromboxane B2 production.309
The physiological significance of alterations in thromboxane and 
prostacyclin biosynthesis during pregnancy relate to control of both vascular 
reactivity, particularly in the placental circulation, and platelet reactivity. 
Prostacyclin seems likely to have an important role in lowering resistance in the 
placental vascular bed.311 Furthermore, increased prostacyclin production may be 
the mechanism which leads to a reduced systemic pressor response to infused 
angiotensin II which is observed during healthy pregnancy.312,313 There is evidence 
of the presence of thromboxane receptors in the placental vasculature314 and 
endoperoxide analogues have been shown to constrict human umbilical arteries315 
and increase resistance in isolated perfused human cotyledon.316 
In relation to platelets, the increase in urinary thromboxane metabolites in 
pregnancy is of significance firstly as a further marker of in vivo platelet activation 
during pregnancy, and secondly because increased biosynthesis of thromboxane 
may itself promote platelet activation. It cannot be determined from these in vivo
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studies whether there are primary alterations in the platelet biosynthetic pathway 
for thromboxane which give rise to the increase in urinary thromboxane 
metabolites during pregnancy.
The changes in prostaglandin biosynthesis which have been described raise 
the question of why increased platelet activation in vivo occurs during normal 
pregnancy in the presence of increased prostacyclin production. Even if the 
increase in prostacyclin formation is insufficient to exert a systemic anti platelet 
effect, this is unlikely to explain the apparent lack of efficacy on in vivo platelet 
reactivity during pregnancy as the placenta has been proposed as an important site 
of platelet activation and intravascular coagulation in pregnant women3,5 and is 
also the main source of prostacyclin formation. Intrinsic alterations in platelet 
reactivity during pregnancy, including altered responses to the prostaglandins 
which regulate their behaviour could theoretically provide an explanation for the 
observations.
6.4 Studies of Platelet Behaviour In Vitro.
In vitro studies of platelet behaviour during pregnancy support the 
hypothesis that platelets from pregnant women are intrinsically more active 
compared with those from non pregnant females. The literature on platelet 
behaviour in vitro during pregnancy includes studies of a wide variety of aspects 
of platelet behaviour and platelet second messengers. Each will be reviewed in 
turn.
Studies on Platelet Aggregation in Platelet Rich Plasma
There are many published studies on platelet aggregation in platelet rich 
plasma (PRP) during pregnancy. These have given rise to varied results, probably 
because of differences in experimental technique, the choice of parameter 
analyzed, the type and concentration of agonists employed and the patients
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selected. One early study reported no change in platelet aggregation patterns in 
PRP317 and two studies have reported reduced platelet aggregation responses 
associated with pregnancy.318,319 Studies investigating minimum threshold 
concentrations of agonists required to induce a full aggregation response have, 
however, generally shown increased platelet reactivity during pregnancy. A 
number of investigators have shown that the minimum concentration of ADP 
required to induce irreversible aggregation in PRP is reduced in the third trimester 
of pregnancy.295,320,305 One early study also showed that secondary aggregation 
was observed more frequently in response to low concentrations of adrenaline in 
PRP from pregnant subjects compared with non pregnant controls.320
Two published studies provide evidence of increased platelet reactivity in 
PRP in response to arachidonic acid (AA) in healthy pregnant women. The first 
was a cross-sectional study, which compared healthy mothers at delivery with 
their neonates and with non pregnant female controls321 and the second was a 
longitudinal study which showed that platelets were more sensitive to AA from 
16 weeks gestation in normal pregnancy.322 Platelet behaviour returned to a 
pattern similar to that of non pregnant controls by the sixth postnatal week.
The influence of factors such as changes in haematocrit and plasma 
albumin must be taken into account when interpreting platelet aggregation 
responses during pregnancy. One study showed that when the citrate 
concentration in PRP was adjusted for haematocrit, enhanced responsiveness of 
platelets to adrenaline, which had been demonstrated in standard citrated PRP 
from pregnant subjects, was no longer evident.323 Other studies have shown no 
correlation between haematocrit and platelet aggregation parameters.322 As AA 
binds to albumin, reductions in plasma albumin during pregnancy324 could result 
in an increase in free AA being available for platelet activation. Studies showing
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changes in AA induced platelet aggregation responses have, however, shown no 
correlation with plasma albumin levels.321,322 
Platelet Aggregation In Whole Blood
All of the studies described so far have investigated platelet aggregation in 
PRP. Some investigators have extended the observations on platelet behaviour 
during pregnancy to the investigation of platelet responses in whole blood.
One of the first published studies of platelet aggregation in whole blood 
investigated spontaneous aggregation and the effect of different anticoagulants 
in vitro.325 The study was longitudinal in design and used a platelet counting 
technique.Spontaneous platelet aggregation (SPA) in whole blood anticoagulated 
with heparin was increased from 16 weeks gestation, and increased further as 
pregnancy progressed. The increase in SPA, although still significant, was less 
marked in citrated blood. Heparin did not have the effect of increasing SPA in 
blood from non pregnant controls. In addition to providing information on platelet 
reactivity during pregnancy, this study also defined the importance of effects of 
different anticoagulants and concluded that heparin would not be a suitable 
anticoagulant for studies of platelet behaviour during pregnancy. The implications 
of these observations for the use of heparin therapeutically in the treatment of 
thromboembolic disease during pregnancy are not clear, but this would be worthy 
of further investigation.
Agonist induced platelet aggregation in whole blood has been measured 
during pregnancy by the electrical impedance method, showing increased platelet 
aggregation in response to ADP, collagen and AA.326 A longitudinal study in 
normal pregnancy of platelet reactivity in whole blood, employing the single 
platelet counting technique, has been published by Louden et al.327 Increased 
platelet aggregation in response to 0.2m M arachidonic acid was noted from 16
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weeks gestation onwards, and platelets were more responsive to 1 uM adrenaline 
from 28 weeks gestation. Six weeks following delivery, there was no statistically 
significant difference in platelet behaviour compared with the preconceptional 
parameters, but the extent of platelet aggregation in response to AA and 
adrenaline had not fully returned to baseline values.
Platelet Release Reaction
There are less data available on the platelet release reaction in vitro during 
pregnancy than on platelet aggregation. Nevertheless, some studies have 
investigated dense granule release and the results generally reflect the increased 
platelet reactivity observed in platelet aggregation experiments. In one study, 
platelets from pregnant women underwent a release reaction in response to lower 
concentrations of AA than those from non pregnant controls, but the extent of the 
release reaction did not differ between groups of subjects.322 Studies conducted 
in whole blood, however,showed increased 14C-5HT release in response to 
adrenaline from 28 weeks gestation onwards, reflecting the increased platelet 
aggregation observed with this agonist.327
General Patterns of Platelet Reactivity Purina Preanancv as Assessed bv Platelet 
Aggregation and Release Experiments
Evidence has been presented from studies conducted in PRP and in whole 
blood of increased platelet reactivity during pregnancy. Longitudinal studies 
suggest that at least some of the changes in platelet reactivity are detectable early 
in the second trimester and persist throughout pregnancy, reverting to the non 
pregnant pattern between 6 and 12 weeks postnatally.
In general, pregnancy related alterations in platelet behaviour are most evident 
when agonists are chosen which have a thromboxane dependent component in 
their mechanism of action, for example arachidonic acid,321,322,327 adrenaline,320,327
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and the secondary phase of aggregation in response to ADP.295'305,320 Furthermore 
in studies conducted in whole blood, cyclooxygenase inhibition by the 
administration of low dose aspirin to healthy pregnant women inhibited platelet 
behaviour ex vivo in response to arachidonic acid and adrenaline at times during 
the gestational period when increased platelet reactivity to these agents was 
demonstrable in a group of healthy pregnant women who were randomised to 
receive placebo.328 This provides further evidence that thromboxane A2 has a role 
in the increased platelet reactivity observed during pregnancy. It cannot be 
determined from simple studies of platelet aggregation and release whether this 
is due to increased synthesis of thromboxane by platelets or increased sensitivity 
of platelets to thromboxane. The data already discussed relating to thromboxane 
production in vivo309 suggest that in this situation platelet thromboxane production 
is increased, but this does not provide information about the intrinsic reactivity of 
the platelet thromboxane pathway, and studies of platelet thromboxane production 
in vitro have yielded conflicting results.
Platelet Thromboxane Production.
Published studies have measured serum levels of thromboxane B2 (TXB2), 
the stable hydrolysis product of thromboxane A2. This reflects platelet 
thromboxane production under conditions of spontaneous clotting of whole blood 
in vitro. A cross sectional study comparing pregnant women at various gestations 
with non pregnant and puerperal women showed significantly higher serum TXB2 
in pregnant women, regardless of gestation, and in puerperal women than in 
controls.329 A longitudinal study from the same centre did not confirm increased 
serum TXB2 during pregnancy,292 but, as subjects were not studied prior to 
conception, this may have been missed if changes in platelet thromboxane 
production occur early in the gestational period and take some time to return to
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pre-pregnancy levels in the puerperium. A subsequent longitudinal study which 
included preconceptional women, however, has also failed to confirm changes in 
serum TXB2 during healthy pregnancy.327 The question of the contribution of the 
absolute amount of thromboxane synthesis by platelets to increased platelet 
reactivity during pregnancy remains unresolved and the possibility of altered 
platelet sensitivity to thromboxane should not be discounted.
Platelet Sensitivity To Aoents Which Inhibit Their Behaviour
There have been some reports of a reduction in platelet sensitivity to 
inhibition of aggregation by prostacyclin and its stable analogues in vitro during 
pregnancy.330,331 332
Outwith the context of pregnancy, it has been shown that incubation of 
PRP in vitro with thromboxane synthetase inhibitors (TSIs) leads to inhibition of 
platelet behaviour in some individuals ('responders') but not in others ('non- 
responders').249,251*254 One study has shown that the majority of healthy pregnant 
women are non responders to thromboxane synthetase inhibitors, whilst most non 
pregnant women in the child bearing age group are responders.322 This is of 
interest since inhibition of platelet behaviour by thromboxane synthetase inhibitors 
is mediated by PGD2 produced from cyclic endoperoxides by a diversion pathway 
operating when thromboxane synthetase is blocked.247,248 Although acting on 
distinct surface receptors on the platelet membrane, prostacyclin and PGD2 both 
exert their inhibitory effects on platelets via an increase in cyclic AMP. These data 
raise the possibility of a defect in cyclic AMP dependent inhibitory pathways in 
platelets during pregnancy.
6.5 Platelet Second Messenger Systems In Pregnancy.
In recent years investigators have studied platelet second messenger 
systems during pregnancy in an attempt to elucidate the mechanisms underlying
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the observed changes in platelet behaviour. Attention has been mainly directed at 
intracellular free calcium [Ca2+]j. The first study investigating platelet [Ca2+]j during 
pregnancy showed no change in either basal [Ca2+]j or in transient increases in 
[Ca2*]j upon platelet stimulation with ADP or 5-HT, when third trimester healthy 
pregnant women were compared with non pregnant women.333 A subsequent 
publication reported a "slight increase" in basal [Ca2'f ]j in platelets from pregnant 
women, with no difference in stimulated platelet [Ca2+]j in response to thrombin 
and angiotensin II when compared with platelets from non pregnant women.334 
Both of these studies, employed the calcium sensitive indicator quin-2, which is 
known to significantly quench increases in platelet [Ca2+lj resulting from platelet 
stimulation.109 110,335 Furthermore, the method used to prepare washed platelets in 
the first study may have led to significant loss of the most active platelets.
The calcium sensitive fluorophore fura-2 has the advantage of weaker calcium 
chelating properties than quin-2.335 A more recent study using fura-2 to measure 
intracellular free calcium has shown a significant increase in platelet basal [Ca2+lj 
in the third trimester of pregnancy in comparison with data from non pregnant 
female volunteers.336 This has subsequently been borne out by a prospective 
longitudinal study by the same authors which confirmed a significant increase in 
basal [Ca2+]j in platelets by the 28th week of pregnancy, which returned to 
baseline by 6 weeks postpartum.337 These data are extremely interesting and may 
throw some light on the mechanism of increased platelet reactivity observed 
during pregnancy. One could speculate, for example, that platelets which have 
elevated basal intracellular free calcium require a lesser rise of [Ca2+]j upon 
stimulation by an agonist in order to reach a certain threshold required for a 
response such as aggregation or release. It is also noteworthy in this respect that 
phospholipase A2, the enzyme involved in mobilising arachidonic acid from the
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platelet membrane for thromboxane A2 synthesis, is highly calcium dependent.74,117 
Some questions regarding the role of intracellular free calcium in platelet activation 
during pregnancy, however, remain unresolved. The significance of basal [Ca2+lj 
in determining patterns of platelet behaviour is largely ill defined; studies outwith 
the context of pregnancy have shown poor correlations between basal ICa2**']i and 
platelet reactivity.338 It is also quite possible that the increased platelet basal 
[Ca2*]; in vitro reflects a degree of platelet activation in vivo, and is not a direct 
mediator of the increased platelet reactivity observed during pregnancy. 
Nevertheless, the study of platelet intracellular free calcium may make a significant 
contribution to knowledge in the area of platelet behaviour in pregnancy, and 
further studies on the role of [Ca2*]i, particularly if including parallel measurements 
of platelet behaviour and examining stimulated [Ca2+Jit would be useful.
There have been few studies of the inhibitory second messengers in 
platelets during pregnancy. Two studies have investigated platelet cyclic AMP 
levels in pregnancy. Goser et al in 1980 showed no change in basal platelet cyclic 
AMP over the gestational period, except in association with the use of beta 
agonists to suppress labour.339 Long-term use of such agents resulted in a 
reduction in basal platelet cyclic AMP levels. Stimulated cyclic AMP levels were 
not measured in this study, and a radioimmunoassay was employed, which is less 
sensitive than some other established methods of measuring platelet cyclic AMP. 
A later investigation of platelet cyclic AMP during pregnancy, which employed a 
more sensitive assay and examined basal and PGE1 stimulated platelet cyclic AMP 
levels, also demonstrated no change in platelets from pregnant women compared 
with those from non pregnant controls.323 This study, however, included only 5 
pregnant subjects all of whom were near term.
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7 .THE ROLE OF PLATELETS IN PRE-ECLAMPSIA
7.1 Classification of Hypertension in Pregnancy and Definition of Pre- 
eclampsia.
Pre-eclampsia is a complication of pregnancy characterised by 
hypertension, proteinuria, and oedema. The syndrome occurs most frequently in 
primigravidae, and is associated with significant maternal and fetal morbidity and 
mortality. Before reviewing the literature on platelet behaviour in pre-eclampsia, 
it is appropriate to consider the definition of pre-eclampsia and pregnancy induced 
hypertension in relation to the classification of the hypertensive disorders of 
pregnancy and also to describe the clinical, epidemiological, and 
pathophysiological features of pre-eclampsia.
Research and clinical practice in the hypertensive disorders of pregnancy 
has been complicated by the use of different classifications and diagnostic criteria 
by different clinicians and investigators. In 1986 Davey and McGillivray proposed 
the following classification,340 which has been adopted by the International Society 
for the Study of Hypertension in Pregnancy:
Chronic Hypertension: Hypertension occurring in pregnancy in a woman 
with pre-existing hypertension. This situation may arise in essential 
hypertension, in chronic renal disease or in other less common forms of 
secondary hypertension.
Pregnancy Induced Hypertension: Hypertension developing during 
pregnancy and resolving following delivery in a woman previously known 
to be normotensive.
Pre-eclampsia: The combination of pregnancy induced hypertension and 
significant proteinuria
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Eclampsia: Generalized tonic/clonic seizures usually but not necessarily 
occurring in a woman with previous pre-eclampsia in the absence of any 
other neurological explanation for the seizures.
As this thesis is concerned with the role of platelets in pregnancy induced 
hypertension (PIH) and pre-eclampsia, rather than chronic hypertension all 
subsequent discussion refers to those hypertensive disorders developing during 
pregnancy.
The definition of the hypertensive disorders specific to pregnancy follows 
on from the above classification. Again, varying criteria for the definition of raised 
blood pressure and significant proteinuria have often been used. The definition of 
pregnancy induced hypertension recommended by the American College of 
Obstetricians and Gynaecologists will be used for the purposes of this thesis.341 
PIH is defined as being present when a systolic blood pressure of greater than 
140 mmHg or a diastolic blood pressure of greater than 90 mmHg, using Korotkov 
phase IV, is recorded after the 20th week of pregnancy, or if there is a rise of 
greater than 30 mmHg in systolic or greater than 15mmHg in diastolic pressure, 
compared with the blood pressure recordings in the first trimester of pregnancy. 
Blood pressure recordings should be confirmed by two readings at least 6 hours 
apart. The advantage of this definition is that it allows a rise in pressure to be 
taken into account rather than solely relying on an arbitrary blood pressure level 
to be reached.
A widely accepted definition of pre-eclampsia is the fulfilment of the above 
blood pressure criteria together with the excretion of >  0.3g of protein in the 
urine in a 24 hour period.340 As otherwise healthy pregnant women may 
occasionally demonstrate proteinuria in excess of 0.3g per 24 hours, others have 
considered the use of 0.5g proteinuria in 24 hours as a more suitable threshold for
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the definition of significant proteinuria and therefore for the definition of pre­
eclampsia.342,343 The latter has been used for the purposes of this thesis. Pre­
eclampsia may follow on from PIH, but patients may also present de novo with 
proteinuric hypertension.
Although these definitions are somewhat arbitrary it has been shown that 
there is an increased risk to the fetus when the maternal diastolic pressure rises 
above dOmmHg344 and to both mother and fetus when significant proteinuria 
develops.345,348
7.2 Clinical Features of PIH and Pre-eclampsia.
Pregnancy induced hypertension uncomplicated by proteinuria is usually 
asymptomatic, and the raised blood pressure is often the only clinical abnormality. 
The main significance of pregnancy induced hypertension is as a precursor of pre­
eclampsia.347 Furthermore, there is an increased incidence of placental abruption 
in PIH 346>348>349
Pre-eclampsia may also be asymptomatic, but is often accompanied by 
clinical features other than hypertension and proteinuria. Oedema is classically 
listed as one of the clinical signs of pre-eclampsia, but simple dependent oedema 
is so common in healthy pregnancy that this sign is of no discriminatory value.350 
Facial oedema, which usually does not occur in normal pregnancy, however, may 
occur in pre-eclampsia.350 A raised serum urate is a common feature of pre­
eclampsia, and occurs as a result of reduced renal clearance.351 A raised urate is 
useful both diagnostically and prognostically, being associated with a greater 
perinatal mortality for any given level of blood pressure.352 A modest fall in 
platelet count is an early feature of pre-eclampsia,353 but the development of 
clinically significant thrombocytopenia indicates a severe form of the condition. In 
such cases activation of the coagulation cascade and disseminated intravascular
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coagulation may occur.354 In severe pre-eclampsia, hepatic congestion giving rise 
to epigastric pain may occur. This is usually associated with raised hepatic 
transaminases, and is a sign of impending eclampsia.350 A variant of pre­
eclampsia, in which microangiopathic haemolysis, elevated liver enzymes, and low 
platelets are the predominant features has been described and referred to as the 
HELLP syndrome.355 This syndrome carries a particularly bad prognosis for mother 
and fetus. Other less common clinical features which may occur in severe pre­
eclampsia are uraemia,348 pulmonary oedema,358 cerebral haemorrhage348,357,358 and 
even transient blindness.359 The ultimate maternal complication of pre-eclampsia 
is the occurrence of eclamptic seizures, thought to arise as a result of cerebral 
ischaemia and cerebral oedema.358 Vasospasm may make a contribution to the 
cerebral ischaemia of eclampsia.358,380
7 .3  M anagem ent and Prognosis of Pre-eclampsia.
By definition, the clinical features of pre-eclampsia and eclampsia resolve 
after delivery of the fetus, and delivery therefore remains the most effective 
treatment of pre-eclampsia.348 The timing of delivery must be optimised to 
minimise risks to both mother and fetus. Clearly in some cases delivery must be 
undertaken in the maternal interest when the fetus is still immature and therefore 
at risk of all the complications of prematurity in the neonatal period. Unfortunately 
as the primary cause of pre-eclampsia remains unknown little effective medical 
treatment is available and the mainstay of medical management is supportive. 
Such supportive measures include the administration of drugs to lower blood 
pressure, for example hydralazine,348,381 the prevention of seizures using either 
phenytoin343,348 or magnesium sulphate,382 optimal intravenous hydration,383,384 and 
the correction of coagulation abnormalities using fresh frozen plasma and
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occasionally cryoprecipitate and platelet transfusions in the presence of bleeding 
due to disseminated intravascular coagulation or thrombocytopenia.385
In uncomplicated PIH and in mild pre-eclampsia, a double blind placebo 
controlled trial conducted by Rubin et al showed that the administration of the 
beta blocker atenolol lowered maternal blood pressure, reduced hospital 
admissions, reduced the development of proteinuria in those with uncomplicated 
PIH, and was not associated with any adverse effects on the fetus.342 There was 
also a reduction in the incidence of neonatal respiratory distress syndrome, but 
larger trials would be required to demonstrate any difference in perinatal mortality 
in atenolol versus placebo treated pregnancies. Agents such as atenolol are 
particularly useful in cases of PIH and mild pre-eclampsia when the fetus is 
relatively immature and risks to the neonate may be improved by prolonging the 
pregnancy.
Small clinical trials have suggested a possible beneficial effect of aspirin in 
the prophylaxis of pre-eclampsia in those at risk,388,387,388'389 and larger multicentre 
studies are currently in progress to attempt to determine definitively whether 
aspirin is useful in the prevention or treatment of pre-eclampsia.
PIH has been reported to be associated with increased fetal death when the 
maternal diastolic blood pressure is above SOmmHg,344 but other large studies 
have disagreed, suggesting that perinatal mortality is unaffected by non proteinuric 
PIH.370 Maternal prognosis is not altered by uncomplicated PIH. Predictably, pre­
eclampsia carries a higher perinatal mortality than pm345'348*370 and a worse 
prognosis for the mother. Pre-eclampsia and eclampsia are still amongst the most 
common causes of maternal death. In the U.K., pre-eclampsia and eclampsia 
accounted for 12.1 deaths/million pregnancies in the period from 1985-1987.371 
The perinatal death rate was reported as 33 .7 /1000  in pregnancies complicated
74
by pre-eclampsia and eclampsia in the British Births Survey of 1970.370 Intrauterine 
fetal growth retardation and the need for premature delivery in the maternal 
interest contribute both to fetal mortality and morbidity.345,372
7 .4  Epidemiology of Pre-eclampsia.
Early studies by MacGillivray in Aberdeen suggested that pre-eclampsia was 
more common in primigravidae.347,373 In this series, 24%  of nulliparae developed 
PIH and 5.5%  developed proteinuric pre-eclampsia, compared with figures of 10- 
12% and 1 % respectively for multiparae. This was confirmed in the DHSS Report 
on Inpatient Inquiry for England and Wales (1973-1976).374 Furthermore, the 
incidence of renal biopsy lesions characteristic of pre-eclampsia, has been shown 
to be greater in primigravidae with hypertension and proteinuria than in 
multiparae.375 For this reason it has been considered that studies relating to pre­
eclampsia which include primigravid women only are less likely to have 
inadvertently selected women with other pathology. Parous women with new 
partners, however, may have an increased risk of pre-eclampsia.375,377 There is also 
an increased incidence of pre-eclampsia in subsequent pregnancies in women who 
have developed pre-eclampsia or eclampsia in their first pregnancy.373
The incidence of pre-eclampsia increases with maternal age and there is a 
particular increase in maternal mortality from pre-eclampsia in women over the age 
of 35.378 Interestingly, women less than 20 also show an increased incidence of 
pre-eclampsia. There may be a relationship in this age group with lack of antenatal 
care and concealed pregnancies.375
There is now considerable evidence that pre-eclampsia is under genetic 
control, and it has been postulated that it may be an autosomal recessive 
condition with variable penetrance.378,379
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There has been some controversy as to whether race influences the 
incidence of pre-eclampsia. Carefully conducted studies in the USA have shown 
that the incidence of pre-eclampsia is similar in Caucasian and in black 
Americans.376 There is some evidence, however, that pre-eclampsia is more 
common in Indian women than in women from other racial groups.380
Other maternal factors which have been associated with pre-eclampsia 
include underlying essential hypertension and diabetes.343,376 In both conditions it 
is difficult to separate out cases of hypertension complicated by renal disease from 
true pre-eclampsia.
Some fetal factors have been associated with an increased risk of pre­
eclampsia. These include conditions associated with hyperplacentosis such as twin 
pregnancy, fetal hydrops, and fetal triploidy.343,376,381 The presence of a fetus is 
not a pre-requisite for the occurrence of pre-eclampsia, as the condition has an 
association with hydatidiform mole.381 Molar pregnancy should be suspected in 
any patient presenting with clinical signs of pre-eclampsia before 24 weeks 
gestation.350
7.5 Pathophysiological Mechanisms in Pre-eclampsia.
Despite much research having been directed at the subject, the primary 
cause of pre-eclampsia remains unknown. A substantial amount of knowledge of 
the secondary pathophysiological mechanisms involved in the condition, however, 
has been accumulated over the years, and changes in the cardiovascular system, 
kidneys, and haemostatic and endocrine systems have been well documented. 
The "gold standard” for the pathological diagnosis of pre-eclampsia is the presence 
of a characteristic lesion on renal biopsy referred to as glomerular 
endotheliosis.382,383 This lesion consists of swelling of the glomerular capillary 
endothelial cells, an increase in size and number of intercapillary cells and the
76
deposition of fibrinoid material within the cells and beneath the basement 
membrane. Immunofluorescent techniques have demonstrated that this fibrinoid 
material contains fibrinogen or its derivatives.384 Proteinuria and hyperuricaemia 
are related to these histological changes.343,352,385 Renal plasma flow and 
glomerular filtration rate are both reduced in pre-eclampsia.343,383 Although the 
renal lesion described is characteristic of pre-eclampsia, it is almost certainly a 
secondary phenomenon and there is no evidence that pre-eclampsia is primarily 
a renal disease.
Vasoconstriction and a reduction in intravascular volume contribute to the 
reduced perfusion of the kidneys and other vascular beds supplying major organs 
in pre-eclampsia, but it is uncertain whether the contracted plasma volume 
stimulates compensatory vasoconstriction or whether widespread vasoconstriction 
shuts off plasma volume expansion.386 It has been shown, however, that the 
contracted plasma volume does not, as expected, lead to stimulation of the renin- 
angiotensin system,313,343 as measured by plasma renin activity and plasma 
angiotensin II concentrations. Both of these hormones have been shown to be 
present in reduced concentrations in plasma in proteinuric PIH compared with 
healthy pregnancy.313,343 The changes in the renin-angiotensin system in pre­
eclampsia appear complex as there is some evidence of a role for renin 
synthesised locally in the uteroplacental circulation in pre-eclampsia.313 
Furthermore, it is established that women destined to develop pre-eclampsia show 
an enhanced pressor response to infused angiotensin II as early as 22 weeks 
gestation.387,388 Altered vascular responsiveness to angiotensin II could therefore 
contribute to widespread vasoconstriction and to raised blood pressure.
The combination of reduced intravascular volume and arteriolar 
vasoconstriction in pre-eclampsia is reflected in haemodynamic parameters
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measured using a Swan-Ganz catheter which have shown a reduced pre-load, 
reduced cardiac output and elevated left ventricular afterload.303 Raised blood 
pressure is consequent upon arteriolar vasoconstriction.303
Reduced uteroplacental blood flow plays a central role in the fetal 
complications of pre-eclampsia. Placental ischaemia and infarction have been well 
documented but are non specific findings.348 Furthermore in the early stages of 
placentation there is failure of invasion by the trophoblast of the myometrial 
segments of the spiral arteries.389,380 The latter therefore retain their thick muscular 
wall and fail to convert to thin walled high flow/low resistance uteroplacental 
vessels. This failure of the normal physiological processes involved in placentation 
is thought to play a key role in reducing maternal blood flow to the placenta.349
Reduced perfusion of renal, uteroplacental and other vascular beds in pre­
eclampsia is closely tied in with changes in the haemostatic system and with the 
mechanisms that control primary haemostasis. It has been documented from as 
far back as the late 19th century that eclampsia is associated with widespread 
thrombosis in the microcirculation.391 In 1953 M cKay described the presence of 
fibrin deposits in the vasculature of the placenta and the kidney in pre-eclampsia.3 
"Acute atherosis" of the arterial vessels supplying the placenta has been 
subsequently described in cases of pre-eclampsia and intrauterine growth 
retardation.392 This lesion consists of fibrinoid necrosis and accumulation of fat 
laden macrophages in the vessel wall often associated with intraluminal deposition 
of fibrin and platelets. In severe cases of pre-eclampsia consumption of 
coagulation factors and platelets may occur to such a degree that clinically overt 
disseminated intravascular coagulation may occur.354,393 Much research has 
therefore been directed towards delineating changes in the coagulation factors and 
in platelets in pre-eclampsia. The principle changes which occur in coagulation
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factors and their inhibitors consist of a reduction in the ratio of Factor VIII:C to 
von Wiilebrand Factor antigen,394 an increase in fibrin degradation products395 and 
in fibrinopeptide A levels,293 and a reduction in antithrombin III levels.2,396 There 
also appears to be a net reduction in fibrinolysis.2 Most of these changes are 
consistent with increased fibrin generation with consequent consumption of 
coagulation factors. The reduction in antithrombin III is also likely to reflect 
consumption. The primary stimulus resulting in the activation of the coagulation 
system has not been revealed by such studies.
In recent years the study of the haemostatic system in pre-eclampsia has 
focused on platelets and the mechanisms regulating primary haemostasis. There 
is good evidence of platelet consumption early in the course of the disease, often 
before clinical manifestations occur.353 This has led to the suggestion that platelets 
may play a key role in the pathophysiology of the disease. The publication of some 
small studies showing that the administration of aspirin as an antiplatelet agent 
may be useful in the prophylaxis of pre-eclampsia in those at risk has lent further 
support to this hypothesis.366'369 Finally, a further attraction of a hypothesis 
involving a central role for platelets is that changes in haemostasis could be tied 
in with some of the changes in vascular reactivity which have been described. 
Activated platelets produce substances which are powerful vasoconstrictors such 
as thromboxane A2 and 5-hydroxytryptamine. 5HT has been shown to synergise 
with angiotensin II in terms of vasoconstrictor effects.2 Studies of prostaglandin 
urinary metabolites in pre-eclampsia have revealed increased thromboxane 
production in vivo158,159 together with reduced prostacyclin synthesis.160,298,310 
Isolated placental and umbilical blood vessels from pregnancies complicated by 
pre-eclampsia have also been shown to produce reduced amounts of 
prostacyclin.397,398 Studies have also shown that placental tissues from patients
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with pre-eclampsia produce reduced vasodilatory PGE2 and increased 
vasoconstrictory PGF2ff.399 Taken together, these changes in prostaglandin 
synthesis would favour both platelet activation and vasoconstriction. The 
alterations in prostaglandins in themselves are unlikely to account for the 
widespread systemic vasoconstriction which results in raised blood pressure in 
pre-eclampsia, as circulating levels are too low to exert a generalised systemic 
effect,151,152,298 but they probably exert an important influence on vascular control 
at a local level particularly in the placental circulation,298,301,311,314,318 thus 
contributing to reduced placental blood flow. Furthermore, relative deficiency of 
prostacyclin may be responsible for the observed enhancement of vascular 
sensitivity to angiotensin II in pre-eclampsia, as it has been shown that the pressor 
effects of angiotensin II can be modulated by vasodilator prostaglandins.312,313 
Studies relating to platelet behaviour in pre-eclampsia will now be reviewed in 
detail.
7.6 Evidence of Platelet Activation in Vivo in PIH 
and Pre-eclampsia.
Platelet Count and Indices of Platelet Size.
Most authors agree that the platelet count falls in peripheral blood in pre­
eclampsia.288,353,400'404 Some have also noted a reduction in mean platelet count in 
uncomplicated p ih 400,401 in comparison with normal pregnancy, but others 
disagree.288 Redman et al353 showed that in a group of women at risk of pre­
eclampsia because of chronic hypertension, platelet count fell early in the 
evolution of the disease in women who developed "pre-eclampsia" as determined 
by a sustained rise in the serum urate level. Only 37%  of the "pre-eclamptic” 
patients had proteinuria, but raised serum urate has been shown to correlate with 
the appearance of lesions typical of pre-eclampsia on renal biopsy.343,352,385
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Despite the well documented reductions in platelet count in both pre-eclampsia 
and PIH, only 15% of those with pre-eclampsia and 6% of those with PIH develop 
thrombocytopenia as defined by a peripheral blood platelet count of less than 150 
x 109/l.400
Indices of platelet size in PIH and pre-eclampsia show an increase in MPV 
beyond that occurring in normal pregnancy.286,400'401403 Studies vary in their 
conclusions regarding PDW, some reporting an increase in PIH beyond that 
occurring in normal pregnancy,403 and others suggesting no difference in PDW in 
PIH compared with healthy pregnancy.286 On the whole, these indices suggest a 
megakaryocyte response to peripheral platelet consumption.
Platelet Lifespan
Platelet lifespan, determined by the non radioisotopic technique as 
described for the studies in normal pregnancy, has been shown to be significantly 
reduced in pre-eclampsia,291 although one longitudinal study disagreed292 and 
another investigating women with PIH, only showed a reduction in platelet lifespan 
in those who also demonstrated poor fetal growth.405 
Plasma Levels of Platelet Alpha Granule Proteins
Plasma £-thromboglobulin levels increase significantly in PIH and to a 
greater degree in pre-eclampsia, compared with healthy pregnant controls. 293,294,406‘ 
408 This implies that platelet alpha granule release, already occurring in vivo in 
normal pregnancy is further enhanced in PIH and pre-eclampsia. One study 
showed that, in contrast with normal pregnancy, this was accompanied by an 
increase in fibrinopeptide A in both PIH and pre-eclampsia, but there was no 
correlation between plasma levels of £-TG and FPA.293 This suggests that although 
significant thrombin generation occurs in vivo in hypertensive pregnancy, 
mechanisms other than thrombin mediated platelet stimulation are at least in part
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responsible for platelet activation in vivo in this condition. Changes in plasma 
platelet factor 4  appear to be less marked than for £-TG, one study showing an 
increase which just failed to reach significance in comparison with normal 
pregnancy,294 and another showing no difference between healthy and 
hypertensive groups.408 As 0-TG  but not PF4 is cleared by the kidneys,296 a 
contribution of impaired renal function to the changes in fi-JG  in pre-eclampsia 
cannot be excluded.
Very recently, a novel approach has been used to detect platelet activation 
in vivo in pre-eclampsia. Studies employing whole blood flow cytometric analysis 
in conjunction with fluorescein conjugated specific monoclonal antibodies, 
detected increased fibrinogen binding together with increased surface expression 
of a lysosomal membrane marker in resting platelets from women with pre­
eclampsia compared with those from healthy pregnant women.409 There is 
therefore considerable evidence of platelet activation in vivo in PIH and pre­
eclampsia, which occurs to a greater degree than in normal pregnancy. 
Furthermore, increased platelet production can no longer fully compensate for the 
increased peripheral platelet activation and reduced platelet lifespan, and a 
reduction in platelet count results.
7 .7  Prostaglandins and Platelet Activation in Vivo  
in Pre-eclampsia.
Further evidence of platelet activation in vivo beyond levels occurring in 
normal pregnancy comes from studies of urinary metabolites of thromboxane. 
Fitzgerald et al have shown that there is a marked increase in urinary excretion of 
2,3-dinor-thromboxane B2 and 1 1-dehydro-thromboxane B2 in pre-eclamptic 
subjects compared with healthy third trimester pregnant subjects.158 In the pre­
eclamptic subjects, urinary thromboxane metabolites fell rapidly following delivery.
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This group also carried out a prospective longitudinal study of urinary thromboxane 
metabolites in each trimester, but could not demonstrate any significant difference 
between healthy pregnant women and those who subsequently developed 
pregnancy induced hypertension.298 Another group of investigators, however, have 
claimed that urinary thromboxane metabolites are increased before the 
development of clinical signs of pre-eclampsia in pregnant women at risk of the 
disease on the basis of an enhanced pressor response to angiotensin II.159 
Fitzgerald et al have also shown a reduction in the urinary excretion of the 
prostacyclin metabolite 2,3,-dinor-PGF1# in pre-eclamptic compared with healthy 
pregnant subjects.160,298,310 This ties in with evidence that isolated placental and 
umbilical vessels from pre-eclamptic subjects show reduced prostacyclin 
synthesis.397,398 Furthermore, in the case of prostacyclin, there is good evidence 
that reductions in biosynthesis precede the development of clinical features of pre­
eclampsia, being detectable as early as the first trimester of pregnancy.180 
The significance of alterations in thromboxane and prostacyclin biosynthesis in 
relation to the vascular changes in pre-eclampsia has already been discussed. 
Clearly, these changes would also shift the balance in the vasculature to 
conditions favouring platelet activation, but it cannot be determined at present 
whether thromboxane/prostacyclin imbalance is the primary factor triggering 
platelet activation in pre-eclampsia. Whilst the evidence suggests that prostacyclin 
deficiency, perhaps resulting from endothelial damage, occurs early, there may be 
intrinsic changes in platelet reactivity in women who develop pre-eclampsia over 
and above those occurring in normal pregnancy. A great many studies have been 
carried out to investigate platelet reactivity in vitro in pre-eclampsia and PIH, the 
majority of which have examined platelet aggregation.
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7.8 Studies of Platelet Behaviour in Vitro in Pre-eclampsia.
Platelet Aggregation Studies in PRP in Pre-eclampsia and PIH.
In 1971, Howie et al404 showed a reduced platelet aggregation response to 
ADP in vitro in PRP in severe pre-eclampsia. No differences were noted in this 
respect between patients with non proteinuric PIH, and healthy pregnant controls. 
Reduction in ADP induced platelet aggregation in severe pre-eclampsia was later 
confirmed by Maki.410 It has also been reported that a significant reduction in 
maximum rate of platelet aggregation occurs in PRP in severe pre-eclamptics in 
response to arachidonic acid compared with healthy pregnant controls and in 
response to collagen and vasopressin compared with non pregnant women.317
By contrast, a study investigating the threshold concentration of ADP 
giving rise to secondary aggregation in PRP showed no change in pre-eclampsia 
compared with healthy pregnancy.295 Socol et al found that platelet reactivity in 
response to collagen was unchanged in pre-eclampsia.408 O'Brien et al showed no 
significant differences in maximal platelet aggregation in PRP in response to a 
range of agonists in pre-eclampsia compared with normal pregnancy, but this 
study was rather unusual in being amongst the few reporting reduced platelet 
aggregation in healthy pregnancy.319
Morrison et al322 studied platelet sensitivity to arachidonic acid in PRP in 
PIH as measured by the lowest concentration of arachidonic acid giving rise to 
visible aggregates and a release reaction. Platelets from women with PIH showed 
an increased sensitivity to AA compared with those from healthy pregnant 
women, and subgroup analysis showed that this difference was confined to 
subjects with a raised serum urate. Interestingly, the increased sensitivity to AA 
was still evident in PRP from this group of women 6 weeks after delivery, a time 
at which changes in platelet reactivity had resolved in healthy pregnant women.
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Platelet Aggregation in Whole Blood in Hypertensive Pregnancy
Spontaneous aggregation in whole blood from women with PIH does not 
differ from that observed in blood from healthy pregnant women.325
A more recent study of agonist induced platelet aggregation in whole blood, 
measured by a platelet counting technique, showed reduced platelet responses to 
ADP in pre-eclampsia compared with normal pregnancy.411 The method employed 
by these investigators, however, had some disadvantages as centrifugation was 
undertaken prior to platelet counting. A study by Louden et al412 using a more 
standard platelet counting technique of measuring platelet aggregation in whole 
blood showed no significant differences in agonist induced platelet aggregation 
from women with either PIH or pre-eclampsia compared with healthy pregnant 
controls, except when adrenaline was used to stimulate platelets. In the case of 
adrenaline induced responses, there was a significant reduction in platelet 
aggregation in pre-eclampsia, and a similar trend was noted in PIH which did not 
reach statistical significance. A trend towards reduced aggregation to arachidonic 
acid was also noted in pre-eclamptic subjects, but this also failed to reach 
statistical significance.
Platelet Release Reaction In Hypertensive Pregnancy
Morrison et al322 showed no overall change in the extent of 14C-5HT release 
in PRP in response to arachidonic acid (AA) in patients with PIH, some of whom 
met the criteria for pre-eclampsia, compared with both healthy pregnant and non 
pregnant women.ln whole blood it has been shown that platelets from women 
with pre-eclampsia release less 14C-5HT in response to adrenaline, than those from 
healthy pregnant women, mirroring the reduced platelet aggregation in response 
to this agonist in pre-eclampsia.412
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General Patterns of Platelet Reactivity In Pre-Eclampsia
Although studies of platelet behaviour in PIH and pre-eclampsia have 
differed in their findings, many have shown reduced platelet reactivity in vitro 
when compared with healthy pregnancy.317,404,41 °^12 Full clinical details have not 
been provided by all investigators, but close examination of those available 
suggest that the studies showing reduced platelet responsiveness in vitro in 
hypertensive pregnancy have included patients with moderate to severe pre­
eclampsia and therefore more severe disease than those which have demonstrated 
either no change or increased platelet reactivity. This may arise because, in severe 
pre-eclampsia, sufficient platelet activation in vivo has taken place to result in the 
circulation of exhausted platelets413 which are subsequently hypoaggregable when 
tested in vitro. This is supported by the findings of one study which showed a 
reduction in intraplatelet 5-HT content in patients with severe pre-eclampsia who 
demonstrated platelet hyporesponsiveness in vitro.317 The possibility of platelet 
activation during preparation of PRP also cannot be discounted as a factor 
contributing to these findings. Studies in whole blood, however, have tended to 
support a reduction in platelet responsiveness in vitro in pre-eclampsia.411,412 If 
reduced platelet reactivity in vitro occurs as a result of platelet activation in vivo, 
then in vitro studies of platelet behaviour in established pre-eclampsia may not 
yield data which will elucidate whether alterations in intrinsic platelet reactivity, 
over and above those occurring in normal pregnancy, contribute to the 
pathophysiology of pre-eclampsia. The study by Morrison et al322 is interesting in 
this respect since it does suggest that in women with PIH whose disease is less 
severe, platelets may be more responsive to AA than in normal pregnancy, and 
this difference was still detectable postnatally, when the clinical signs of PIH had 
resolved.
86
Platelet Thromboxane Production in Hypertensive Pregnancy.
The data relating to thromboxane production in vivo which have already 
been discussed above/58,298 suggest that thromboxane A2 is produced in greater 
amounts in pregnancies complicated by pre-eclampsia, than in healthy pregnancy. 
Studies of platelet thromboxane production in vitro have, as in normal pregnancy, 
been conflicting. As a measure of reactivity of the platelet thromboxane pathway, 
Wallenburg et al405 measured malondialdehyde formation in PRP following 
stimulation with thrombin, and found this to be increased in PIH, but only when 
the pregnancy was also complicated by intrauterine fetal growth retardation. By 
contrast, Pekonen et al292 found no difference in serum thromboxane B2 levels 
between women with pre-eclampsia, and healthy third trimester women. Some of 
the pre-eclamptic subjects in this study were receiving treatment with 
antihypertensive drugs, but a more recent study has also shown unaltered levels 
of thromboxane B2 in serum from untreated women with PIH and pre-eclampsia.412 
Platelet Sensitivity to Inhibitory Agents in Hypertensive Preonancv.
As in normal pregnancy, platelets from women with PIH and pre-eclampsia 
have been shown to be less susceptible to inhibition of their behaviour by 
prostacyclin and by thromboxane synthetase inhibitors.322,331,332 Two reports 
suggest that reduction in prostacyclin sensitivity in platelets from pre-eclamptic 
women may be more marked than in those from healthy pregnant women.331,332
7 .9  Platelet Second Messengers in PIH and Pre-eclampsia.
As in the case of healthy pregnancy, studies of platelet second messengers 
in PIH and pre-eclampsia have concentrated on intracellular free calcium.
The first report on platelet intracellular free calcium, using quin-2 showed 
no difference in basal or ADP stimulated platelet intracellular free calcium levels 
in PIH or in pre-eclampsia compared with healthy pregnancy.333 There was,
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however, a significant reduction in 5-HT stimulated lCa2+]j in platelets from pre­
eclamptic women.333 The reasons for this latter finding are unclear, but 5-HT 
induced responses in platelets are known to be particularly easily suppressed as 
a result of prior platelet activation.414
Two subsequent studies have shown an increase in basal intracellular free 
calcium levels in platelets from women with pre-eclampsia, over and above that 
observed in healthy pregnancy.334,333 This was not the case in non proteinuric 
PIH.333 The differing conclusions of the studies of platelet [Ca2+]j in hypertensive 
pregnancy probably result from differences in methodology as described in the 
discussion of platelet lCa2+lj in healthy pregnancy. Again, it is difficult to ascertain 
from the data available whether the increase in basal platelet [Ca2+lj is a reflection 
of the presence of a population of partially activated platelets or is in itself a cause 
of altered platelet reactivity in pre-eclampsia. There is some evidence, however, 
from a recently published study, that alterations in stimulated platelet [Ca2+]j 
precede the development of clinical signs of pre-eclampsia. The study was 
prospective and investigated a group of primiparous women from a population 
with a high incidence of pre-eclampsia. Women who subsequently developed pre­
eclampsia showed higher platelet [Ca2+]j levels following stimulation with arginine 
vasopressin as early as the first trimester of pregnancy, but basal platelet [Ca2+]j 
was unaltered.415
7.10 ANGIOTENSIN II and Platelets in Pre-eclampsia.
Angiotensin II receptors on platelets represent a new area of research in the 
field of platelet studies in pre-eclampsia. The aim of these studies is to further 
elucidate the role of the renin angiotensin system in pre-eclampsia by using 
platelets as a model for vascular smooth muscle. The relevance of the data 
emerging from such studies in relation to haemostasis and platelet reactivity is at
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present unclear. Nevertheless, preliminary findings are of interest and will 
therefore be described briefly.
Platelets possess small numbers of angiotensin II binding sites. Baker et 
al416 have recently shown that platelets from normal pregnant women exhibit 
reduced angiotensin II binding, and preliminary data suggests that this reverts 
towards non pregnant binding patterns in pre-eclampsia.417 These results are of 
interest as they mirror the pressor effects of intravenously infused angiotensin II 
in the clinical situation, and therefore the sensitivity of vascular smooth muscle to 
angiotensin II. In normal pregnancy, reduced pressor effects of angiotensin II are 
observed.387 An increase in the pressor response to infused angiotensin II occurs 
prior to the onset of clinical signs of pre-eclampsia,387,388 and has been used as a 
means of predicting pre-eclampsia, although this would be impractical for 
widespread clinical use. Clearly, if platelet angiotensin II binding proved to be of 
predictive value, this could be very useful in the clinical management of patients 
thought to be at risk of pre-eclampsia.
The role of angiotensin II binding sites in relation to platelet behaviour is 
unknown, but there are reports suggesting that angiotensin II may enhance 
platelet aggregation responses to ADP and adrenaline.418,419 Unpublished work in 
the Department of Medicine, University of Nottingham, however, has not 
reproduced these findings (Fox and Heptinstall, personal communication). On the 
other hand, a role for angiotensin II in platelet activation is supported by a study 
showing that platelet intracellular free calcium levels could be raised by 
angiotensin II in vitro, and this rise was greater in platelets from women with pre­
eclampsia.334 This ties in with the findings of an enhanced platelet [Ca2+]j response 
to the pressor agent arginine vasopressin in pre-eclampsia.415
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7.11. The Role of Antiplatelet Drugs in Pre-eclampsia.
As there is considerable evidence of thromboxane/prostacyclin imbalance 
in vivo in pre-eclampsia, there is a rationale for the use of low dose aspirin in the 
prophylaxis and treatment of the condition. A number of small clinical studies have 
suggested that low dose aspirin may indeed be of benefit in preventing pre­
eclampsia in patients deemed at risk either on clinical grounds or on the basis of 
angiotensin II induced pressor responses. Although a total of four such studies 
have now been published36*'369 the numbers of patients involved are small, and the 
results of ongoing multicentre studies in the U.K. and in the U.S.A. should be 
awaited before the use of aspirin in pre-eclampsia is adopted into routine clinical 
practice. Furthermore, the possibility of harmful effects of aspirin, such as 
suppression of maternal prostacyclin production and effects on haemostasis in the 
neonate should be borne in mind. Available data, however, are encouraging in this 
respect, as one study showed that administration of 60mg daily of aspirin did not 
reduce urinary excretion of the prostacyclin metabolite 6-keto-prostaglandin F1(r,369 
and several investigators have shown that lose dose aspirin has little effect on 
neonatal platelet reactivity and thromboxane production.328’369,420 The clinical 
studies on aspirin in pre-eclampsia also lend support to a role for platelets in the 
pathophysiology of the disease.
Other antiplatelet agents have been used clinically in pre-eclampsia, but 
their evaluation has been even more limited than in the case of aspirin. Beta 
blockers are sometimes administered to women with pre-eclampsia to control 
blood pressure. There is some evidence that the combined alpha/beta blocker 
labetolol can inhibit ADP induced platelet aggregation ex vivo in subjects with 
PIH.421 This may be due to its membrane stabilising properties and beta blockers 
which are less lipid soluble would not be expected to affect platelet behaviour.
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Thromboxane synthetase inhibitors422 and infusions of prostacyclin423,424,425 have 
also been used as therapeutic agents in pre-eclampsia. Reports of the use of both 
of these agents are anecdotal, and often involve patients with very advanced 
disease. It is therefore difficult to draw any conclusions about efficacy. It would 
be surprising, however, in view of the in vitro data with thromboxane synthetase 
inhibitors,322 if these agents were beneficial if used alone, but a case could be 
made for investigating their effects in combination with a thromboxane receptor 
blocker. In the case of prostacyclin there are good theoretical grounds for its 
therapeutic use in pre-eclampsia. On practical terms, however, its role is limited 
by vasodilator side effects,423,424,425 and outwith the context of pre-eclampsia, 
rebound platelet hyperactivity has been described.263,284 Newer, more stable 
prostacyclin analogues have not been used to date in pre-eclampsia.
8.RATIONALE OF THESIS
In the foregoing sections of this introductory chapter, evidence has been 
presented of profound changes in platelet behaviour both in normal pregnancy and 
in pre-eclampsia. Prostaglandins have an important role in regulating platelet 
behaviour in vivo. Studies to date have shown that biosynthesis of both pro- 
aggregatory and anti-aggregatory prostanoids increases markedly in healthy 
pregnancy, and in pre-eclampsia there is some evidence for a disturbance in the 
balance of these prostanoids, favouring both vasoconstriction and platelet 
activation. Studies of platelet behaviour in vitro in healthy pregnancy have 
demonstrated increased reactivity of platelets towards agonists which have a 
thromboxane dependent component in their mechanism of action, but conclusive 
data regarding the intrinsic reactivity of the thromboxane pathway in platelets 
during pregnancy is lacking. Furthermore, results of published studies to date have
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also failed to fully explain the occurrence of increased platelet activation in vivo 
in healthy pregnancy in the context of a very marked increase in the synthesis of 
inhibitory prostaglandins, particularly prostacyclin. Whilst a reduction in sensitivity 
of platelets from pregnant women to prostacyclin has been demonstrated in vitro, 
the mechanisms underlying this observation have not been elucidated, nor is it 
known whether sensitivity to other inhibitory prostaglandins is altered. The studies 
described in the following chapters of this thesis were designed to test the 
hypothesis that alterations in platelet responses to inhibitory and pro~aggregatory 
prostaglandins may be involved in determining platelet reactivity during pregnancy.
A further aim was to elucidate the mechanism of any such changes in 
platelet responses to the inhibitory prostaglandins by studying the accumulation 
of platelet cyclic AMP, the second messenger involved in signal transduction 
linking interaction of these agents with receptors on the platelet membrane and 
response of the cell.
Finally, on the background of physiological data relating to platelet 
responses to prostaglandins in healthy pregnancy, studies have been conducted 
to determine whether any further alterations in such parameters occur in platelets 
from women suffering from or at risk of pre-eclampsia. Ultimately, a fuller 
understanding of the mechanisms underlying the pathological platelet activation 
which occurs in pre-eclampsia may lead to a more rational basis for treatment of 
this important obstetric complication.
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CHAPTER 2.
MATERIALS AND METHODS 
1. MATERIALS
Anticoagulants.
For platelet studies, blood was anticoagulated with trisodium citrate dihydrate, 
supplied by BDH. A 3.13%  solution was prepared in distilled water and stored 
tightly capped at 4°C. The solution was replaced every 4  weeks. For estimation 
of full blood count, pre-prepared tubes containing tripotassium ethylene diamine 
tetra-acetic acid (EDTA) were purchased from Becton Dickinson Ltd.
Agents For In Vitro Investigation.
Platelet Agonists: Arachidonic acid was supplied by the Sigma Chemical 
Company Ltd in 1 gram quantities as the 99%  pure acid on dry ice. This was 
weighed out accurately into 10ml of absolute alcohol to give an approximately 
300m M stock solution. The concentration of each batch of stock solution was 
calculated, and the solution stored in 0.2ml aliquots in tightly capped tubes at 
-70°C. Immediately before use, arachidonic acid was converted to the sodium salt 
by adding 0.5g/100m l sodium carbonate (BDH Ltd) in 0 .1 5M saline (Polyfusor 
saline for intravenous infusion). The amount of sodium carbonate solution added 
was adjusted according to the concentration of the stock solution of arachidonic 
acid.
9,11 dideoxy-11 alpha, 9 alpha epoxymethano-prostaglandin F2# (U46619) 
was manufactured by the Upjohn Company and supplied by the Sigma Chemical 
Company, as a powder. 10mg was dissolved in 1ml ethanol, and 1.854ml of 
phosphate buffered saline (Dulbecco's Formula, supplied by Flow Laboratories) 
was added to make a 10mM stock solution. This was stored in aliquots at -70°C. 
Further dilutions were made in phosphate buffered saline immediately prior to use.
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Platelet Inhibitors: lloprost (0.1 mg/ml) was supplied as a gift from Schering 
Health Care Ltd. This was stored at 4°C. Dilutions were made in 0 .1 5M saline 
(Polyfusor) and a stock solution (1ug/ml) was stored in aliquots at -70°C. Further 
dilutions in normal saline were made on the day of each experiment.
Prostaglandins D2, Ev and E2 were supplied by the Sigma Chemical 
Company and stored as solutions in ethanol (1 mg/ml) at -70°C. In each case, 
further dilutions were made in 0 .1 5M saline (Polyfusor) immediately prior to use.
Forskolin was purchased from Calbiochem and stored as a 5mg/ml solution 
in ethanol at -70°C. Further dilutions were made in normal saline on the day of 
each experiment.
The phosphodiesterase inhibitor AH-P719 was supplied as a gift from 
Boehringer Ingelheim in the form of a salt. A 10mM stock solution was prepared 
in normal saline and stored protected from light in aliquots at *70°C. On the day 
of each experiment further dilutions were made in saline.
Adenosine was purchased from the Sigma Chemical Company. Adenosine 
was dissolved in normal saline to a concentration of 2.5m M and stored in aliquots 
at -70°C. Adenosine deaminase, used to remove adenosine in some experiments, 
was of type VI from calf intestinal mucosa and was purchased from Sigma. The 
2,000U/m l solution was stored at 4°C. Immediately prior to use, a working 
solution was prepared by dilution in normal saline.
The thromboxane synthetase inhibitor dazmegrel was donated by Pfizer 
Central Research as a white powder. Fresh solutions were prepared for each 
experiment by dissolving 25mg of dazmegrel in 1ml of 0.1 M sodium hydroxide 
(BDH). Further dilutions were made in 0 .1 5M saline (Polyfusor).
The thromboxane receptor antagonist ICI 192605 was a gift from ICI 
Pharmaceuticals. A 0.1M  stock solution was prepared in ethanol and stored at
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4°C. On the day of each experiment further dilutions were prepared in normal 
saline (Polyfusor).
Other Solutions for Platelet Aggregation and Release Experiments.
Aspirin was purchased from the Sigma Chemical Company. Solutions were 
prepared in distilled water and stored at room temperature for no longer than 7 
days.
The fixing solution for measurement of platelet aggregation in whole blood 
was prepared from formalin (Timstar Laboratory Supplies Ltd), 0 .1 5M saline 
(Polyfusor), disodium EDTA (Sigma), potassium dihydrogen phosphate (Eagle 
Scientific), disodium hydrogen phosphate (Fisons), and sodium chloride (M&B). 
Phosphate buffered saline (pH 7.4) was prepared by dissolving 9g sodium chloride, 
0.5427g potassium dihydrogen phosphate, and 1.5846g disodium hydrogen 
phosphate in 100ml distilled water. A 0 .077M  solution of disodium EDTA was 
prepared in distilled water and formalin was diluted to 4%  in distilled water. The 
solutions were then mixed in the following proportions: 3ml 0 .077M  disodium 
EDTA, 5ml 4%  formalin, 2ml phosphate buffered saline, 10ml distilled water, and 
30ml normal saline.
Cyclic AMP Assay.
"Cold” adenine was used as a diluent for 3H-adenine, and was supplied by 
S’gma. A stock solution was prepared in distilled water. The concentration of the 
stick solution varied depending on the adenine content of each batch of 3H- 
acenine, such that a 1 in 10 dilution of radioactive adenine in cold adenine gave 
a final adenine concentration of 1.2uM when 10ul of this solution was added to 
440ul of platelet rich plasma.
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Solutions For Column Chromatography.
Concentrated hydrochloric acid was supplied by Fahrenheit Lab Supplies 
Ltd, Nottingham, and diluted to a concentration of 0 .5M  with distilled water.
Sodium hydroxide was supplied by BDH and dissolved in distilled water to 
a concentration of 0.5M .
Trichloroacetic acid (BDH) was dissolved to 10% and 15% weight/volume 
solutions in distilled water.
Ammonium formate was purchased from Sigma and 0.2M  solutions were 
prepared in distilled water.
Potassium phosphate buffer was prepared by making 1mM solutions of 
dipotassium hydrogen phosphate (M&B) and sodium dihydrogen phosphate (BDH), 
and adding a sufficient quantity of the latter to the 1 mM dipotassium hydrogen 
phosphate to result in a final solution of pH 7.3. The working solution was 
prepared freshly for each experiment.
Imidazole was purchased from Sigma and 0.1M  solutions were prepared 
in distilled water. On the day of each experiment the pH of the solution was 
adjusted to 7.5 by adding a few drops of 0.5M  hydrochloric acid.
Materials For Column Chromatography.
Dowex (50 x 8-400, 8% cross linked, 200-400 dry mesh , H+ form) was 
supplied by Sigma. Before use, it was prepared according to the manufacturer's 
instructions by washing 50g of the resin sequentially with 300ml distilled water, 
300ml 0 .5M  sodium hydroxide, 300ml 0 .5M  hydrochloric acid, and a further 
300ml distilled water. During storage the prepared resin was kept under distilled 
water in a covered container at 4°C.
Dowex columns were made from 14cm glass Pasteur pipettes (Bilbate Ltd). 
The end of each pipette was plugged with glass wool and Dowex resin prepared
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as above was added until the packed volume was 1.5ml. Distilled water was 
placed over the resin and the columns capped off when not in use.
Neutral alumina (type WN-3, activity grade 1) was purchased from Sigma. 
Alumina columns were prepared using glass pipettes (1 Oml 'E-Mil' B, 0.8  x 30cm). 
The end of each pipette was plugged with glass wool and 1.5g of dry alumina was 
added and allowed to settle at the bottom of the pipette Alumina columns were 
stored dry at room temperature.
Reagents for the Thromboxane B., Assay.
"Cold" thromboxane B2 was used as a thromboxane standard and was 
purchased from Sigma. A 1 mg/ml stock solution was prepared in ethanol and 
stored at -70°C.
Tris-saline buffer was prepared by dissolving 8.19g sodium chloride (M&B 
Ltd) and 0.9g trizma hydrochloride (Sigma) in 1 litre distilled water. The pH was 
adjusted to 7.4 with hydrochloric acid. The composition of Tris-saline/gelatine was 
as above except 3g of gelatine (Fisons) was added to each litre of buffer.
Charcoal (BDH) was mixed with dextran T70 (Pharmacia) and with tris- 
saline and tris-saline gelatin buffers on the day of each experiment in the following 
proportions: 200ml of tris-saline gelatin, 100ml of tris saline, 1.5g charcoal, 0 .1 5g 
dextran.
Radiochemicals.
14C-5hydroxytryptamine creatinine sulphate complex was purchased from 
Amersham International. The specific activity was 56mCi/mM. The solution was 
stored as 50ul aliquots at -20°C in a freezer reserved for radiochemicals. A fresh 
aliquot was used for each experiment.
[adenine-U-14C]-adenosine 3 ',5 '-cyclic phosphate, ammonium salt was 
purchased from Amersham International (specific activity 306mCi/mmol). A 1 in
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100 dilution in distilled water was prepared and the resultant stock solution stored 
in 250//I aliquots at -20°C in the radiochemical freezer. A fresh aliquot was used 
for each experiment.
[2,8-3H]-adenine, specific activity 17-31 Ci/mmol, was purchased from 
New England Nuclear and was stored at 4°C in a refrigerator reserved for 
radiochemicals. A fresh solution was prepared on the day of each experiment by 
dilution of the 3H-adenine by a factor of 10 in cold adenine.
5,6 ,8 ,9 ,11,12,14,15-(n)-3H-thromboxane B2 (specific activity 210 Ci/mmol) 
was purchased from Amersham International. This was stored at -20°C for no 
longer than 2 months. On the day of each experiment, a working solution was 
prepared by adding 10ul 3H-thromboxane B2 to 33ml tris-saline gelatin buffer. 
Liquid Scintillant and Vials.
Packard-199 scintillant was supplied by Packard Instrument company Inc. 
Optiphase-Hisafe II was supplied by LKB/Pharmacia. Plastic and glass scintillation 
vials were also purchased from LKB/Pharmacia Ltd.
Reagents for Running the Coulter Counter (model Z_)
Isoton II was used as a diluent for platelet rich plasma prior to platelet 
counting. This diluent, together with the calibrating and control reagents for the 
counter (S-Cal calibrator, and CTC-3 thrombocyte control) were purchased from 
Coulter Electronics Ltd.
Test Tubes and Miscellaneous Disposables.
PAP-4 microsiliconised glass test tubes for measurement of platelet 
aggregation in platelet rich plasma, paper for the PAP-4 aggregometer, and micro 
stir bars were purchased from LEP Scientific Ltd. General purpose polystyrene test 
tubes (75x12mm) and polystyrene test tubes (64x11mm) for the platelet release 
and whole blood platelet aggregation assays were obtained from LIP Equipment
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and Supplies Ltd. Polypropylene test tubes (75x1 Omm) for the cyclic AMP assay 
were purchased from Sarstedt Ltd. "Eppendorf" polypropylene tubes were 
purchased from Elkay products Inc.
Polystyrene 30ml universal containers for blood collection were supplied by 
Media Disposables Ltd, 19 gauge butterfly needles by Abbott Ireland Ltd, and 
20ml "Plastipak" polypropylene syringes by Becton Dickinson. Plastic 3 way taps 
were from Nipro Medical Industries Ltd.
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2. CLINICAL METHODS
2.1 Subjects
All studies were approved by the ethical committee at the University 
Hospital, Nottingham. All subjects gave informed consent. The broad criteria used 
for subject selection will be described here, but further detail on individual study 
design and subjects included will be provided at the beginning of each subsequent 
chapter.
Healthy non pregnant women were selected as controls from staff and 
students at the University Hospital Nottingham. All were between the ages of 16 
and 35 and had not been on an oral contraceptive for at least 12 weeks prior to 
the study date. Phase of menstrual cycle was not used as a criterion for selection, 
but the first day of the last period was noted.
Healthy pregnant women aged 16-35 years were selected randomly at the 
antenatal clinic. All of these women were primigravidae. For cross sectional 
studies, primigravid women in the third trimester of pregnancy (after the 24th week 
of gestation) were chosen and studied on one occasion only. Any woman thought 
to be in early labour was excluded.
A small group of healthy pregnant women was studied longitudinally 
through pregnancy. Most of these subjects were selected pre-conceptionally by 
asking for volunteers from female hospital staff and female blood donors who 
were planning their first pregnancy, and by referral of such women from general 
practitioners. A minority of healthy pregnant subjects in the longitudinal study 
were chosen from those referred to hospital before the 12th week of pregnancy 
for antenatal care. Subjects in longitudinal studies were asked to donate blood at 
the time of selection, as soon as pregnancy was confirmed, at 12, 24, and 36 
weeks gestation, and after the 6th postnatal week.
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All subjects acting as non pregnant controls and those classified as healthy 
pregnant women were questioned regarding their past medical history. Any 
women with chronic illnesses or on chronic drug therapy (with the exception of 
iron and vitamin supplements) were excluded. For example, women suffering from 
diabetes, hypertension, epilepsy, chronic asthma or renal disease did not meet the 
criteria for selection. Women with a past history of thromboembolic disease were 
also excluded. On the day of study a drug history was taken, and any subject 
who had ingested any drug likely to alter platelet function within a period of 14 
days was excluded. Subjects were questioned specifically about ingestion of 
aspirin and other non steroidal anti-inflammatory drugs. Blood pressure was 
measured prior to venepuncture and no subject was included whose blood 
pressure was greater than 140/90 or, in the case of pregnant subjects, if any of 
the criteria for a diagnosis of pregnancy induced hypertension were fulfilled (see 
below).
Women with pregnancy induced hypertension (PIH) or pre-eclampsia were 
selected from those admitted to hospital with these diagnoses. The definition of 
PIH was a rise in diastolic blood pressure of greater than 15mmHg compared with 
the level recorded in the first trimester of pregnancy, and an absolute blood 
pressure of greater than 140/90.341 In the case of women with non proteinuric 
PIH, only those women in whom raised blood pressure was confirmed by two  
measurements at least 6 hours apart were included.
To be classified as pre-eciamptic, greater than 0.5g protein had to be 
excreted in the urine over a 24 hour period in addition to meeting the above blood 
pressure criteria.342 343 As a few women in this group required urgent delivery, 
confirmation of blood pressure recordings after 6 hours and quantification of 
proteinuria were not possible on every occasion. In such cases, the clinical
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evidence of pre-eclampsia was indisputable, and all had heavy proteinuria on 
"dipstick" testing of random urine specimens. Most subjects with PIH or pre­
eclampsia were primigravid; a minority were not, but either had a previous history 
of pre-eclampsia, or had a new partner for the pregnancy studied.377 The majority 
of subjects with PIH or pre-eclampsia had received no drug treatment at the time 
of study. A small number of critically ill subjects had received medication, the 
details of which are provided in the relevant chapter. Subjects with PIH or pre­
eclampsia who had ingested aspirin or other non steroidal anti-inflammatory drugs 
were excluded, and no woman with evidence of essential hypertension was 
included.
A small group of multiparous women considered to be at risk of pre­
eclampsia because of a previous history of the condition, was studied 
longitudinally during pregnancy. These women were selected from the combined 
medical/obstetric clinic run at the University Hospital, Nottingham, to supervise 
the antenatal care of high risk pregnancies. Most were recruited in the second 
trimester of pregnancy. Drug treatment was recorded and subjects taking aspirin 
were excluded.
2 .2  M easurem ent of Blood Pressure.
Blood pressure was measured over the brachial artery after 5 minutes rest 
in the supine position, using a standard sphygmomanometer. Phase IV of the 
Korotkov sounds was used to determine the diastolic blood pressure.
2 .3  Blood Collection.
Blood was withdrawn from a large vein in the antecubital fossa using a 19 
gauge butterfly needle for venepuncture. A tourniquet was applied just prior to 
venepuncture, but excessive stasis was avoided. Depending on the studies 
conducted, between 30ml and 90ml blood was withdrawn using 20ml polystyrene
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syringes and a 3 way tap. For platelet studies, blood was immediately dispensed 
into polystyrene universal containers, containing 3.13%  trisodium citrate 
dihydrate, 9 parts blood to 1 part anticoagulant. The tubes were mixed gently by 
inverting three times. For each subject, blood was also placed in a tube containing 
EDTA for measurement of a full blood count and, where appropriate blood was 
dispensed into a glass tube and allowed to clot to prepare serum samples suitable 
for estimation of serum thromboxane B2 or for measurement of urea and 
electrolytes and uric acid.
2.4 Collection of Urine Specimens.
Subjects with PIH or pre-eclampsia were asked to supply a complete 24 
hour collection of urine, unless the clinical condition demanded urgent delivery of 
the baby. Subjects were asked to empty their bladder of residual urine and then 
to place all urine passed over the next 24hours in a large plastic bottle containing 
mercurothiolate preservative.
Healthy pregnant women and those women with pre-eclampsia in whom 
a 24 hour urine collection was impractical were asked to provide a mid stream 
specimen of urine which was tested for protein using "Multistix” (Bayer 
Diagnostics).
3. LABORATORY METHODS
All platelet studies were completed within 3 hours of venepuncture. Platelet 
studies were carried out either in platelet rich plasma or in whole blood.
3.1 Preparation of Platelet Rich Plasma.
Platelet rich plasma was prepared by centrifugation of whole citrated blood 
at 150g for 10 minutes at room temperature. The upper layer of platelet rich 
plasma (PRP) was carefully aspirated off using a plastic Pasteur pipette and placed
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in a tightly capped polystyrene tube or universal container. The remaining blood 
was immediately further centrifuged at 2000g for 10 minutes at room temperature 
to prepare platelet poor plasma (PPP). The platelet count in PRP was measured as 
detailed below, and the count adjusted to 250 x 109/l using the autologous PPP. 
The adjusted PRP was covered with a layer of 5% C 02 in air and tightly capped 
to prevent pH changes.
Measurement of Platelet Count in PRP.
A Coulter counter (model Z J  was used to measure the platelet count in 
PRP. Prior to counting, PRP was diluted by a factor of 1 in 3 ,000 , by measuring 
6.67ul of PRP using a positive displacement pipette into 20ml "Isoton II" and 
mixing thoroughly by inversion. The background particle count in the Isoton was 
previously checked and the diluent was discarded and replaced with fresh solution 
if the background count was greater than 1 particle/ul. The platelet count in the 
diluted PRP was measured 3 times, the mean calculated, and the background 
particle count subtracted. The Coulter counter was set to measure platelets as 
particles whose volume was between 3 and 36 fl, and the machine was calibrated 
regularly by the half count method426 against a red cell preparation with a known 
MCV ( Coulter S^, ). The calibration was checked against Coulter platelet 
standards (CTC 3).
3.2 Platelet Aggregation in PRP.
Platelet aggregation was estimated in PRP by a turbidometric method as 
first described by Born,51 using a Biodata PAP 4 platelet aggregometer with an in­
built chart recorder. This method is dependent on detecting an increase in light 
transmission by PRP as platelets form aggregates and the optical density of the 
plasma suspension changes to resemble that of platelet poor plasma. The 100%  
baseline (representing the optical density of the solution if all platelets formed
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aggregates) was set using autologous platelet poor plasma and the 0%  baseline 
was set using untreated PRP before inducing platelet aggregation with an agonist. 
The temperature in the aggregometer wells was maintained at 37°C throughout 
experiments. Experiments were carried out in microtubes made of siliconised 
glass, and samples were stirred at 1,000 r.p.m. using metal stir bars placed in the 
base of the tubes before adding PRP. 200ul of PRP was used in each experimental 
tube and 20ul of the appropriate platelet agonist was added to induce aggregation 
after a 2 minute pre-incubation period in the aggregometer. Hamilton syringes 
were used to obtain accurate measurement of agonist solutions and to ensure that 
the agonist was dispensed directly into the PRP at the base of the tube. Where 
drugs were added to inhibit platelet aggregation, 20ul of the appropriate solution 
was placed in the experimental tubes before the PRP was added. In such cases, 
the volume of PRP in each tube was adjusted to 180ul. Aggregation reactions 
were always allowed to proceed for 6 minutes after addition of the agonist in each 
case. Maximum % aggregation and slope ( the slope of the tangent taken to the 
steepest part of the aggregation curve ) could be read off the tracing produced by 
the in-built chart recorder on the PAP 4 aggregometer. The coefficient of variation 
for maximum aggregation was between 2% and 10% depending on the particular 
agonist and its concentration, and for the slope was between 6%  and 9% .
3.3 Platelet Release Reaction.
Platelet dense granule release in PRP was measured by using a 14C-5- 
Hydroxytryptamine (5-HT) labelling technique, based on the method described by 
Heptinstall et al.427 This method was used to compare the effect, in vitro, in 
different subject groups, of various pharmacological agents which would inhibit 
platelet behaviour. In all cases the effect of these agents on arachidonic acid 
induced platelet dense granule release was studied.
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Platelet dense granules were labelled with 14C-5-HT by placing 6ul of 
radiolabelled 5-HT (specific activity 57.5 mCi/mmol) in the anticoagulant prior to 
collecting the blood. 14C-5-HT is rapidly and extensively taken up into platelet 
dense granules and is available for subsequent release upon stimulation by an 
agonist.69 460ul of adjusted PRP was added to polystyrene tubes containing 20ul 
of the inhibitory agents under investigation and a metal stir bar. In control tubes 
the inhibitory pharmacological agents were replaced with saline. On the addition 
of the PRP, each tube was immediately placed in a waterbath at 37°C over a 
magnetic stirring base set to ensure a constant stirring speed of 1,000 rpm. After 
2 minutes equilibration platelet aggregation and release were induced by the 
addition of 20ul of arachidonic acid (final concentration 1mM) or 20ul 
saline/sodium carbonate was added to control tubes. Incubation and stirring were 
continued for a further 6 minutes, at which time 50ul of a supersaturated solution 
(2.5mg/ml) of aspirin was added and the tubes cooled rapidly by placing on ice, 
thus ensuring that no further release took place. The presence or absence of 
visible aggregates was noted and the samples were then centrifuged at 2°C at 
4,000g for 10 minutes to deposit the platelets and aggregates, leaving released 
14C-5-HT in the supernatant. Duplicate aliquots of 50ul of the supernatant were 
then pipetted into plastic vials, 10ml scintillation fluid was added (Packard 199), 
and radioactivity in the vials counted using an LKB 1215 Rackbeta liquid 
scintillation counter, on the 14C single isotope program. The counting efficiency for 
14C at the quench of the samples was 90% .
The extent of the release reaction was then calculated, by expressing 14C- 
5HT in the supernatant as a percentage of the total 14C-5HT taken up into the 
platelet dense granules. The latter was calculated from the counts present in 
untreated and uncentrifuged PRP, and those present in platelet poor plasma
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prepared by centrifuging the control tube to which saline/sodium carbonate only 
had been added. The formula used to calculate 14C-5-HT release, together with a 
worked example are shown in Appendix 1. In practice, a computer program based 
on this formula, prepared by Dr A Kelman, University of Glasgow, was used to 
calculate the percentage release in all experiments. The intra-assay coefficient of 
variation for the extent of 14C-5-HT release induced by 1 mM arachidonic acid in 
the absence of an inhibitor was 6.8% .
3.4 Measurement of Platelet Cyclic AMP.
Principles of the Assay.
Cyclic AMP is formed in platelets from ATP by the action of the enzyme 
adenylate cyclase. Cyclic AMP can be assessed in platelets by measurement of 
absolute cyclic AMP concentrations by a protein binding assay428 or by 
radioimmunoassay.428 Alternatively, radioactive cyclic AMP can be measured in 
platelets prelabelled with 3H-adenine, which is incorporated into the metabolic 
adenine nucleotide pool and subsequently converted to 3H-cyclic AMP.430 Cyclic 
AMP can be extracted by lysing the platelets with trichloroacetic acid.430,431 The 
radiolabelled cyclic AMP in the extract is then separated from other nucleotides 
by column chromatography. This type of assay does not measure total amounts 
of cyclic AMP, but gives information about changes in the rates of synthesis and 
steady state levels. Its main advantage is that it excludes extracellular cyclic AMP, 
the levels of which are significant in plasma, and this type of assay is therefore 
more sensitive to small physiologically relevant changes in cyclic AMP, the 
baseline levels of which are very low.
Adenine Nucleotide Labelling.
3H-adenine added to PRP is actively taken up by platelets.432 Adenine 
metabolism does not occur in plasma, so all of the adenine added to PRP is
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available for uptake.433 It has been shown that the rate of uptake of 3H-adenine by 
platelets is dependent on the platelet count,254 the incubation temperature,254 the 
total adenine concentration,433 and the extent of uptake on the incubation time.254 
The ideal platelet count for uptake of adenine appears to be 300  x 109/1 but 
uptake is little affected unless the platelet count falls below 200 x 109/l.254 An 
initial total adenine concentration of 1.2uM and an incubation temperature of 37°C 
also give rise to maximum rates of uptake.254,433 It was shown by Gray that the 
rate of uptake of 3H-adenine by PRP is initially rapid, and thereafter slows, 
reaching a plateau by 90 minutes.254
3H-adenine taken up by platelets is converted to 3H-AMP by adenine- 
phosphoribosyl transferase.433 The 3H is then distributed amongst the metabolic 
pool of adenine nucleotides by the action of adenylate kinase giving rise to 3H-ADP 
and 3H-ATP.433,434 It has been shown that 3H is distributed amongst AMP, ADP and 
ATP in proportion to the endogenous amounts of these metabolically active 
adenine nucleotides.434 Adenine nucleotides in the storage pool are not labelled 
when 3H-adenine is incubated with PRP.434 The labelled adenine nucleotides are 
catabolized in platelets to inosine monophosphate and hypoxanthine.434 Variable 
amounts of 3H-ATP are converted to 3H-cyclic AMP by action of adenylate 
cyclase. At basal adenylate cyclase activity the rate of conversion of ATP to cyclic 
AMP is very low189 but increases considerably in the presence of adenylate cyclase 
stimulators. The amount of 3H-cyclic AMP formed at a given time point will also 
be increased above basal levels if the rate of metabolism of cyclic AMP to 5'-AMP 
is reduced in the presence of a phosphodiesterase inhibitor.182 
Isolation of 3H-cvclic AMP.
The sensitivity and accuracy of a 3H-adenine labelling assay for cyclic AMP 
is dependent on the efficiency of the isolation procedure. In 1968, Krishna et al
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showed that cyclic AMP could be separated from ATP by column chromatography 
on Dowex cation exchange resin, followed by precipitation with zinc sulphate and 
barium hydroxide.435 Subsequently, White and Zenser,436 and Ramachandran437 
showed that cyclic AMP separation from ATP could be achieved using columns 
packed with alumina ion exchange resin. Alumina is an amphoteric ion exchange 
resin, absorbing either anions or cations, depending upon the pH.437 The separation 
of cyclic AMP on such columns is dependent on the fact that cyclic AMP is 
monovalent at neutral pH and can therefore be eluted off the column, whereas 
ATP, ADP, and AMP are polyvalent and are retained on the alumina.437
In 1974, using an adenylate cyclase assay based upon labelling of 
hepatocytes with 32P-ATP, Salomon showed that improved separation of cyclic 
AMP from ATP could be achieved using both Dowex and alumina columns.438 In 
1981, Haslam and McClenaghan showed that a double column separation 
technique using alumina and Dowex was applicable to the separation of 3H-cyclic 
AMP from other 3H labelled products in an assay of cyclic AMP in washed 
platelets incubated with 3H-adenine.430 This assay, with only minor modifications, 
was then used for the measurement of platelet cyclic AMP in PRP by Gray, who 
extensively evaluated the technique.254 This isolation method involved the 
application of a trichloroacetic acid extract of PRP to a column of neutral alumina 
primed with 10% trichloroacetic acid. The alumina column was then washed with 
10% trichloroacetic acid, which gives improved purification of the plasma 
extract431 and delays the elution of the cyclic nucleotides.438 The column was 
subsequently washed with distilled water to elute the bases438 (adenine and 
hypoxanthine) which are non ionic at neutral pH. Finally, cyclic AMP was 
displaced from the column by exchange with the formate anion (HCOO) in 
ammonium formate (pH 6.0).431,438,437 To ensure complete separation of cyclic
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AMP, particularly from ATP,435,438 the eluate from the alumina column was then 
applied to a column of Dowex 50W  ion exchange resin which had been previously 
primed with hydrochloric acid and distilled water. The cyclic AMP was eluted from 
this column with potassium phosphate buffer (pH 7.3). The final eluate was then 
freeze dried to reduce sample volume prior to liquid scintillation counting.
Gray showed by thin layer chromatography that the final column eluate appeared 
to contain no other substances except cyclic AMP.254 As significant loss of cyclic 
AMP occurs during the isolation procedure in this assay, a recovery label must be 
used in each sample. The use of 14C-cyclic AMP, added to the trichloroacetic acid 
used to carry out the extraction of cyclic AMP from platelets, is a convenient 
method of monitoring recovery, provided facilities are available for dual label liquid 
scintillation counting.430
In view of the improved sensitivity of this assay compared with protein 
binding and radioimmunoassays, I chose to use this method for measurement of 
platelet cyclic AMP. Furthermore the choice of an assay based on pre-labelling 
with 3H-adenine allowed the sensitive measurement of platelet cyclic AMP in PRP 
without the necessity of preparing washed platelets.
The experiments carried out to validate the technique, which was set up 
by myself for the first time in the Department of Therapeutics, Nottingham 
University, and was based upon the work of Gray254 and Haslam and 
McClenaghan430 will now be described in detail.
Validation of the Assay of Platelet Cyclic AMP.
Uptake of 3H-adenine bv Platelets.
PRP in which the platelet count had been adjusted to 250 x 109/l was 
incubated with [2,8-3H]-adenine ( specific activity 23Ci/mmol) which had been 
previously diluted by a factor of 10 in a solution of cold adenine immediately prior
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to use. The concentration of the coid adenine solution was such that the total final 
concentration of adenine (radioiabelled and unlabelled) in PRP was 1.2uM when 
the solution was added to the PRP at a 1 in 45 dilution (10ul of adenine solution 
added for every 440ul of PRP). Incubation of the PRP with adenine was carried out 
at 37°C for 90 minutes. These incubation conditions corresponded to those used 
by Gray254 except for the platelet count which was adjusted to 250 x 109/l instead 
of 300  x 109/l. 250 x 109/l was chosen as it was anticipated there may be 
difficulty in achieving a final adjusted PRP count of 300 x 109/l in some pre­
eclamptic subjects. Aliquots of 450ul of PRP were removed after 90 minutes and 
added to polypropylene tubes containing 50ul of saline (corresponding with the 
volume of additions to PRP in experiments where incubation of 3H-adenine labelled 
PRP with pharmacological agents was subsequently carried out). These tubes 
were immediately centrifuged at 4,000g at 2°C for 10 minutes to deposit a 
platelet pellet. 50ul of supernatant was then carefully removed from each tube and 
dispensed into liquid scintillation vials labelled N3H uptake" to which 15ml of 
Optiphase Hisafe II scintillation cocktail was added. 10ul of the 3H-adenine/cold 
adenine solution was pipetted in triplicate into scintillation vials labelled "3H totals" 
and scintillation cocktail added as before. 3 vials containing scintillation cocktail 
only were also prepared to determine the background radioactivity. All vials were 
then counted on a Beckman scintillation counter (model LS 8000) with automatic 
quench correction on a dual isotope program, set so that all 3H counts appeared 
in channel 1. Percentage of 3H-adenine remaining in the supernatant was
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calculated from the formula :
% 3H-adenine not taken up by platelets =
Mean cpm in totals - mean background x 10* x 100
Mean cpm in uptakes - mean background cpm
* to correct for counting of 50ul out of a total of 500ul in "uptake vials".
The result of the above calculation was then subtracted from 100% to give the 
% uptake of 3H-adenine by platelets.
During pilot studies uptake of 3H adenine was determined using this 
protocol in 12 healthy individuals of both sexes, aged 18-40 years,on no 
medication. The mean and standard deviation of uptake of 3H-adenine by platelets 
in PRP was 74.2%  +  /- 9 .6% , with a range of 56.8%  to 92.5% . As these figures 
corresponded closely to those quoted by Gray254 it was decided to accept this 
incubation protocol for use in subsequent studies. It is noteworthy that there is a 
large amount of variation between individuals in the % uptake of 3H-adenine by 
platelets. It is therefore necessary to express the conversion of 3H-adenine to 3H- 
cyclic AMP by platelets as a percentage of 3H-adenine taken up by the platelets. 
As the subsequent drug incubation protocols of pharmacological agents with 
labelled PRP took a maximum of 34 minutes to carry out, it was necessary to 
ensure that uptake of 3H-adenine did not alter significantly over this time period. 
During pilot experiments, uptake of 3H-adenine was therefore determined after the 
90 minute incubation period of 3H-adenine with PRP, immediately before drug 
incubations were carried out and again at the end of a 34 minute drug incubation 
protocol. It was found in a study of 12 subjects that uptake of 3H-adenine only 
varied by 1.37%  ±_ 1.79%  over this short period.
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Determination of Elution Profile of Cyclic AMP from Alumina and Dowex Columns.
The elution profile of cyclic AMP from alumina and Dowex columns was 
determined using 14C-cyclic AMP (specific activity 276mCi/mmol). Alumina and 
Dowex columns were prepared exactly as described by Gray.254 The alumina 
columns were made by adding 1.5g of neutral alumina (type WN3) to 10ml 
graduated glass pipettes (see materials section) plugged with glass wool. Dowex 
ion exchange resin was prepared, as recommended by the supplier, by washing 
50g of the Dowex (50x8-400; 8% cross linked; 200-400 dry mesh, H + form) in 
a Buchner flask under vacuum with 330ml distilled water, then 330ml 0 .5M  
sodium hydroxide, followed by 330ml 0 .5M  hydrochloric acid, and finally a further 
330ml distilled water. Glass Pasteur pipettes (length 14cm) were plugged with 
glass wool and filled with the prepared Dowex so that each column contained 
1.5ml packed volume of ion exchange resin. The alumina and Dowex columns 
were primed as described by Gray254 and by Haslam and M'Clenaghan430 with 
10ml 10% trichloroacetic acid (TCA) for the alumina columns and with 10ml 0 .5M  
hydrochloric acid (HCI) followed by 15ml distilled water for the Dowex columns. 
The elution profile of 14C-cyclic AMP on the alumina columns was then determined 
using the protocol for separating cyclic AMP described by Haslam and 
McClenaghan430 as follows. A solution of 14C-cyclic AMP in 15% trichloroacetic 
acid was prepared containing approximately 10,000 cpm/ 2ml TCA. 2ml of this 
solution (corresponding to the acid platelet extract in the assay of platelet cyclic 
AMP) was then applied to each of four alumina columns which were washed with 
solutions as illustrated in the flow chart (Figure 2.1). 1ml fractions of the eluate 
from the columns were collected in glass scintillation vials and 15ml Optiphase 
Hisafe II scintillation cocktail was added. Vials labelled "totals" were prepared 
containing scintillation cocktail and 200ul of the solution of 14C-cyclic AMP in
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FIGURE 2.1
ELUTION OF CYCLIC AMP FROM ALUMINA COLUMNS 
APPLY 14C-cAMPin 2ml TCA
I
W ASH W ITH 9ml 10%  TCA
I
W ASH W ITH 9ml DISTILLED H20
I
W ASH W ITH 7ml 0 .2 M  A M M O N IU M  FORMATE (pH 6 .0 )
I
COLLECT 1ml FRACTIONS of ELUATE 
THROUGHOUT PROCEDURE
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The figure show s the mean cum ulative elution o f 14C -cA M P  as a %  of the  
to tal applied to 4  alumina colum ns, plotted against fraction num ber in mis of 
the colum n eluate. The arrow s indicate the fraction num bers b etw een  w hich  
m ost o f the cyclic A M P  w as eluted and w hich  w ere  subsequently chosen as 
those to be collected during routine use o f the assay.
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TCA. The radioactivity in all of the vials together with blanks was counted on the 
Beckman LS8000 scintillation counter on a program in which the parameters had 
been optimised for UC. Total u C>cyclic AMP applied to each column was calculated 
by multiplying the counts in "totals” vials by 10 after subtracting the background 
radioactivity. The mean counts in each 1ml fraction were then plotted against 
fraction number, as illustrated in Figure 2.2. It was found that 82.5%  of the cyclic 
AMP added to the columns was eluted in the 3rd to the 7th ml inclusive of ammonium 
formate added to the columns (corresponding to fraction numbers 23-27). This 
corresponded exactly to the findings of Gray,254 but differed slightly from those of 
Haslam and McClenaghan,430 who noted that the cyclic AMP was eluted in the 3rd to 
5th ml inclusive of ammonium formate added to the columns.
The elution profile of 14C-cyclic AMP from the Dowex columns was then 
determined by a very similar procedure, but in this case 14C-cyclic AMP was diluted 
in 0 .2M  ammonium formate to give approximately 10,000 cpm per 5ml ammonium 
formate. 5ml of this solution (corresponding to the fraction of the eluate from the 
alumina columns shown to contain cyclic AMP) was applied to each of four Dowex 
columns which were then washed as shown in Figure 2.3. The potassium phosphate 
buffer used to elute the cyclic AMP was prepared by titrating a solution of 1mM 
K2HP04 with 1mM NaH2P04 until the pH reached 7.3. 1ml fractions of the column 
eluates were collected as before and the radioactivity of these samples counted 
together with totals and blanks. In this case the totals were prepared using 0.5ml of 
the ammonium formate/14C-cyclic AMP solution. The mean counts in each 1ml 
fraction were then plotted against fraction number as illustrated in Figure 2.4. It was 
shown that 89.4%  of the added 14C-cyclic AMP was eluted in the 4th to 11th ml 
inclusive of potassium phosphate buffer added to the columns. Again, these findings 
corresponded exactly with those of Gray,254 but differed from those of Haslam and
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FIGURE 2.3
ELUTION OF CYCLIC AMP FROM DOWEX COLUMNS 
APPLY 14C-cAMP in 5ml AMMONIUM FORMATE
WASH WITH 11ml POTASSIUM PHOSPHATE BUFFER (pH 7.3)
.
i
I
COLLECT 1ml FRACTIONS of ELUATEI
THROUGHOUT PROCEDURE
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118
ELUTION PROFILE OF CYCLIC AMP
FROM DOWEX COLUMNS
100-1
.§ 80- 
•4— >
ZDi—I
CD 60-
CD
>
ro
20 -
0 2 4 6
fraction number
FIGURE 2 .4 .
The figure show s the mean cum ulative elution o f 1*C -cA M P  as a %  o f the  
to ta l applied to 4  D ow ex colum ns, plotted against fraction num ber in mis of 
the colum n eluate. The arrows indicate the fraction num bers b etw een  w hich  
m ost o f the cyclic A M P  w as eluted and w hich w ere  subsequently chosen as 
those to be collected during routine use of the assay.
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M cClenaghan,430 who found that cyclic AMP was eluted in the 7th to 15th ml of 
potassium phosphate added.
In view of the above findings it was decided in subsequent experiments for 
assay of platelet cyclic AMP to adhere to the sequence of elution buffers for each set 
of columns as described, and to collect the fraction eluting from the alumina columns 
on the addition of the 3rd to 7th ml of ammonium formate, which would then be 
applied to the Dowex columns. The fraction eluting from the latter on the addition of 
the 4 th to 11th ml of potassium phosphate buffer would subsequently be collected. 
Further Modification of Procedure for Isolating Cyclic AMP.
Although the final column eluate using the isolation procedure described had 
been shown in the past by thin layer chromatography to be free of contaminating 
substances, I found during the establishment of the platelet cyclic AMP assay that 
on some occasions, basal levels of cyclic AMP were higher than those documented 
by previous investigators using this technique. This was noted to occur more 
frequently with a particular batch of 3H-adenine, and was particularly marked when 
the uptake of 3H-adenine by the platelets was lower than average. In view of this, 
contamination of the cyclic AMP containing fraction of the column eluate with a 
tritiated compound present in the 3H-adenine, or with 3H-adenine itself, was 
suspected. This was confirmed by the following experiment. Counts in collected 
fractions of eluate from columns to which 2ml 15% TCA containing no radioactivity 
had been applied in place of a sample were equivalent to counts in blank vials. By 
contrast, the application of 400 ,000  cpm 3H-adenine diluted in 2ml TCA 
(approximately equivalent to the amount of 3H-adenine remaining in plasma if uptake 
by platelets was 50% ) applied to columns resulted in the presence of 219 cpm in the 
final eluate collected. Although this represents a small amount of contamination in 
percentage terms, this is significant as basal levels of cyclic AMP are very low
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(equivalent to approximately 200 3H counts) and the error introduced would therefore 
be considerable. Details of the chemical purity of the 3H~adenine supplied by the 
manufacturer showed that the 3H-adenine was 97%  pure. It was therefore very likely 
that a low level contaminant in the 3H>adenine was eluting along with the cyclic AMP 
fraction on column chromatography. It is improbable that its exact nature could have 
been easily identified as it was present in extremely small amounts in chemical terms. 
It was therefore decided to modify the isolation procedure in an attempt to further 
purify the final column eluate, rather than to attempt to positively identify the 
contaminant. In the dual column cyclic AMP assay described by Salomon,438 cyclic 
AMP was isolated by applying the sample first to a Dowex column, followed by an 
alumina column, which was developed by washing with imidazole. A possible means 
of increasing the purity of the isolation procedure in the present assay was to add on 
a third stage to the column chromatography procedure, by applying the eluate from 
the Dowex to a further alumina column and using the method of Salomon438 to elute 
cyclic AMP from this column. Columns containing 1.5g of alumina were prepared as 
previously described and washed with 10ml 0.1M  imidazole (pH 7.5). 8ml aliquots 
of potassium phosphate buffer (equivalent to the eluate from the Dowex columns) 
containing either 3H-adenine or 14C-cyclic AMP were then applied to these columns, 
which were subsequently washed with 6ml 0.1M  imidazole. 1ml fractions of the 
column eluate following the application of these samples were collected and the 
elution profile of 3H counts and 14C counts determined. The results are illustrated in 
Figure 2.5. It can be seen that the majority of 3H counts were eluted as the sample 
ran through, whereas 14C-cyclic AMP was retained on the column and eluted with the 
imidazole wash. The addition of this step to the dual column chromatography 
described by Haslam and McClenaghan was likely to improve the isolation procedure 
considerably. This was borne out in subsequent formal comparison of assay results
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The figure show s the m ean cum ulative elution o f 3H-adenine ( □ )  and 14C -cA M P  
( • )  from  4  alum ina columns primed w ith  and then w ashed w ith  0 .1 M  
im idazole, as a %  of the to tal 3H and 14C counts applied to  the colum ns. The  
radiolabelled adenine and cyclic A M P  w ere  applied to  the colum ns in 8ml 
potassium  phosphate buffer. The arrow s indicate the  fraction numbers  
betw een  w hich  m ost o f the cyclic A M P  w as eluted from  the  colum n, and 
w hich  w ere  subsequently chosen as those to be collected during routine use 
o f the assay. It is evident th a t m ost o f the 3H counts w ere  eluted earlier than  
the cyclic A M P .
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using dual and triple column chromatography. An example of counts obtained and 
calculated results of basal platelet cyclic AMP levels in PRP from one individual 
assayed by both methods simultaneously is shown in Table 2.1. As well as providing 
a purer cyclic AMP isolate the triple column method was practically more convenient. 
The final eluate volume was lower, allowing its direct uptake by Optiphase Hisafe II 
scintillant obviating the need for freeze drying to reduce sample volume. This also 
gave rise to improved cyclic AMP recovery as freeze drying resulted in considerable 
cyclic AMP loss. Using the triple column method, recovery was generally between 
40%  and 80%  and varied considerably from column to column. As described by 
Haslam and McClenaghan,430 1,000 dpm 14C-cyclic AMP was added to each 
experimental sample in the TCA used to lyse the platelets and "stop" the reaction 
after incubation of PRP with pharmacological agents. This was achieved by preparing 
a solution containing 18ul of a 1 in 10 dilution in distilled water of stock 14C-cyclic 
AMP per 2ml 15% TCA. Percentage conversion of 3H-adenine to 3H-cyclic AMP in 
each sample could then be corrected for cyclic AMP recovery, by comparison of 14C 
counts in samples of column eluate with total 14C-cyclic AMP originally added to each 
sample.
Column Washing and Regeneration.
After elution of the cyclic AMP, the first set of alumina columns were washed 
with 5ml of 0 .2M  ammonium formate, followed by 5ml 10% TCA, the Dowex 
columns were washed with 5ml 1mM potassium phosphate buffer, and the final 
alumina columns with 10ml 0.1M  imidazole. The purpose of this was to ensure 
complete elution of any remaining cyclic AMP to prevent carry over between 
experiments. When 14C-cyclic AMP was added to columns and eluted as described, 
2.8%  of 14C counts were recovered on washing the Dowex with 5ml potassium 
phosphate buffer, and further washing did not elute any more cyclic AMP. For the
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first set of alumina columns, 6% of 14C counts were recovered in the first 3ml the 
ammonium formate wash, and further washing resulted in no further recovery of 14C- 
cyclic AMP. For the second set of alumina columns, UC counts in the 10ml imidazole 
wash were equal to the background count.
Before use on each occasion columns were primed as follows: the first set of 
alumina columns with 10ml 10% TCA as described by Gray; Dowex columns with 
10ml 0 .5M  HCI and 15ml distilled water as recommended by the manufacturer; and 
the final alumina columns with 10ml 0.1M  imidazole as described by Salomon.438
All columns were replaced every 3 months, and with this protocol no 
deterioration in cyclic AMP recovery or any increase in basal cyclic AMP levels was 
noted in successive experiments.
Counting of Samples.
All samples were counted in glass vials on a Beckman LS 8000 counter after 
adding 15ml Optiphase Hisafe II liquid scintillant. The windows were set so that 
virtually all of 3H emissions were counted in channel 1 with negligible spillover to 
channel 2 (Channel 1 =  0 -4 5 0 ,3H spillover to channel 2 =  0 .18% ). The majority of 
14C emissions were counted in Channel 2 (450-655 ), but, on average, 33%  spillover 
of 14C counts to Channel 1 occurred, making it necessary to correct for spillover of 
14C counts to channel 1 when results were calculated. Two vials containing only 14C- 
cyclic AMP were used as crossover controls. The Beckman LS 8000 was calibrated 
using a series of quenched standards for 3H and 14C supplied by the manufacturer. 
The counting efficiencies for 3H and for 14C respectively using the dual isotope 
program, at the quench of the experimental samples, were 51%  and 94% . The 
program used incorporated an automatic quench control which adjusted the cpm in 
each channel for sample quench. Uniformity of quench in samples and totals in the 
cyclic AMP assay was in any case ensured by adding 6ml imidazole to samples used
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to assess 3H and 14C totals, those used to assess UC crossover, and those used to 
assess uptake of 3H>adenine, as cyclic AMP in experimental samples was eluted from 
the columns in 6ml imidazole.
In each assay, the following totals and controls were counted along with 
experimental samples. Vials containing 10ul of the 3H-adenine solution originally 
added to the PRP were counted in triplicate to assess the total 3H-adenine added to 
each sample. In order that 3H-adenine uptake could be calculated, 2 vials containing 
50ul of platelet poor plasma were counted. The platelet poor plasma was prepared 
at the end of the 90 minute incubation period of PRP with 3H-adenine, as described 
in the section above on 3H-adenine uptake. Total 14C counts added to each sample 
were assessed by counting 18ul of the solution of 14C-cyclic AMP prepared by 
diluting the stock radiochemical by a factor of 10 in distilled water. Crossover 
controls were prepared by adding 18ul of the undiluted stock 14C-cyclic AMP to 
scintillation vials. Finally, blank vials containing only imidazole and 15ml of 
scintillation cocktail were counted to enable correction of all counts for background 
radiation.
Calculation of Results.
The procedure used for calculating % conversion of 3H-adenine to 3H-cyclic 
AMP is summarised in the Appendix 2 together with a worked example of the 
calculation of results from raw data. In practice, a computer program written by Dr 
A. Kelman, University of Glasgow was used to calculate results in each experiment 
in the studies undertaken. The program was validated by comparing results calculated 
by myself from raw data with those obtained using the program, and showing that 
results obtained by both methods were identical.
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Final Protocol For Measurement of Platelet Cyclic AMP.
A flow chart summarising the final protocol used for the assay of platelet 
cyclic AMP is illustrated in Figure 2.6. Centrifugation of the 3H labelled PRP for 
measurement of 3H-adenine uptake was carried out at 2°C, at 4,000g for 10minutes. 
Details of drug incubation protocols for each study are given in the relevant chapters. 
In all cases samples in each subject studied were assayed in duplicate. Samples were 
thoroughly vortex mixed for 1 minute following the addition of the trichloroacetic acid 
to lyse the platelets and extract cyclic AMP. Subsequent centrifugation to deposit 
platelet debris was carried out at 2°C, at 4,000g for 30 minutes for the first spin, and 
5 minutes for the second spin. The details of column chromatography are not shown 
in Figure 2.6, but were exactly as described in the foregoing text.
Intra-Assav Variation.
Using the final protocol described, the intra-assay variation was 6.5%  for 
measurement of basal cyclic AMP levels, 5.2%  for measurement of platelet cyclic 
AMP in the presence of maximal concentrations of the phosphodiesterase inhibitor 
AH-P719, and 5.8% -9.6%  for measurement of cyclic AMP when platelets were 
incubated with an adenylate cyclase stimulator, depending on the nature of the 
pharmacological agent and its concentration.
Determination of Platelet Cyclic AMP Responses to Adenvlate Cvclase Stimulators 
and a Phosphodiesterase Inhibitor.
Some pilot experiments were carried out to ensure that dose dependent 
increases in cyclic AMP could be detected using the 3H-adenine pre-labelling assay 
when platelets were incubated with standard adenylate cyclase stimulators and with 
a phosphodiesterase inhibitor. The results of these experiments were also taken into 
account when choosing concentrations of pharmacological agents for subsequent 
study protocols. Examples of dose response curves obtained when platelets from
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FIGURE 2.6 FINAL PROTOCOL FOR MEASUREMENT OF 
PLATELET CYCLIC AMP 
CITRATED PRP (platelet count =  2 5 0  x 1 0 9/l)
1
INCUBATE W ITH  3H-ADENINE 37°C  90  M INUTES
i /  1
REMOVE 450u l x 2  DRUG INCUBATIONS
+ 50ul saline 450u l PRP +  50ul drug additions
i
Centrifuge
i STOP W ITH 2ml 15%  TCA with
Count 50//I 14C-cAM P  recovery label
of supernatant: CENTRIFUGE X  2
assess 3H-adenine uptake
SEQUENTIAL COLUMN CHROMATOGRAPHY
ALUM!NA:ELUTE IN 5ml A M M O N IU M  FORMATE
DOWEX:ELUTE IN 8ml K PHOS. BUFFER
ALUMINA:ELUTE IN 6ml IMIDAZOLE
COUNT W ITH TOTALS
ON SCINTILLATION COUNTER
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healthy subjects were incubated with the PGI2 analogue iloprost, with PGD2, and with 
the phosphodiesterase inhibitor AH-P719 are illustrated in Figures 2 .7-2.9 .
3.5 Assay of Thromboxane B? in Serum and in PRP.
Sample Preparation.
For estimation of serum thromboxane B2 blood was taken into a glass tube 
containing no anticoagulant and was allowed to clot at 37°C for 30 minutes. The 
sample was then centrifuged at 2,000g at room temperature for 10 minutes and the 
upper layer of serum carefully aspirated off using a plastic Pasteur pipette. The serum 
was immediately frozen at -70°C and, within 3 months, was subjected to 
radioimmunoassay for thromboxane B2, the stable hydrolysis product of thromboxane 
A 2.
Platelet Thromboxane Production.
For measurement of platelet thromboxane B2 production, adjusted PRP was 
incubated and stirred at 1,000rpm in the Biodata PAP 4 aggregometer for 2 minutes 
before adding arachidonic acid, final concentration 1mM. Platelet aggregation was 
then allowed to proceed for 4 minutes, at which time 200ul PRP was pipetted out 
and immediately added to a plastic Eppendorf tube containing 200ul of ice cold 
absolute alcohol. The tube was thoroughly vortex mixed. This procedure served to 
"stop" the reaction and to lyse the platelets, releasing the thromboxane B2. The 
sample was then immediately frozen at -70°C and radioimmunoassay for 
thromboxane B2 carried out within 3 months.
Thromboxane B7 Radioimmunoassay.
This assay depended upon competition between 'cold' thromboxane in the 
unknown sample or standard with 3H-thromboxane B2 for binding to a specific anti­
thromboxane B2 antibody.
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PLATELET CYCLIC AMP RESPONSE TO AH-P719
Oi T 1.0 10.0 100 T 1000
AHT719conc W
FIGURE 2 .7 .
A concentration-response curve of platelet cyclic A M P  levels fo llow ing  
trea tm en t o f PRP w ith  A H -P 7 1 9  is show n. The data w ere  obtained from  a 
single experim ent. The x axis has a log scale. PRP w as incubated w ith  the  
phosphodiesterase inhibitor for 8 m inutes. A H -P 7 1 9  appears to  exert its 
m axim um  e ffe c t a t a concentration of 1 0 0 //M .
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PLATELET CYCLIC AMP RESPONSE TO ILOPROST
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FIGURE 2 .8 .
A concentration-response curve of p latelet cyclic A M P  levels follow ing  
trea tm en t of PRP w ith  iloprost in the presence of A H -P 7 1 9  (1 0 0 //M ) is show n. 
The data illustrated w ere  obtained from  a single experim ent. The x axis has 
a log scale. PRP w as incubated w ith  the phosphodiesterase inhibitor for 2 
m inutes before adding iloprost; incubation w as then continued for a further 6 
m inutes.
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PLATELET CYCLIC AMP RESPONSE TO PGD2
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FIGURE 2 .9 .
A  concentration-response curve of platelet cyclic A M P  levels fo llow ing  
tre a tm en t o f PRP w ith  PGD2 in the presence o f A H -P 7 1 9  ( 1 0 0 //M ) is show n. 
The data w ere  obtained from  a single experim ent. The x axis has a log scale. 
PRP w as incubated w ith  the phosphodiesterase inhibitor for 2 m inutes before  
adding PG D2, and incubation w as then continued for a fu rther 6 m inutes.
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On the day of performing the assay serum and platelet samples were allowed to 
reach room temperature. The platelet samples were centrifuged at full speed in a 
microfuge (Eppendorf Centrifuge 5414 S) for 3 minutes to deposit platelet debris, and 
the supernatant was carefully pipetted off. All samples were then diluted in Tris-saline 
assay buffer. Serum samples were diluted 1 in 500 and 1 in 1,000. Platelet samples 
were diluted 1 in 1,000, 1 in 2 ,000 and 1 in 5 ,000. Cold thromboxane Bj standard 
was diluted in tris-saline assay buffer to concentrations ranging from 1 pg/1 OOul to 
100pg/100ul. An internal quality control standard, prepared from a single batch of 
cold thromboxane B2, was also run with each assay. The 3H-thromboxane B2 (specific 
activity 210Ci/mmol, chemical concentration 0.476M ) was diluted by adding 10ul of 
the radiochemical to 33ml Tris-saline with gelatin. The anti-thromboxane B2 antibody 
was diluted from stock to a final dilution of 1 in 80 ,000  in Tris-saline with added 
gelatin. This was shown in an antibody dilution curve to result in 50%  binding of 3H- 
thromboxane B2 when conditions were as standard in the assay, except that Tris- 
saline buffer replaced cold thromboxane B2. The antibody dilution curve is illustrated 
in Figure 2.10. One hundred microlitres of each of the following was then added to 
assay tubes in duplicate: 1) diluted unknown sample or diluted standard, 2) diluted 
3H-thromboxane B2, 3) diluted antiserum. The following control tubes were also set 
up in duplicate: 1) B0 tubes containing 3H-thromboxane B2, and antiserum, but with 
Tris-saline in place of unknown sample, 2) 'totals' (CT) and 'non specific binding' 
(NSB) tubes containing 3H-thromboxane B2 with assay buffer in place of antiserum 
and unknown sample. All the tubes were then vortex mixed, capped and left at 4°C 
overnight. The following day, 1 ml of a solution of charcoal was added to all tubes 
except the 'totals', to adsorb the remaining unbound 3H-thromboxane B2 in the 
sample. 1 ml of a mixture of 1 part Tris-saline buffer and 2 parts Tris-saline gelatin 
was added to the 'totals' tubes. All tubes were allowed to stand for 12 minutes at
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ANTIBODY DILUTION CURVE 
FOR ANTITHROMBOXANE B2 ANTIBODY
O
O
70-X
CD
U 1:z:
CD
cn  zz:
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CD
RECIPROCAL OF ANTIBODY DILUTION
FIGURE 2 .1 0
The %  specific binding of 3H-throm boxane B2 to  the anti-throm boxane B2 
antibody is plotted against the reciprocal o f the  antibody dilution. The scale 
on the  x axis is a log scale. No "cold" throm boxane B2 w as present in this 
experim ent. The antibody bound 5 0 %  of the 3H -throm boxane w hen  it w as at 
a dilution o f 1 :8 0 ,0 0 0 . B0 =  dpm in tubes containing 3H -T X B 2 and antibody, 
fo llow ing adsorption of unbound 3H -T X B 2; C T =  total 3H -T X B 2 added to tubes; 
NSB (non specific binding) =  dpm  in tubes containing 3H -T X B 2, but no 
antibody, in w hich  unbound 3H -T X B 2 had been adsorbed.
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4°C and then all tubes except 'totals' were centrifuged at 4,000g for 10 minutes at 
4°C. The supernatant was then carefully decanted into scintillation vials and 10ml of 
Packard 199 scintillation cocktail added. The entire contents of the 'totals' vials were 
also placed in scintillation vials to which scintillation fluid was subsequently added. 
All vials were counted for 5 minutes on an LKB 1215 Rackbeta scintillation counter 
on a single label program whose parameters were optimised for counting tritium. The 
counting efficiency for tritium at the quench of the samples was 32.6% . The mean 
of duplicate dpms for each sample was calculated, and a standard curve constructed 
by plotting % 3H-thromboxane B2 binding to antibody in standard samples against 
concentration of standard. Percentage binding was calculated as follows:
dpm of standard - dpm in NSB 
dpm in B0 * dpm in NSB
% binding in unknown samples was then calculated and thromboxane B2
concentration read from the standard curve. The quality of the assay was monitored
1) by calculating the percentage binding of the 3H-thromboxane B2 to antibody in the
absence of competition from cold thromboxane (dpm B0/dpm CT x 100); 2) by
calculating the % non specific binding (dpm NSB/dpm CT); 3) by ensuring that the
internal quality control standards lay on the standard curve when values of %  binding
in these samples were plotted against their concentration. Values of % Bq/CT were
considered acceptable if they lay between 35%  and 50% . % NSB was acceptable if
it was below 4% . Any assay run not fulfilling these criteria was repeated. The
coefficient of variation of the assay, calculated by assessing the mean and standard
deviation of values obtained for a serum sample assayed four times within the same
assay run, was 9.9% .
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3.6 Platelet Aggregation In Whole Blood.
Measurement of platelet aggregation in whole blood offers the advantages that 
subpopulations of active platelets are not lost, as they may be during preparation of 
PRP, and platelet behaviour may be examined in a more physiological milieu. Two 
techniques are available for assessment of platelet aggregation in whole blood. The 
first depends upon changes in electrical impedance when platelets form aggregates,54 
the second involves the measurement of the reduction in number of single platelets 
in whole blood as aggregation proceeds. I have chosen to use the platelet counting 
method, as first described by Fox et al.52 For such studies, blood collected into 
3 .13%  trisodium citrate (1 part citrate : 9 parts blood) was allowed to equilibrate at 
37°C in a waterbath for 30 minutes. 0.48ml aliquots of whole blood were then 
pipetted out and placed in polystyrene tubes containing a metal stir bar. These tubes 
were immediately placed in a circulating waterbath at 37°C over a magnetic stirring 
base set to ensure a constant stirring speed of 1,000 rpm. After 2 minutes 20ul of 
a solution of an appropriate platelet agonist was added to induce aggregation, and 
incubation and stirring continued for a further 8 minutes. 15ul subsamples of blood 
were removed before placing the experimental tubes in the waterbath, at 0 .25 , 0.5, 
0 .75 , 1, 2, 4, and 8 minutes following the addition of the agonist. These 15ul 
subsamples were immediately placed in polystyrene tubes containing 30ul of a 
platelet fixing solution (see materials section). When experiments designed to assess 
the effects of inhibitors upon platelet aggregation in whole blood were carried out, 
20ul of a solution of the inhibitor was placed in the experimental tubes before adding 
the blood, and the volume of blood added was adjusted to 0.46m l, ensuring that the 
final volume in each experimental tube was always 0.5ml.
The platelet count in the subsamples was measured within 3 hours using the 
Ultraflo-100 which measures the platelet count in whole blood by a technique
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dependant on counting the ratio of platelets to red cells. The machine was primed 
using intravenous infusion saline (0 .15M), and an arbitrary red cell count was dialled 
in. 30ul of fixed blood was added to plastic Ultraflo vials filled with 9.1ml of infusion 
saline, the vials mixed by inversion, and counted in duplicate. The background count 
in a vial containing saline only was previously checked and the solution discarded if 
the count was greater than 2. The percentage reduction in single platelets in each 
original experimental sample was calculated from the platelet counts in each timed 
subsample and those in the subsample taken before stirring and incubation was 
begun. A worked example of the calculation is shown in the Appendix 3. In practice 
a computer program prepared by Dr A. Kelman, University of Glasgow, based upon 
this calculation, was used to calculate experimental results. When an arbitrary red cell 
count is dialled into the Ultraflo, the true platelet count in each subsample can be 
determined by multiplying the count obtained by the ratio of true red cell 
count/arbitrary red cell count. Although the true red cell count was determined for 
each experimental subject, the platelet counts obtained from the Ultraflo were not 
corrected in this way as the final results were expressed as the percentage decrease 
in platelet count, and this was unaffected by correction for true red cell count. The 
intra-assay coefficient of variation for measurement of platelet aggregation in whole 
blood following stimulation with 0.3uM U46619 was between 5% and 11% for all 
time points except at 15seconds after the addition of the agonist, when the 
coefficient of variation was 18%.
3.7 Haematology and Biochemistry.
Full blood counts were performed on blood collected into EDTA from each subject 
in all studies. This was carried out in the Department of Haematology, University 
Hospital, Nottingham, using a Coulter counter model S plus IV for the majority of 
samples. For the studies described in Chapters 6 and 7, full blood counts were
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performed using a Sysmex NE8000 multiparameter counter. Both machines were 
subject to regular internal and external quality control.
For those studies in which patients with PIH or pre-eclampsia formed one of the 
study groups, serum samples were analyzed in all subjects for urea and electrolytes 
and uric acid, and urinary protein content was quantified in subjects with PIH or pre­
eclampsia. These analyses were carried out in the Department of Clinical Chemistry, 
University Hospital, Nottingham. Serum urea, creatinine, and urate were analyzed on 
a Hitachi 712 analyzer (Boehringer Mannheim Ltd) using diacetyl monoxime, alkaline 
picrate and uricase methods respectively. Urine total protein was measured by 
nephelometry following precipitation with a mixture of sulphosalicylic acid (30g/l) and 
sodium sulphate (140g/l).
4. STATISTICAL ANALYSIS
As much of the data generated from platelet studies were not normally distributed, 
non parametric statistical tests were generally used unless otherwise stated. For 
cross sectional studies involving 2 subject groups, the Mann-Whitney U test was 
employed, and for those where the objective was to compare 3 subject groups, the 
Kruskal-Wallis one way analysis of variance was used. In general, p values less than
0.05  were considered statistically significant, but for studies of platelet aggregation 
in whole blood, only p values less than 0.01 were considered significant as the 
design of the experiments demanded that repeated two sample tests were performed 
on data from the same subjects, and after taking statistical advice, no suitable non 
parametric analysis of variance could be found. For clarity of illustration results are 
shown as means +. standard error of the mean (SEM) unless otherwise stated. All 
statistical analysis was carried out using a computer program provided by Dr A. 
Kelman, University of Glasgow (Statis 3, Clydesoft Statistical and Scientific 
Software).
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CHAPTER 3.
A CROSS SECTIONAL STUDY OF THE EFFECT OF 
INHIBITORY PROSTAGLANDINS AND OTHER CYCLIC AMP 
MANIPULATORS ON PLATELET BEHAVIOUR IN HEALTHY 
AND HYPERTENSIVE PREGNANCY
A CROSS SECTIONAL STUDY OF THE EFFECT OF INHIBITORY 
PROSTAGLANDINS AND OTHER CYCLIC AMP MANIPULATORS ON 
PLATELET BEHAVIOUR IN HEALTHY AND HYPERTENSIVE PREGNANCY
1. INTRODUCTION
There is some evidence that platelets during pregnancy may be less 
sensitive to the inhibitory effects of prostacyclin in vitro,330,331,332 and that this 
effect may be more marked in pre-eclampsia.331,332 Furthermore, one study showed 
that the thromboxane synthetase inhibitor dazoxiben was less effective as an 
inhibitor of platelet behaviour in vitro in PRP from healthy and hypertensive 
pregnant women.322 As discussed in the introductory chapter, prostacyclin 
produces its inhibitory effects on platelets by acting on a specific receptor195,186 
to stimulate adenylate cyclase,165,166 resulting in an increase in the level of 
intracellular cyclic AMP. The inhibitory effects of thromboxane synthetase 
inhibitors are also at least in part mediated by cyclic AMP, as PGD2 is synthesised 
from cyclic endoperoxides by a diversion pathway when thromboxane synthetase 
is blocked.247,248,249
The study reported in this chapter was designed to investigate whether the 
loss of platelet sensitivity to prostacyclin during pregnancy could be demonstrated 
in vitro with other pharmacological agents which inhibit platelet behaviour by 
increasing cyclic AMP, and also to determine whether there were further 
differences in platelet responses to these agents in PIH and pre-eclampsia. A wide 
range of cyclic AMP manipulators which act at different points in the pathway has 
been investigated with the purpose of gaining some insight into the mechanism 
of any changes demonstrated in platelet responses to inhibitory prostaglandins.
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2. METHODS
2.1 Subjects.
The study was cross sectional in design with a total of 84 subjects who 
were divided into three groups: 1) 26 healthy non pregnant women, age 26.+ 0.9  
years (mean ±_ SEM); 2) 27 healthy third trimester primigravid women, age 
2 3 .2 ji0 .9 6  years; 3) 31 women with PIH or pre-eclampsia , age 24_±0.75 years. 
The criteria for subject selection were as outlined in Chapter 2. Twenty-four 
women in the PIH/pre-eclampsia group met the criteria for pre-eclampsia, while 
seven had non proteinuric PIH. Twenty-seven of the PIH/pre-eclampsia group were 
primigravid, four patients were multiparous, three of whom had a previous history 
of pre-eclampsia, and one had a new partner for the pregnancy studied. Twenty- 
six patients in the hypertensive group had received no treatment, three patients 
had received labetolol, one had received phenytoin for seizure prophylaxis, and one 
had received intravenous hydralazine some hours before the study. In all of these 
cases clinical signs of severe pre-eclampsia were present at the time of study. 
Subjects were placed in the supine position and after 5 minutes rest blood 
pressure was measured and blood withdrawn for platelet studies, full blood count, 
serum thromboxane B2 and urea and electrolytes and uric acid.
2 .2  Laboratory Methods.
Platelet studies were conducted in PRP in which the platelet count had 
been adjusted to 250 x 109/l. In eight subjects, all of whom had pre-eclampsia, it 
was not possible to conduct experiments at a final adjusted PRP count of 250 x 
109/l. All of these subjects had whole blood platelet counts less than 200 x 109/!, 
and six had thrombocytopenia as defined by a whole blood platelet count less than 
150 x 109/l. The final adjusted PRP counts in these cases ranged from 85 x 109/l
141
to 245 x 109/l. There was, however, no overall difference between subject groups 
in the platelet count in adjusted PRP (p =  0.2908).
The effect of cyclic AMP manipulators on platelet 14C-5HT release induced 
by 1mM arachidonic acid was examined. The pharmacological agents used were 
as follows: the stable prostacyclin analogue iloprost at final concentrations of 0.1 - 
10ng/ml, PGD2 0.01-0.5ug/m l, forskolin 0.2-4.0ug/ml, the cyclic AMP specific 
phosphodiesterase inhibitor AH-P719 0.005uM -1uM , and the thromboxane 
synthetase inhibitor dazmegrel at final concentrations of 10OuM and 500uM. PRP 
was incubated for 2 minutes at 37°C with these inhibitory agents in all cases 
before inducing aggregation and release with 1mM arachidonic acid (AA). Details 
of the laboratory methods used for measuring 14C-5HT release from platelet dense 
granules, and for estimation of serum thromboxane B2 have already been 
documented in Chapter 2.
For the purpose of statistical analysis, subjects with PIH and pre-eclampsia 
were treated as one group, since no difference in laboratory results could be 
demonstrated between subjects in these categories when treated separately. All 
comparisons between non pregnant, healthy pregnant, and hypertensive pregnant 
groups were carried out using Kruskal-Wallis one way analysis of variance by 
ranks. The Mann-Whitney U test was used to check similarity of gestation in 
healthy pregnant and hypertensive pregnant groups. The Fisher exact test was 
used to analyze the responder status to the thromboxane synthetase inhibitor in 
the three subject groups.
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TABLE 3.1
PERIPHERAL BLOOD HAEMATOLOGY
The table shows some haematological data from the non pregnant subjects 
(NP), the healthy pregnant subjects (HP) and the subjects w ith PIH or pre­
eclampsia (PIH). Values are means ±  SEM for all parameters
NP HP PIH p value Comparison
PCV 0.380 ±0.005 0.355±0.0009 0.362±0.008 <0.01
<0.05
NP v HP 
NP v PIH
Platelet Count 
(xl 09/l)
265± 12 272± 15 202 ±14 <0.01
<0.01
NP v PIH 
HP v PIH
MPV (fl) 8.81 ±0.19 8.36 ±0.32 10.52 ± 0.37 <0.01
<0.01
NP v PIH 
HP v PIH
PDW 16.27 ±0.08 17.15 ± 0.14 17.3 ± 0.14 <0.01
<0.01
NP v HP 
NP v PIH
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TABLE 3 .2
BIOCHEMICAL PARAMETERS OF RENAL FUNCTION
The table shows some biochemical parameters for the non pregnant subjects (NP), 
the healthy pregnant subjects (HP) and the subjects with PIH or pre-eclampsia (PIH). 
Values are means ± SEM for all parameters NA = not applicable
NP HP PIH p value Comparison
Proteinuria* - 2.64 ±0.70t NA -
Serum urate 206 ±10.12 
U'mol/I)
230 ±14 378 ± 24.6 <0.01
<0.01
NP v PIH 
HP v PIH
Serum urea 4.06 ±0.16
(mmol/l)
3.15 ±0.15 4.29 ±0.29 <0.01
<0.01
NP v HP 
HP v PIH
Serum creatinine
U/mol/l) 83.2 ±2.28 73.4 ± 2.49 87.8 ±4.5 <0.05
<0.05
NP v HP 
HP v PIH
"Proteinuria was not quantified in non pregnant and healthy pregnant subjects as none 
showed proteinuria on urine dip-stick testing. In six out of 31 hypertensive pregnant 
subjects the requirement for urgent delivery of the baby precluded quantification of 
proteinuria. All six showed unequivocal proteinuria on dip-stick testing. Data are 
shown for the remaining 25 subjects
t 7 out of 25 patients had non proteinuric PIH
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3 .RESULTS
3 .1  Clinical Data.
The normal pregnant patients were at 3 5 .4 ^ 0 .7 3  weeks gestation at the 
time of study, and those with hypertension at 34.1_±0.74 weeks (p = 0 .1988). 
None of the subjects was in labour at the time of study. Diastolic blood pressure 
was significantly higher (p<0.01)in  the hypertensive pregnant group 
(96.4jfc.1-92 mmHg) than in the healthy pregnant (70 .5± ,2 .0  mmHg) and non 
pregnant groups (71 .5jfc,1.88 mmHg). The majority of the hypertensive group met 
the criteria for pre-eclampsia.
3 .2  Haematoloov and Biochemistry.
Haematological and biochemical data are illustrated in Table 3.1 and 3.2. 
Packed cell volume (PCV) was significantly lower in normal and hypertensive 
pregnant subjects compared with non pregnant subjects. There was no difference 
in platelet count in whole blood between non pregnant and pregnant subjects, but 
the platelet count was significantly lower in the hypertensive pregnant group in 
comparison with both other groups, and seven subjects with pre-eclampsia were 
thrombocytopenic, as defined by a whole blood platelet count less than 150 x 
109/l. Mean platelet volume (MPV) was likewise significantly higher in the 
hypertensive group, and platelet distribution width (PDW) was significantly and 
similarly increased in both healthy and hypertensive pregnant subjects compared 
with that in non pregnant women. Uric acid was raised in the hypertensive 
pregnant subjects in comparison with healthy pregnant and non pregnant women.
3 .3  Arachidonic Acid Induced Platelet Dense Granule Release.
In the absence of inhibitors, the extent of 14C-5HT release was greater in 
response to stimulation with 1 mmol/1 arachidonic acid (AA) in PRP from pregnant 
individuals than in PRP from non pregnant women (Fig 3.1). There was no
145
Arachidonic Acid Induced Platelet 
Dense Granule Release
<D
V)CO_0)
0)
cc
I
inI
O
Non Pregnant 
Pregnant
Hypertensive Pregnant
6 0 -
4 0 -
2 0 -
Arachidonic Acid 1m M
Figure 3.1
The figure shows the extent of the platelet release reaction on stimulation with 
1 mmol/l arachidonic acid in the absence of inhibitors of platelet behaviour in the three 
subject groups. Hypertensive pregnant = pregnancy induced hypertension and pre­
eclampsia. Means and standard errors are illustrated. # * =  p < 0 .0 1 , comparing non 
pregnant with pregnant; * =  p < 0 .0 5  comparing healthy pregnant with hypertensive 
pregnant subjects.
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Figure 3 .2
The figure shows the effect on the arachidonic acid induced platelet release 
reaction of increasing concentrations of iloprost in PRP from one subject. The x 
axis has a log scale. In this case the release reaction is abolished at or above 
1 ng/ml iloprost. Concentrations less than 1 ng/ml have little effect on the extent of 
the release reaction. The "threshold" concentration of iloprost is therefore 1 ng/ml.
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difference between non pregnant and hypertensive pregnant women, but the latter 
demonstrated significantly less dense granule release than the healthy pregnant 
group. Some of the patients with severe pre-eclampsia showed particularly 
reduced secretory responses, three subjects with fulminating disease releasing 
< 4 0 %  14C-5HT following stimulation with 1mmol/l arachidonic acid. Although 
coagulation studies were not formally included in this study, coagulation screens 
were carried out as part of the clinical investigation in the majority of subjects in 
the PIH/pre-eclampsia group. These data were retrieved retrospectively in view of 
the possibility that the reduction in dense granule release was due to platelet 
'exhaustion' secondary to disseminated intravascular coagulation (D.I.C.). Two out 
of the three pre-eclamptic patients demonstrating <  40%  14C-5HT release had 
evidence of D.I.C. with thrombocytopenia, prolonged thrombin clotting times, 
raised fibrin degradation products and microangiopathic haemolysis.
3 .4  Inhibition of Arachidonic Acid Induced Platelet Behaviour bv Cyclic 
AM P Manipulators.
When PRP from all subjects was incubated in the presence of iloprost, 
PGD2, forskolin, and AH-P719, as the concentration of the inhibitor was increased, 
a clear point was reached at which total abolition of platelet aggregation and 
release occurred. This was termed the threshold concentration of the inhibitor and 
was noted for each of these agents in each subject. An example of how the 
threshold was determined for iloprost is shown in Figure 3.2.
Inhibition of Platelet Behaviour bv Adenvlate Cvclase Stimulators 
Acting via Surface Receptors.
The threshold concentrations of iloprost and PGD2 required to abolish 
platelet aggregation and release are shown in Figures 3.3 and 3.4. Significantly 
higher concentrations of both prostaglandins were required to inhibit platelet
148
"Threshold” Concentration of cAMP Manipulators
Required to Abolish Platelet Aggregation and Release
4
D  Non Pregnant 
I I  Pregnant
0  Hypertensive Pregnant
2
0
llo p ro s t Forsko lin
lloprost = ng/ml 
Forskolin = jig/m l
Figure 3 .3
The figure shows the lowest concentration of iloprost and of forskolin at which 
AA induced platelet aggregation and release were totally abolished. Values are 
means with bars indicating S.E.M. In each case, comparison of non pregnant with 
healthy pregnant, and non pregnant with hypertensive pregnant subjects yielded a 
p value of < 0 .0 1 .
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"Threshold" Concentration of cAMP Manipulators
Required to Abolish Platelet Aggregation and Release
4
□  Non Pregnant 
H  Pregnant 
0  Hypertensive Pregnant
1
A H P 719PGD
P G D 2 = jig/ml 
A H P719 = }iM
Figure 3 .4
The figure shows the lowest concentration of PGD2 and of AH-P719 at which AA  
induced platelet aggregation and release were totally abolished . Values are means 
with bars indicating S.E.M. In each case, comparison of non pregnant with healthy 
pregnant, and non pregnant with hypertensive pregnant subjects yielded a p value 
of < 0 .0 1 .
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Effect of lloprost on the Platelet Release Reaction
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Figure 3 .5
Percentage release of 14C-5HT is plotted against concentration of iloprost for each 
subject group. The x axis has a log scale. All values are means _+ S.E.M. The 
concentration-response curve is shifted to the right in both healthy and 
hypertensive pregnant subjects compared with non pregnant subjects.
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Effect of prostaglandin D2 on the
Platelet Release Reaction
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Figure 3 .6
Percentage release of 14C-5HT is plotted against concentration of PGD2 for each 
subject group. The x axis has a log scale. All values are means _+ S.E.M. The 
concentration-response curve is shifted to the right in healthy and hypertensive 
pregnant subjects, compared with non pregnant subjects.
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behaviour in both healthy pregnant and hypertensive pregnant groups compared 
with the non pregnant group. There was no difference between normal 
primigravidae and women with PIH or pre-eclampsia. The loss of platelet 
sensitivity to inhibition of their behaviour by these prostaglandins during 
pregnancy could also be demonstrated by a shift in the concentration response 
curve to the right as illustrated in Figure 3.5 and 3.6.
Inhibition of Platelet Behaviour bv Forskolin.
A similar pattern was seen when the effects of forskolin on arachidonic 
acid induced platelet dense granule release were investigated. Figure 3 .3  shows 
that a higher concentration of forskolin was required to abolish platelet 
aggregation and release in healthy and hypertensive pregnant women compared 
with non pregnant controls. Again, there was no difference between normal 
pregnant subjects and those in the PIH/pre-eclampsia group. The loss of sensitivity 
to forskolin is also evident from the concentration response curve illustrated in 
Figure 3.7.
Inhibition of Platelet Behaviour bv the Phosphodiesterase Inhibitor AH-P719.
Threshold concentrations of the PDE inhibitor AH-P719 required to abolish 
platelet aggregation and release in each subject group are illustrated in Figure 3.4  
and the concentration response curve for this agent is shown on Figure 3.8. It can 
be seen that platelet sensitivity to AH-P719 was again significantly and similarly 
reduced in both pregnant groups of subjects compared with non pregnant controls, 
although this effect was less marked than in the case of the adenylate cyclase 
stjmulators.
Inhibition of Platelet Behaviour Bv Dazmeorel.
It was not appropriate to analyze the data relating to the thromboxane 
synthetase inhibitor dazmegrel in terms of an inhibitory threshold concentration as
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Figure 3 .7
Percentage release of 14C-5HT is plotted against concentration of forskolin for 
each subject group. The x axis has a log scale. All values are means _+ S.E.M. The 
concentration-response curve is shifted to the right in healthy and hypertensive 
pregnant subjects, compared with non pregnant subjects.
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Effect of AHP719 on the
Platelet Release Reaction
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Figure 3 .8
Percentage release of 14C-5HT is plotted against concentration of AH-P719 for 
each subject group. The x axis has a log scale. All values are means +_ S.E.M. The 
concentration-response curve is slightly shifted to the right in healthy and 
hypertensive pregnant subjects, compared with non pregnant subjects.
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NON RESPONDERS/PARTIAL RESPONDERS TO DAZMEGREL
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PREGNANT
Figure 3 .9
The bar graph shows the proportion of subjects in each group who were "non 
responders" to the thromboxane synthetase inhibitor dazmegrel. The shaded bars 
represent those subjects whose platelet behaviour was not completely inhibited by 
either 100/;M  or 500/;M  dazmegrel, and the unshaded bars represent subjects 
whose platelet behaviour was completely inhibited by 500 //M  but not by 100/yM 
dazmegrel. The number of non responders to dazmegrel was significantly 
increased in both healthy and hypertensive pregnancy (p < 0 .0 0 0 1  for 100uM  
dazmegrel, and p < 0 .0 0 0 0 1  for 500//M  dazmegrel, Fisher exact test).
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PLATELET RELEASE REACTION IN PRESENCE OF DAZMEGREL
1 1 ^°nI I Pregnant
rm Hypertensive 
^  Pregnant
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CONTROL DAZMEGREL
lOOfiM
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FIGURE 3 .1 0
The bar graph shows the effect on the extent of the arachidonic acid induced platelet 
release reaction of the thromboxane synthetase inhibitor dazmegrel. It is evident that 
the release reaction was inhibited to some extent in all groups of subjects by both 
concentrations of dazmegrel. In the presence of 100//M  dazmegrel, the p value for 
Kruskal-Wallis ANOVA was 0 .0 0 0 2 , and extent of the release reaction was 
significantly greater in pregnant compared with non pregnant and hypertensive 
pregnant subjects (p <  0 .01 ). In the presence of 500//M  dazmegrel, the Kruskal- 
Wallis ANOVA p value was < 0 .0 0 0 0 1 , and the extent of the release reaction was 
significantly greater in pregnant (p <  0 .01 ) and hypertensive pregnant (p <  0 .05 ) 
subjects compared with non pregnant women. In this case comparison of the 
pregnant and hypertensive pregnant groups revealed no significant difference.
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TABLE 3.3
SERUM THROM BOXANE B2
The table shows means and SEM of levels of thromboxane B2 in serum in 
the three subject groups. There was no significant difference in results
between groups (p =  0 .9 6 8 ).
GROUP SERUM THROMBOXANE B2 
pm oles/107 platelets
Non Pregnant 3 3 .8 6  ± 3 .2 0
Healthy Pregnant 3 3 .7 2 ±  3 .4 6
Hypertensive Pregnant 4 2 .4 8  ± 7 .7 5
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the effects of only two concentrations were investigated. It is well established 
outwith the context of pregnancy that individuals can be divided into 'responders' 
or 'non responders' to thromboxane synthetase inhibitors depending upon whether 
complete inhibition of their platelet behaviour is observed in vitro in the presence 
of the drug.247*249,252,253 In the present study, when subjects were divided into 
responders and non responders for each concentration of dazmegrel there was a 
significantly increased proportion of subjects in both healthy and hypertensive 
pregnant groups who fell into the category of non responders (p <  0.0001 for 
100uM dazmegrel, p <  0.00001 for 500uM dazmegrel). There was no difference 
in the distribution of responder status between healthy and hypertensive pregnant 
subjects. Response to dazmegrel in each subject group is illustrated in Figure 3.9. 
As some degree of inhibition of dense granule release occurred even in non 
responders to the thromboxane synthetase inhibitor, data were also analyzed with 
respect to the extent of the release reaction. The effect of dazmegrel on 14C-5HT 
release induced by 1mM arachidonic acid is shown in Figure 3.10.
3.5 Serum Thromboxane B?.
There was no difference between subject groups in serum thromboxane B2 
levels, although the levels were more variable in hypertensive pregnant women. 
The data are shown in Table 3.3.
4. DISCUSSION
It has been previously reported that platelets from pregnant women are less 
sensitive to inhibition of their behaviour by prostacyclin.330,331,332 This study has 
extended these observations to other cyclic AMP modulators, and has compared 
non pregnant women, healthy pregnant women and those with PIH or pre­
eclampsia.
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The study has shown that during pregnancy, platelets release more 5-HT 
in response to stimulation with arachidonic acid than those from non pregnant 
women. Although it has been previously reported that, during pregnancy, platelets 
are more sensitive to arachidonic acid,321,322,327 no change in the extent of the 
release reaction in PRP was found in these studies.321,322 In the present study, in 
the hypertensive pregnant group, the trend reverted and there was a significant 
reduction in the release reaction compared with results in healthy pregnant 
women. These findings differ from other studies of platelet behaviour in PIH,322 but 
are in keeping with those of an early study by Whigham et al, in which, as in the 
present study, the majority of hypertensive pregnant subjects had pre­
eclampsia.317 Some of the present pre-eclamptic subjects, two of whom had 
disseminated intravascular coagulation (DIC), demonstrated a markedly reduced 
release reaction, which may be a result of the presence of exhausted platelets, as 
described in other clinical conditions in which in vivo platelet activation and DIC 
occur.413,439
The results presented in this chapter also indicate that platelets in healthy 
and hypertensive pregnancy are generally less sensitive to the inhibitory effects 
of a wide range of agents which act by increasing cyclic AMP. There was no 
difference in this respect between healthy pregnant women and those with PIH 
or pre-eclampsia. This is unlikely to be due to patient selection as the subjects in 
the PIH/pre-eclampsia group demonstrated a number of features associated with 
significant disease such as proteinuria and raised serum uric acid, both of which 
have been associated with other changes in platelet behaviour in previous 
studies.322,353 Furthermore, the hypertensive subjects had a reduced platelet count 
and indices of platelet size in keeping with a degree of platelet activation in 
vivo.289,290
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Reduction of platelet sensitivity during pregnancy to inhibitory 
prostaglandins which stimulate adenylate cyclase via a receptor and G protein 
dependent mechanism40,18®'195*198,202 has been demonstrated, but similar results 
were obtained with forskolin which can act directly on the catalytic subunit of 
adenylate cyclase.200 Although slightly less marked, a statistically significant 
reduction in platelet sensitivity to the cyclic AMP specific phosphodiesterase 
inhibitor also occurred in both healthy and hypertensive pregnant groups. 
Furthermore, findings reported in a previous study322 have been confirmed by the 
demonstration of an increase in proportion of non responders to the thromboxane 
synthetase inhibitor dazmegrel in both pregnant groups. This is in keeping with the 
reduction in platelet sensitivity to PGD2 during pregnancy as there is evidence that 
this prostaglandin, synthesised in platelets when thromboxane synthetase is 
blocked, plays a role in inhibition of platelet behaviour by thromboxane synthetase 
inhibitors.247,248,249 Indeed, outwith the context of pregnancy, platelets from 
individuals who were non responders to the thromboxane synthetase inhibitor 
dazoxiben, have been shown to synthesise less cyclic AMP in response to both 
PGD2 and the combination of dazoxiben and AA.249,254
When considering the effects of any inhibitory agent on arachidonic acid 
induced platelet behaviour, the influence of the activity of the thromboxane 
biosynthetic pathway must be taken into account. Any increase in thromboxane 
A 2 generation in healthy or hypertensive pregnant subjects could theoretically 
contribute to a reduction in efficacy of cyclic AMP manipulators in these subject 
groups. In agreement with some previous studies,292,327 however, the present 
study has demonstrated no change in levels of thromboxane B2, the stable 
hydrolysis product of thromboxane A2, in serum in either healthy or hypertensive 
pregnancy. Serum thromboxane B2 reflects platelet thromboxane production under
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conditions of spontaneous clotting of whole blood in vitro. Other investigators, by 
contrast, have shown evidence of increased platelet thromboxane production both 
in vivo309 and in vitro329 in pregnancy. The findings of the present study would not, 
however, support a major role for alterations in thromboxane A2 synthesis in the 
observed reduction in sensitivity to cyclic AMP manipulators during pregnancy.
On the basis of the data presented, the hypotheses could be formed that 
platelets from pregnant women are either less sensitive to the inhibitory effects 
of cyclic AMP itself or that less cyclic AMP is synthesised in response to a wide 
range of pharmacological agents capable of increasing the level of this inhibitory 
second messenger. The measurement of platelet cyclic AMP levels was carried out 
to address this question, and the resulting data are presented in the following 
chapter.
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CHAPTER 4.
A CROSS-SECTIONAL STUDY OF PLATELET CYCLIC AMP IN
HEALTHY AND 
HYPERTENSIVE PREGNANCY.
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CHAPTER 4.
A CROSS-SECTIONAL STUDY OF PLATELET CYCLIC AMP IN HEALTHY 
AND HYPERTENSIVE PREGNANCY.
1 .INTRODUCTION.
The data presented in Chapter 3. demonstrated that platelets from healthy 
and hypertensive pregnant women were less sensitive to the inhibitory effects of 
not only prostacyclin, but of a wide range of agents which act by increasing cyclic 
AMP. In order to determine whether this results from reduced synthesis of cyclic 
AMP by platelets during pregnancy, platelet cyclic AMP was measured in a cross- 
sectional study carried out in parallel with that investigating the effects on platelet 
behaviour of cyclic AMP manipulators.
2. METHODS.
Subjects corresponded exactly with those who took part in the study 
presented in the previous chapter, and were divided as before into non pregnant, 
healthy pregnant, and hypertensive pregnant groups. Blood was taken at the same 
time, using the same venepuncture as for the studies reported in Chapter 3. 
Trisodium citrate dihydrate 3.13%  w/v was again used as the anticoagulant (9 
parts blood : 1 part citrate).
Platelet rich plasma in which the platelet count was adjusted to 250 x 109/l 
was assayed for basal and stimulated cyclic AMP by the 3H-adenine labelling 
method described in Chapter 2. Following the 90 minute incubation period with 
3H-adenine, PRP was incubated in duplicate aliquots of 0.45m l at 37°C in an 
unstirred system with various pharmacological agents that raise cyclic AMP levels
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or with saline for measurement of basal platelet cyclic AMP. Samples were pre­
incubated for 2 minutes in the water bath at 37°C in the presence of either 25ul 
saline or 25ul of the phosphodiesterase inhibitor AH-P719, before adding 25ul of 
an adenylate cyclase stimulator. Incubation was continued for a further 6 minutes 
before stopping the reaction and lysing the platelets with 2ml ice cold 15%  
trichloroacetic acid containing 14C-cyclic AMP as a recovery label. Following 
centrifugation, the assay was completed by column chromatography on the 
platelet supernatants as described in Chapter 2.
The same pharmacological agents were used as in the release reaction 
experiments but final concentrations were as follows: iloprost was used at 0.5 , 
5, and 50ng/ml; PGD2 at 0 .05 , 0 .5 , and 5ug/ml, forskolin at 4ug/ml, and 
dazmegrel at 500uM. Concentrations of these agents were chosen from pilot 
experiments in which concentration response curves of their effect on platelet 
cyclic AMP levels were constructed (see Chapter 2). The concentration of 
dazmegrel was chosen to ensure maximal inhibition of thromboxane synthetase, 
based on published data440. Measurements of cyclic AMP in response to adenylate 
cyclase stimulators were generally made both in the presence and absence of 
inhibition of phosphodiesterase with 100uM AH-P719. This concentration of the 
phosphodiesterase inhibitor was at the top of the concentration response curve 
when platelet cyclic AMP was assayed in the presence of a range of 
concentrations of AH-P719 in pilot experiments (see Chapter 2). To investigate the 
effect of the thromboxane synthetase inhibitor, dazmegrel (25ul) was placed in the 
tubes before the PRP and, after 2 minutes, 1mM AA (25ul) was added. No 
phosphodiesterase inhibitor was included in this case. Cyclic AMP was also 
assayed in PRP to which only saline and 1mM AA was added. The effect of AA 
on iloprost stimulated cyclic AMP levels was examined by measuring the cyclic
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AMP response to 5ng/ml iloprost in the presence of 1 mM AA. The drug incubation 
protocol is shown in detail in Appendix 4.
Results were expressed as % conversion of 3H-adenine to 3H~cyclic AMP 
and were corrected both for uptake of 3H-adenine for each subject and for cyclic 
AMP recovery in each sample. There was no difference in uptake of 3H-adenine 
between subject groups (p= 0 .5928 ).
For the purposes of statistical analysis, subjects with PIH and pre-eclampsia 
were again treated as one group as no differences existed between them when 
treated separately. All comparisons between the three subject groups were, as 
before, by Kruskal-Wallis one way analysis of variance by ranks. The Wilcoxon 
matched pairs signed rank test was used to test the effect within subject groups 
of the presence of arachidonic acid on iloprost induced production of cyclic AMP 
by platelets.
3 .RESULTS
Clinical, haematological and biochemical data for the three groups of 
subjects have already been documented in Chapter 3.
3.1 Platelet Cyclic AMP Levels Under Conditions of Basal Adenvlate 
Cvclase Activity.
In the absence of any agents which stimulated adenylate cyclase, there 
was no difference in cyclic AMP generation in PRP from the three groups of 
subjects. This was the case whether or not the phosphodiesterase inhibitor AH- 
P719 was present. The results are shown in Table 4.1.
3.2 Platelet Cyclic AMP levels Stimulated bv Receptor Dependent 
Mechanisms
In response to 0.5ng/ml of iloprost, the rise in cyclic AMP was very small
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Cyclic Amp Levels on Platelet Stimulation
by Receptor Dependent Mechanisms
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Figure 4 .1
The bar graph shows mean and S.E.M. cyclic AMP levels in platelets incubated 
with iloprost. # signifies a p value < 0 .0 5 , * *  signifies p < 0 .0 1 . In each case one 
way ANOVA was used and significant differences were obtained by comparison 
with the non pregnant group.
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Cyclic AMP Levels in Platelets on Stimulation
by Receptor Dependent Mechanisms
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Figure 4 .2
The figure shows platelet cyclic AMP responses to PGD2. * indicates statistical 
significance at p < 0 .0 5 , * # indicates p < 0 .0 1 . Comparisons were made by one 
way ANOVA and all significant values refer to the comparison of both healthy and 
hypertensive pregnant groups with the non pregnant group.
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in ail subjects, and there was no difference between groups. There was marked 
synergism between iloprost and the phosphodiesterase inhibitor AH-P719 in all 
subjects, but cyclic AMP levels remained similar in all three groups of women 
when platelets were stimulated with 0.5ng/ml iloprost in the presence of AH-P719 
(Table 4.1). When platelets were incubated with 0.05ug/ml PGD2, cyclic AMP 
accumulation was reduced in the hypertensive pregnant group, compared with the 
healthy pregnant and non pregnant groups. This difference reached statistical 
significance when the phosphodiesterase inhibitor was also present (p<0.01 in 
comparison with the non pregnant group. Table 4.1)
Significantly less cyclic AMP was generated by platelets from hypertensive 
pregnant women in response to 5ng/ml iloprost when metabolism of the cyclic 
nucleotide was inhibited by AH-P719 (Figure 4.1). When the concentration of 
iloprost was further increased tenfold, there was also a significant reduction in 
platelet cyclic AMP levels in healthy pregnancy, whether or not phosphodiesterase 
was inhibited (Figure 4.1).
Figure 4 .2  shows platelet cyclic AMP responses to PGD2 when present at 
concentrations higher than those generally required to inhibit platelet behaviour. 
A repeating pattern of reduction in stimulated platelet cyclic AMP levels in both 
healthy and hypertensive pregnant subjects was demonstrated.
Although slightly more marked in pregnant women with hypertension, the 
reduced platelet cyclic AMP response to both prostanoids was primarily a 
pregnancy effect. Subgroup analysis of the hypertensive group revealed no 
significant difference in basal or stimulated platelet cyclic AMP levels between 
women with pre-eclampsia and those with non proteinuric PIH. It is also 
noteworthy that the observed differences between subject groups were more 
marked when phosphodiesterase was inhibited with AH-P719.
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Effect of Archidonic Acid 
on Platelet Cyclic AMP Stim ulated with lloprost
□  lloprost 5ng/ml 
H  lloprost 5ng/ml + 1mMAA
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Figure 4 .3
Platelet cyclic AMP responses to 5ng/ml iloprost are shown in the presence and 
absence of 1mmol/l AA. Means and standard errors are illustrated. In the 
hypertensive pregnant group (PIH) only, AA reduced cyclic AMP accumulation in 
response to iloprost (p<  0 .0001 using the Wilcoxon matched pairs signed rank 
test). ANOVA comparing cyclic AMP levels in the presence of ilprost and AA in 
the three subject groups showed that less cyclic AMP was generated in the 
hypertensive pregnant group compared with healthy pregnant (P) and non 
pregnant (NP) subjects (p < 0 .0 5 ).
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TABLE 4 .2
PLATELET CYCLIC AMP LEVELS IN PRESENCE OF 
DAZMEGREL AND ARACHIDONIC ACID
The table shows means and SEM of platelet cyclic AMP in the three groups of 
subjects. All cyclic AMP levels are expressed as % conversion of 3H adenine to 3H 
cyclic AMP. Abbreviations are identical to those in Table 4 .1 .
REAGENT GROUP p value Comparison
NP HP PIH (ANOVA)
A A (lm M ) 0 .0605± 0 .0762± 0.0681 ± 0.1742 all NS
0.0036 0.0061 0.0039
Dazmegrel
(500*/M) 0 .1 168± 0 .1499± 0 .1267± 0.2567 all NS
+ AA(1mM) 0.0084 0.0145 0.0087
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Platelet Cyclic AMP Levels on Direct 
Stimulation of Adenylate Cyclase
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Figure 4 .4
The bar graph shows mean cyclic AMP generation in platelets incubated with 
forskolin and AH-P719. ANOVA was used to compare subject groups. * *  
indicates p < 0 .0 1  for the comparison of the pregnant with the non pregnant 
group; # indicates p < 0 .0 5  for the comparison of hypertensive pregnant with non 
pregnant subjects.
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3.3 Influence of Arachidonic Acid on Platelet Cyclic AMP Stimulated with
lloprost.
Platelet cyclic AMP responses to 5ng/ml iloprost were also measured in the 
presence of 1mmol/l arachidonic acid. The phosphodiesterase inhibitor was not 
included in this case and the samples were unstirred so that no aggregation or 
release reaction took place. AA had no effect on iloprost induced platelet cyclic- 
AMP responses in non pregnant and healthy pregnant subjects. In pregnant 
subjects with hypertension there was a significant reduction in cyclic AMP levels 
on stimulation with iloprost in the presence of AA when compared both with 
measurements made under the same conditions in healthy pregnant and non 
pregnant women and with platelet cyclic AMP responses to iloprost alone in the 
hypertensive pregnant group (Figure 4.3).
3 .4  Platelet Cyclic AM P Levels in the Presence of Dazmeorel and 
Arachidonic Acid.
AA alone produced a slight rise in platelet cyclic AMP above basal levels 
but there was no difference between subject groups. Dazmegrel and AA together 
increased cyclic AMP to a greater extent than AA alone, but, again, there was no 
difference in platelet cyclic AMP levels under these conditions between the three 
groups of subjects.(Table 4.2)
3 .5  Platelet Cyclic AM P Levels on Direct Stimulation of Adenvlate Cvclase.
Platelet cyclic AMP responses to forskolin were examined only in the 
presence of AH-P719. Results are shown on Figure 4 .4 . There was again a 
significant reduction in cyclic AMP generation in both healthy and hypertensive 
pregnant subjects.
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4 .DISCUSSION
This cross-sectional study has compared basal and stimulated cyclic AMP 
levels in healthy third trimester pregnant women, those with PIH or pre-eclampsia 
and healthy non pregnant women. There was no difference between groups under 
conditions of basal adenylate cyclase activity, whether or not phosphodiesterase 
was inhibited. In contrast, platelets from healthy and hypertensive pregnant 
women produced less cyclic AMP in response to all the adenylate cyclase 
stimulators studied. These results are broadly in keeping with the generalised 
reduction in platelet sensitivity to inhibition of their behaviour by cyclic AMP 
manipulators during pregnancy as demonstrated in the previous chapter.
The reduction in stimulated levels of platelet cyclic AMP, although more 
marked in the hypertensive group, was primarily a pregnancy effect. This is also 
in keeping with the data relating to inhibition of platelet 14C-5HT release discussed 
in Chapter 3. The data show no differences between platelet cyclic AMP levels in 
women with non proteinuric PIH compared with women with pre-eclampsia. The 
few existing and more limited studies of platelet cyclic AMP levels in pregnancy 
report no change323,339, except in association with the administration of beta2 
agonists to suppress labour, which when used long term caused a reduction in 
platelet cyclic AMP339. No patient included in this study had received treatment 
with any tocolytic drug. Previous studies have concentrated on basal platelet 
cyclic AMP or have not used a range of types and concentrations of cyclic AMP 
modulators. Furthermore, the assay employed by the larger of the two published 
studies339 was a radioimmunoassay, which is less sensitive than the type of 
method used in the present study.
It is likely that a complex relationship exists between changes in platelet 
cyclic AMP levels during pregnancy and the reduction in sensitivity to the
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inhibitory effects on platelet behaviour of cyclic AMP manipulators. Pregnancy 
associated reductions in platelet cyclic AMP levels occurred only when the 
concentrations of adenylate cyclase stimulators were higher than those generally 
required to inhibit platelet activation or in the concomitant presence of the 
phosphodiesterase inhibitor. The relative lack of efficacy of the cyclic AMP 
manipulators in pregnant subjects in the release reaction experiments described 
in Chapter 3 would have been determined not only by the level of platelet cyclic 
AMP reached but also by production of thromboxane A2 and possibly other pro- 
aggregatory AA metabolites. Although the results of the studies reported in 
Chapter 3 would not support an increase in the absolute amount of thromboxane 
produced in vitro in pregnancy, the efficacy of cyclic AMP manipulators as 
inhibitors of platelet behaviour could be influenced by platelet sensitivity to the 
pro-aggregatory effects of thromboxane and possibly by inhibition of adenylate 
cyclase by prostaglandins derived from AA. The evidence regarding the effect on 
adenylate cyclase activity of thromboxane is, however, conflicting, with some 
studies suggesting an inhibitory effect,200 whilst others show no such action.207 
Nevertheless, the results of the study described in this chapter show that in the 
presence of arachidonic acid, the platelet cyclic AMP response to 5ng/ml iloprost 
was reduced in the hypertensive pregnant group. This occurred even although 
aggregation and release was deliberately prevented as the PRP was not stirred. 
The explanation for this observation is unclear, but may lie in a difference in the 
effects on adenylate cyclase of AA metabolites such as thromboxane or 
prostaglandin E2.
There was no difference between subject groups in platelet cyclic AMP 
production in the presence of dazmegrel and AA, despite the clear loss of 
response during pregnancy to the inhibitory effects of dazmegrel on AA induced
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platelet behaviour demonstrated in Chapter 3. One interpretation is that cyclic 
AMP production is not a major determinant of responder status to thromboxane 
synthetase inhibitors during pregnancy, and factors such as sensitivity to the pro- 
aggregatory effects of endoperoxides may be more important. A study outwith the 
context of pregnancy has, however, shown that platelets from non responders to 
dazoxiben demonstrated a lesser rise in cyclic AMP in response to this 
thromboxane synthetase inhibitor and AA than those from responders.249 
Measurements in this case, in contrast with the present study, were made in the 
presence of a phosphodiesterase inhibitor. It is therefore conceivable that small to 
moderate differences between subject groups were missed in the present study, 
as the rise in cyclic AMP above basal levels in response to dazmegrel and AA was 
small in the absence of the potentiating effect of a PDE inhibitor.
The reduction in platelet cyclic AMP response to iloprost and to PGD2 in 
healthy and hypertensive pregnant women was most marked in the presence of 
the phosphodiesterase inhibitor AH-P719. The most likely interpretation is that the 
changes noted are due to differences in stimulated adenylate cyclase activity in 
platelets during pregnancy, and that these differences are emphasized by inhibiting 
the breakdown of cyclic AMP. The possibility of differences in metabolism of 
cyclic AMP in platelets from pregnant women cannot, however, be completely 
excluded, as the effects of AH-P719 on the type II phosphodiesterase enzyme are 
unknown. At the concentration used in these experiments, AH-P719 is thought 
to be a highly selective phosphodiesterase inhibitor for the type III enzyme, and 
has no effect on cyclic GMP metabolism (personal communication in writing from 
Dr Hans Weisenberger, Karl Thomae GmbH, subsidiary of Boehringer Ingelheim). 
Metabolism via type III phosphodiesterase is the more usual route for breakdown 
of cyclic AMP, the type II enzyme having a lower affinity for cyclic AMP. When
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cyclic AMP levels are raised by adenylate cyclase stimulators, however, 
metabolism via the type II enzyme can occur.209,210 Ongoing metabolism of cyclic 
AMP in the presence of AH-P719 therefore cannot be excluded. This 
phosphodiesterase inhibitor is, however, one of the most potent inhibitors of cyclic 
AMP metabolism in platelets when compared with other PDE inhibitors,254 and, in 
this study, was used in concentrations shown to result in maximal inhibition of 
phosphodiesterase.249
Given that a change in stimulated adenylate cyclase activity in pregnancy 
is the most likely cause of the observed reduction in cyclic AMP levels, this could 
result from changes in receptors, changes in G proteins, or alterations in the 
enzyme itself. As the reduction in platelet cyclic AMP in pregnancy occurred not 
only with those adenylate cyclase stimulators which act via surface receptors and 
the stimulatory G protein (Gs), but also with forskolin which is capable of acting 
directly on the catalytic subunit of the enzyme,200,201 down regulation of platelet 
prostaglandin receptors could not explain these findings. A change in the catalytic 
component of adenylate cyclase could entirely account for the results. A G protein 
mediated effect could not be completely ruled out, however, as the effects of 
forskolin maybe modulated by G proteins.201 Adenylate cyclase is controlled by 
a stimulatory (G,) and an inhibitory G protein (Gj).40-41-44'135'191 Many prostaglandins 
interact with a population of receptors linked to Gj in addition to those linked to 
Ga.202 Reduced activity of platelet G, or increased activity of Gf during pregnancy 
could be postulated. The data regarding forskolin, however, would suggest that 
any changes in the G proteins would have to be independent of prostanoid control. 
In the case of Gj, there is evidence from studies in other tissues that the a  subunit 
mediates inhibition of ligand stimulated adenylate cyclase activity, whilst the ply  
subunit mediates inhibition of basal activity.441 Both subunits may mediate
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inhibition of forskolin stimulated adenylate cyclase activity.441 As platelet cyclic 
AMP accumulation was unaltered during pregnancy, under conditions of basal 
adenylate cyclase activity, a change in the G; ply  subunit is unlikely. A reduction 
in the activity of the catalyst itself or alterations in the activity of the a  subunits 
of either G protein therefore appear to be the most likely mechanisms accounting 
for the reduction in platelet cyclic AMP responses during pregnancy. This will be 
explored in more detail in Chapter 6.
The data on indices of platelet size presented in Chapter 3 would support 
a degree of platelet activation in vivo in the healthy pregnant subjects289 which 
was more marked in those with PIH and pre>eclampsia. Whether the biochemical 
changes demonstrated in this study of platelet cyclic AMP precede or result from 
platelet activation in the circulation of pregnant women cannot be determined from 
the available data. If, however, reductions in platelet cyclic AMP responses, similar 
to those demonstrated in vitro, do occur in vivo, this could render platelets less 
responsive to important physiological regulatory mechanisms and contribute to 
platelet activation in vivo in healthy and hypertensive pregnant women. The 
relative prostacyclin deficiency in pre-eclampsia160,298,310 could add to the 
physiological pregnancy associated reduction in platelet sensitivity to inhibitory 
prostaglandins, to promote more extensive platelet activation in vivo than in 
normal pregnancy where prostacyclin production is increased.160,298,310
In summary, the studies presented in this chapter have demonstrated that 
reduced platelet cyclic AMP accumulation is associated with the reductions in 
response of platelets from pregnant women to inhibitory agents including 
prostaglandins which play an important regulatory role in vivo.
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CHAPTER 5.
LONGITUDINAL STUDIES OF PLATELET CYCLIC AMP 
DURING PREGNANCY.
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CHAPTER 5.
LONGITUDINAL STUDIES OF PLATELET CYCLIC AMP DURING
PREGNANCY.
1. INTRODUCTION.
In the previous two chapters, I have shown in cross sectional studies that 
platelets from healthy third trimester pregnant women produce less cyclic AMP in 
response to stimulation of adenylate cyclase than those from non pregnant 
women. This is accompanied by a reduction in efficacy of prostaglandins and 
other cyclic AMP manipulators as inhibitors of platelet behaviour. This chapter 
deals with studies which have been carried out to validate the findings in a 
prospective longitudinal manner and to determine the relationship of these changes 
in platelets to gestation as pregnancy progresses. The first study was carried out 
in healthy primigravid women, and the second in women considered at risk of pre­
eclampsia because of a history of the condition in a previous pregnancy. Women 
with a previous history of pre-eclampsia have a 25%  incidence of recurrence of 
the condition in subsequent pregnancies.373
2. METHODS.
2.1 Subjects.
For the first study, subjects were recruited initially from women planning 
their first pregnancy, including volunteers from hospital staff, those referred to me 
from their general practitioners, and volunteers recruited from regular blood 
donors. At least 8 weeks had elapsed from the time of last ingestion of an oral 
contraceptive for all subjects studied pre-conceptionally. Only 5 women recruited
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STUDY DESIGN
WEEKS OF GESTATION
PRE 1ST 2ND 3RD POST-
TRIMESTER NATAL
FIGURE 5 .1 .
The figure sum m arises the study design, x represent tim es for p latelet studies  
in healthy pregnant subjects (HP), w hilst •  represent those for subjects at risk 
o f pre-eclam psia (RP).
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in this manner subsequently became pregnant within the time the study was 
running, and so a further three women were recruited from healthy primigravid 
women who either volunteered for the study in the very early weeks of pregnancy 
or who presented to the hospital antenatal clinic at 12 weeks gestation or less. 
Subjects were studied pre-conceptionally where possible, then as soon as 
pregnancy was confirmed using an ELISA for human chorionic gonadotrophin on 
a random urine sample (Hybritech Icon Kit). The mean gestation for the first study 
time point during pregnancy for those subjects recruited pre-conceptionally was 
5 weeks gestation. All subjects were subsequently studied at 12, 24, and 36 
weeks gestation, and finally after the 6th postnatal week. The study design is 
summarised in Figure 5.1. One subject was excluded from the data analysis in the 
healthy pregnant (HP) group as she developed the H.E.L.L.P. syndrome355 at 38 
weeks gestation, but data for this subject will be presented separately. Some 
demographic details relating to these subjects are presented in Table 5.1. No 
subject ingested any drug except iron and vitamins throughout the period of the 
study.
For the second study, 5 women with a previous history of pre-eclampsia 
were recruited from referrals to the medical obstetric clinic for high risk 
pregnancies at the University Hospital, Nottingham. No such women were seen 
until early in the second trimester. Subjects were studied immediately on 
recruitment and then subsequently at 24, and 36 weeks gestation and after the 
6th postnatal week. Demographic details relating to these subjects are shown on 
Table 5.2. No subject in the "at risk" group (RP) ingested any drug throughout the 
period of the study, with the exception of iron and folate supplements.
On each study day subjects were placed in the supine position, and after 5 
minutes rest, blood pressure was recorded and venepuncture performed as
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described in Chapter 2. Blood was taken on each occasion for platelet studies, full 
blood count, serum thromboxane B2 measurement, and estimation of urea, 
electrolytes and uric acid.
2 .2  Laboratory Methods.
Platelet studies were conducted in citrated PRP in which the platelet count 
had been adjusted to 250 x 109/l. The effect of cyclic AMP manipulators on 
platelet 14C-5HT release induced by 1 mM arachidonic acid was examined using the 
method described in Chapter 2, and exactly the same reagents and laboratory 
protocol detailed in Chapter 3.
Platelet cyclic AMP was measured by the 3H-adenine labelling method 
described previously, using exactly the same reagents and laboratory protocol as 
detailed for the cross-sectional study (see Appendix 4). All results were expressed 
as % conversion of 3H-adenine to 3H-cyclic AMP and were corrected for 3H- 
adenine uptake by the platelets. Platelet uptake of 3H-adenine did not change 
throughout the period of the study in either subject group.
Serum thromboxane B2 was measured by radioimmunoassay as outlined in 
Chapter 2.
2 .3  Statistical Methods
Comparison of data at different time points within subject groups was 
carried out by Friedman two way analysis of variance. As pre-conceptional data 
was not available for some patients in the healthy pregnant group, for the 
purposes of statistical analysis postnatal data in such cases were grouped 
together with pre-conceptional data in the remaining subjects to form a "non 
pregnant" category. In those cases where both pre-conceptional and postnatal 
data were available, comparable results were obtained at these times for all 
parameters. Furthermore, previous studies have suggested that parameters of
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BLOOD PRESSURE
systolic J
diastolic
0 6 12 18 24 30 36 rmpregHt 
gestation (weeks)
FIGURE 5 .2 .
The figure shows systo lic and diastolic blood pressure data for both groups 
o f subjects th roughout the period o f the study. Data fo r HP is shown as a and 
data fo r RP as O . Friedman ANOVA revealed an overall p value o f 0 .0 2 3 5  for 
HP fo r systo lic blood pressure, w ith  a s ign ificant reduction in systo lic pressure 
at 36  weeks compared w ith  12 w eek data (p <  0 .0 5 ,  * ). In RP, systolic 
pressure rose s ign ificantly in late pregnancy ( Friedman ANOVA p = 0 .0 3 9 5 ,  
w ith  p <  0 .0 5  fo r the comparison o f 36  week w ith  24  week data, # ). 
Comparison o f HP and RP showed a s ign ificantly  higher systo lic pressure in 
RP at 36  weeks ( * *  p = 0 .0 0 4 4 ).  There was no sign ificant change in diastolic 
pressure th roughou t the study in either group o f subjects, and no sign ificant 
d ifference between subject groups.
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platelet behaviour return to non pregnant values by the 6th postnatal week 
following healthy pregnancy.322
Comparison of the healthy pregnant group with the "at risk" group was 
made by two way analysis of variance with repeated measures, supplemented by 
the Mann>Whitney U test when overall significant p values were obtained using 
the analysis of variance. As the times of study in the early part of pregnancy did 
not exactly correspond for the two groups of patients, analysis was facilitated by 
dividing the data into four groups as follows: "early pregnancy" (12 week data in 
the healthy pregnancy group and data at first presentation in the at risk group), 
"mid pregnancy" (24 week data for both groups), late pregnancy (36 week data 
for both groups) and "non pregnant" (pre-conceptional or postnatal data for the 
healthy pregnant group and postnatal data for the at risk group).
3 . RESULTS.
3.1  Clinical Data.
All of the seven subjects eligible for inclusion in the healthy pregnant group 
had pregnancies free from major complications. One subject laboured at 36 weeks 
gestation by dates but the baby appeared fully mature at birth. Another subject 
had a small antepartum haemorrhage at 38 weeks. All women had babies of 
normal birth weight for gestational age. Clinical details are shown in Table 5.3, 
and blood pressure data in Figure 5.2. There was no significant change in diastolic 
blood pressure over the period of the study, but there was a significant late 
pregnancy fall in systolic pressure.
In the at risk group three of the subjects had uncomplicated pregnancies, 
but two developed mild labile non proteinuric hypertension in late pregnancy which 
settled with rest in both cases and did not require treatment with drugs. All "at
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risk" women had babies with normal birth weight for gestational age and birth 
weights did not differ between the two groups of subjects. Clinical data are shown 
in Table 5.4, and blood pressure data in Figure 5.2. In the "at risk" group, there 
was a trend towards a rise in diastolic pressure in late pregnancy which just failed 
to reach significance, but systolic pressure rose significantly compared with values 
in mid pregnancy. Two way analysis of variance showed that systolic blood 
pressure was significantly higher at 36 weeks gestation in women at risk of pre­
eclampsia compared with healthy primigravidae. When subjects were not 
pregnant, all were normotensive and there was no difference between groups in 
either systolic or diastolic blood pressure.
3 .2  Haematology and Biochemistry.
Haematological data are shown in Table 5.5 and biochemical data in Table 
5.6. In the healthy pregnant group, there was a significant mid pregnancy 
reduction in packed cell volume (PCV), but in the group at risk of pre-eclampsia 
PCV did not change over the period of study. Direct comparison of the two  
groups, however, showed no significant difference between women at risk and 
healthy women. There was no significant change in platelet count nor in mean 
platelet volume (MPV) during pregnancy in either subject group, although the at 
risk group showed a trend towards a mid pregnancy fall in platelet count.
Serum urea was significantly lower in the healthy pregnant group at 24 and 
36 weeks gestation compared with non pregnant values. Serum creatinine 
reflected these results at 24 weeks gestation. In the group at risk of pre­
eclampsia, urea was slightly but significantly lower at 36 weeks gestation 
compared with postnatal values but creatinine did not change throughout the 
study period. Serum urea was significantly higher in women at risk of pre­
eclampsia compared with healthy women when subjects were not pregnant, but
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PLATELET RELEASE REACTION IN RESPONSE TO 
I bH ARACHIDONIC ACID
65-
CD
CD
CD
CD
CD
55-
t n
£  50-
45-
6 12 IB 24 30 36 post natalpre
gestation (weeks)
F I G U R E  5.3.
The graph show s % 14C -5 H T  release plotted against gestation follow ing  
stim ulation o f PRP w ith  1m M  arachidonic acid in the absence of inhibitors, a 
illustrates results for HP and O  illustrates those for RP. A lthough there w as  
a tendency  for the exten t o f the release reaction to  increase as pregnancy  
progressed, there w as no statistically significant d ifference betw een  results 
at d iffe ren t tim e points nor betw een  the tw o  groups of subjects.
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did not differ during pregnancy. There was no difference between groups in serum 
creatinine at any time. No subject "at risk” had a serum urea above the upper limit 
of the normal range. In the healthy pregnant group, serum urate tended to be 
lower in early and mid pregnancy compared with results in late pregnancy and 
when subjects were not pregnant. The difference between urate levels at 12 
weeks and 36 weeks gestation was statistically significant. In the "at risk” group, 
serum urate was significantly lower early in the second trimester when compared 
with postnatal and 36 week gestational data. Comparison of the two subject 
groups revealed that urate was higher in women "at risk" when subjects were not 
pregnant and in early pregnancy, but results were similar in mid and late 
pregnancy. Urate levels lay within the normal range for all subjects at all time 
points.
3 .3  Arachidonic Acid Induced Platelet Dense Granule Release.
In the absence of inhibitors 14C-5HT release in response to 1mM 
arachidonic acid tended to increase slightly as pregnancy progressed in both 
healthy and "at risk" patients but this did not reach statistical significance. 
Comparison of the healthy pregnant group with the "at risk" group showed no 
difference between the two groups in the extent of the release reaction at any 
time during the study. The data are shown in Figure 5.3.
3 .4  Inhibition of Platelet Behaviour bv Cyclic A M P Manipulators.
During healthy pregnancy there was a gradual reduction in sensitivity of 
platelets to inhibition of their behaviour by all cyclic AMP manipulators tested, 
when compared with non pregnant data. This effect was statistically significant 
in the case of the inhibitory prostaglandins iloprost and PGD2, and the 
phosphodiesterase inhibitor AH-P719, and just failed to reach statistical 
significance with forskolin. The effect reached a maximum at 36 weeks gestation,
195
ILOPROST THRESHOLD
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FIGURE 5 .4
This show s the threshold concentrations o f iloprost required to com pletely  
inhibit A A  induced platelet dense granule release plotted against gestation. 
Results in HP are indicated by a and in RP by O  . In both groups of subjects  
there w as a gradual loss of sensitivity to  the effects  of iloprost as pregnancy  
progressed. * indicates statistical significance for com parison of results at 
d iffe ren t tim e points by Friedman A N O V A  w ith in  subject groups and * *  
indicates statistical significance for com parison of results betw een  groups of 
subjects.
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PROSTAGLANDIN D2 THRESHOLD
20 n
. 1 5 -r— Ie
.10-
o
u
(U
§  . 0 5 -
CX
o
c
6 12 18 24 30 36 postnatalpre
gestation (weeks)
F I G U R E  5.5
The graph show s the threshold concentrations of PGD2 required to abolish A A  
induced 14C -5 H T  release throughout the period of the study. An increase in 
threshold w as again noted in both HP ( a ) and RP (O ) as pregnancy  
progressed. * indicates statistical significance for com parison of tim e points 
w ithin subject groups and * *  indicates statistical significance for com parison  
of data at the sam e tim e point betw een subject groups.
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FORSKOLIN THRESHOLD
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F I G U R E  5.6.
The figure show s threshold concentrations of forskolin required to com pletely  
inhibit A A  induced platelet dense granule release. As before, loss of sensitivity  
to forskolin occurred as pregnancy progressed ; in this case the e ffec t w as  
more m arked in RP (O ) than in HP ( a ) .  * indicates statistical significance for 
com parison w ith in  groups of subjects and * *  indicates significance for 
com parison betw een  subject groups.
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AH-P719 THRESHOLD
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F I G U R E  5.7.
The graph show s threshold concentrations o f the PDE inhibitor A H -P 7 1 9  
required to abolish A A  induced 14C -5 H T  release. In HP ( a ) there w as a 
significant increase in A H -P 7 1 9  threshold at 2 4  and 3 6  w eeks gestation (* )  
com pared w ith  postnatal data. Data for RP is indicated by O  .
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and was well established by 24 weeks. Statistically significant changes were not 
present before 24 weeks gestation in this small study, but the pattern of results 
suggests that the changes may begin around 12 weeks gestation. Results at pre- 
conceptional, 5 week gestational, and postnatal time points were generally closely 
comparable. The data are illustrated in Figures 5.4-5.7 and the statistical results 
are documented in Table 5.7.
In the "at risk" subjects, a similar pattern of loss of platelet sensitivity to 
the inhibitors was evident when data during pregnancy were compared with 
postnatal results. This was statistically significant for forskolin and PGD2 and just 
failed to reach significance for iloprost. The maximal change again occurred at 36 
weeks gestation. Comparison of data at individual time points did not show any 
statistically significant changes prior to 36 weeks, but the overall pattern of 
results as shown in Figures 5.4-5.7 would suggest that changes in platelet 
sensitivity to cyclic AMP manipulators had started to develop before the second 
trimester when these patients were entered into the study.
The data suggest that loss of sensitivity to cyclic AMP manipulators may 
be more marked during pregnancy in women at risk of pre-eclampsia than in 
healthy primigravidae. This was confirmed for all of the pharmacological agents 
by comparing data from the two subject groups by two way analysis of variance 
with repeated measures. In general the differences between groups were most 
marked in late pregnancy, but were detectable in "early" pregnancy. No difference 
was apparent at mid pregnancy. There was also a trend towards reduced 
sensitivity to iloprost postnatally in the at risk group when compared with non 
pregnant data from healthy subjects, but this just failed to reach statistical 
significance. The statistical results of comparison between subject groups are 
illustrated in Table 5.8.
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DAZMEGREL RESPONDER STATUS IN HEALTHY PREGNANCY
Full responders QPartial responders ^ N o n  responders
Number of Weeks Gestation
FIGURE 5 .8 .
The graph show s the num ber o f responders, non responders, and partial 
responders to the throm boxane synthetase inhibitor dazm egrel in healthy  
pregnant subjects at each phase of the study. Full responders w ere  those in 
w hom  A A  induced platelet 14C -5 H T  release w as com pletely  abolished by both  
1 0 0 //M  and 5 0 0 //M  dazm egrel, partial responders w ere  those in w hom  only 
500/yM  dazm egrel resulted in com plete inhibition of p latelet behaviour and 
those in w hom  the release reaction w as not abolished by either concentration  
of the throm boxane synthetase inhibitor w ere  non responders.
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DAZMEGREL RESPONDER STATUS IN SUBJECTS 
AT RISK OF PRE-ECLAMPSIA
4-
3 -
l i
0-
Full 
EJ Responders
□
H
Partial
Reaponder8
Non
Responders
•15 weeks 24 weeks 36 weeks Postnatal
FIGURE 5 .9 .
The figure show s the numbers of responders, non-responders and partial 
responders to  dazm egrel in patients at risk o f pre-eclam psia at each phase of 
the study. The definitions of responder status w ere  as stated in the legend to  
FIGURE 5 .8  and in the tex t.
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TABLE 5 .9  
Serum Thromboxane Bz
Gestation(weeks)
Group NP 5 12/1 5* 24 36
HP 40.94 ± 32.71 ± 30.94 ± 37.36 ± 43.71
6.91 3.88 5.29 2.78 0.93
RP 29.68 ± . 35.32± 33.77 ± 33.57
1.90 2.09 6.85 2.03
*12 weeks for HP and 15 weeks for RP.
All values = pmoles/107 platelets. Means ± SEM are shown.
NP = non pregnant
HP = healthy pregnant subjects
RP = subjects at risk of pre-eclampsia
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3 .5  Responder Status to the Thromboxane Synthetase Inhibitor Dazmegrel.
During healthy pregnancy there was a gradual loss of response to the 
thromboxane synthetase inhibitor dazmegrel. Pre-conceptionally, arachidonic acid 
induced platelet behaviour was completely abolished by both 100uM and 500uM  
dazmegrel in all subjects, but by 36 weeks only one third were full responders, the 
remaining two thirds being complete non-responders. The data are shown in Figure 
5.8. it is apparent that changes in responder status were beginning to become 
apparent at 12 weeks gestation and were established by 24 weeks. Postnatally, 
83%  of women were full responders to dazmegrel, and in the remainder AA 
induced platelet behaviour was abolished by 500uM but not by 100uM dazmegrel 
("partial responders").
In the "at risk” group there were no complete responders at entry to the 
study. This remained the case throughout pregnancy, but postnatally, half of 
subjects were responders (Figure 5.9).
3 .6  Serum Thromboxane S2
The serum levels of thromboxane B2, the stable hydrolysis product of 
thromboxane A2, were similar at all study time points for both the healthy and "at 
risk" groups. Furthermore, there was no difference in serum thromboxane B2 
between the subject groups for any phase of the study. The data are shown in 
Table 5.9.
3 .7  Platelet Cyclic AM P Levels.
Basal adenvlate cvclase activity.
In the absence of any adenylate cyclase stimulators, platelet cyclic AMP 
levels were similar at all study time points in both healthy and "at risk" subjects. 
This was the case whether or not the phosphodiesterase inhibitor AH-P719 was 
present. Furthermore, platelet cyclic AMP levels under these conditions were
206
TABLE 5.10
Platelet Cyclic AMP Levels Under Conditions of 
Basal Adenylate Cyclase Activity
Gestation (weeks)
Group NP 5 1 2 /1 5 * 2 4 3 6
HP (sal) 0.0354± 0.0398 ± 0.0377 ± 0.0370 ± 0.0302±
0.0027 0.0054 0.0044 0.0037 0.0033
RP (sal) 0.0292± - 0.0283± 0.0359 ± 0.0375±
0.0058 - 0.0049 0.0063 0.0054
HP (AH-P719) 0.1661 ± 0.1404± 0.1531 ± 0.1 573± 0.1406±
0.0081 0.0067 0.0062 0.0067 0.0069
RP (AH-P719) 0.1436 ± . 0.1420± 0.1375± 0.1443±
0.0054 0.0061 0.0053 0.0060
* 1 2  weeks for HP and 15 weeks for RP
All values = % conversion 3H-adenine to 3H-cAMP. Means ± SEM are shown.
NP= non pregnant
HP = healthy pregnant subjects
RP = subjects at risk of pre-eclampsia
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comparable in both subject groups. The data are shown in Table 5.10.
Platelet Cyclic AMP Levels Stimulated bv Receptor Dependent Mechanisms.
In the healthy pregnant group there was a reduction in the platelet cyclic 
AMP response to iloprost and PGD2 throughout pregnancy compared with non 
pregnant data. This effect was most pronounced when PRP was incubated with 
relatively high concentrations of the prostaglandins. The results are shown in 
Tables 5.11 and 5.12 and Figures 5.10*5.13. Reduced cyclic AMP responses to 
these agents were evident very early in pregnancy; in some cases as early as 5 
weeks gestation. Platelet cyclic AMP responses to both iloprost and PGD2 
appeared to increase slightly in mid pregnancy but there was no statistically 
significant difference between gestations.
In the group at risk of pre-eclampsia the pattern of results was similar to 
that in healthy pregnancy, but the reduction in platelet cyclic AMP levels during 
pregnancy compared with non pregnant levels in this group appeared less marked, 
just failing to reach statistical significance for iloprost, but reaching significance 
for PGD2. Results during pregnancy were similar for all gestations. Furthermore, 
platelet cyclic AMP responses to iloprost and to PGD2 were generally significantly 
smaller in subjects "at risk" at early and late gestational periods compared with 
healthy pregnant women. There was no difference between the two groups in mid 
pregnancy. There was also a significant reduction in non pregnant platelet cyclic 
AMP responses to 50ng/ml iloprost and to 0.5ug/ml and 5.0ug/ml PGD2 in the 
women with a history of pre-eclampsia compared with the healthy women. 
Platelet Cyclic AMP Levels on Direct Stimulation of Adenvlate Cvclase.
In the healthy pregnant group there was a significant reduction in the 
platelet cyclic AMP response to forskolin during pregnancy compared with non 
pregnant data. This effect reached statistical significance at 5 weeks and 36
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F I G U R E S  5.10
Platelet cyclic A M P  accum ulation is plotted against gestation follow ing  
stim ulation of adenylate cyclase w ith  50n g /m l iloprost. In HP( a ) p latelet cyclic  
A M P  levels tended to be low er at all gestational tim e points com pared w ith  
data w hen  subjects w ere  not pregnant. Friedman analysis o f variance show ed  
an overall p value of 0 .0 1 4 6 ,  w ith  p <  0 .0 5  for the  com parison o f 5 w eek  
data w ith  non pregnant data. In RP (O ) a similar pattern o f results w as  
obtained but the d ifference betw een  gestational and postnatal data just failed 
to reach statistical significance (Friedm an A N O V A  p value =  0 .0 6 5 8 ) .  
Com parison of HP and RP show ed significantly low er cA M P  values in RP in 
late pregnancy and w hen subjects w ere  not pregnant (p =  0 .0 5 ) .  Statistical 
significance for com parisons w ith in  subject groups is denoted by * and 
b etw een  subject groups by * * .
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FIGURE 5 .1 1 .
The figure shows platelet cyclic AMP accumulation plotted against gestation 
following stimulation of adenylate cyclase with 50ng/m l iloprost in the 
presence of the phosphodiesterase inhibitor A H -P 719. Once again, in HP ( a ) ,  
platelet cyclic AM P levels tended to be lower at all gestational time points, 
compared with non pregnant data. Friedman ANO VA showed p =  0 .0 3 0 6 ,  
with p <  0 .0 5  for 36  week data compared with non pregnant data (* ) . In RP 
(O ), the pattern of results was similar but the Friedman A N O VA p value was 
0 .0 8 5 8 . Comparison of HP and RP showed significantly lower cyclic AMP  
levels in RP in early pregnancy and when subjects were not pregnant ( * *  p =  
0 .05 )
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F I G U R E  5.12
The figure show s platelet cyclic A M P  accum ulation fo llow ing stim ulation of 
adenylate  cyclase w ith  PGD2. The pattern o f results w as very  similar to those  
generated fo llow ing exposure of platelets to iloprost. In HP ( a ) the overall p 
value for Friedman A N O V A  w as 0 .0 9 7 9 , and in RP (O ) p =  0 .0 3 2 0 ,  w ith  p 
<  0 .0 5  for com parison of early pregnancy and postnatal data ( * ) .  Com parison  
of HP and RP show ed a significant reduction in cA M P  in RP (A N O V A  p =  
0 .0 0 0 1 ) ,  w ith  p =  0 .0 3 2 8  w hen subjects w ere  not pregnant ( * * ) .
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FIGURE 5 .13 .
The graph show s platelet cyclic A M P  accum ulation fo llow ing stim ulation of 
adenylate  cyclase w ith  PG D2 in the presence of A H -P 7 1 9 . In HP ( a ) cyclic  
A M P  w as low er during pregnancy than w hen subjects w ere  not pregnant 
(Friedm an A N O V A  p =  0 .0 4 4 0 )  w ith  p <  0 .0 5  for com parison o f data at 12, 
2 4 , and 3 6  w eeks w ith  non pregnant data ( * ) .  In RP (O ) the pattern o f results 
w as similar (Friedm an A N O V A  p =  0 .0 4 5 5 ) ,  w ith  p <  0 .0 5  for com parison  
of data in early pregnancy w ith  postnatal d a ta (* ) . In this case, com parison of 
HP and RP revealed no statistically significant d ifference in results.
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The figure illustrates platelet cyclic A M P  responses to forskolin in the presence  
of the phosphodiesterase inhibitor A H -P 7 1 9 . There w as a significant reduction  
in p latelet cyclic A M P  levels in HP ( a ) during pregnancy (Friedm an A N O V A  p 
=  0 .0 0 9 2 ) ,  w ith  p <  0 .0 5  ( * )  at 5 w eeks and 3 6  w eeks gestation com pared  
w ith  non pregnant data. In RP (O ) platelet cyclic A M P  responses to forskolin  
show ed a similar pattern but there w as no significant d ifference betw een  
gestational and postnatal data. In early pregnancy, w om en at risk o f pre­
eclam psia show ed a significantly reduced platelet cyclic A M P  response to  
forskolin com pared w ith  healthy prim igravidae ( p =  0 .0 1 8 8 ,  * * )  and the  
difference betw een  groups approached significance for non pregnant data (p 
=  0 .0 8 1 3 ) .
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weeks gestation (Figure 5.14). A trend towards a mid pregnancy rise was again 
noted but, as with the response to the prostaglandins, there was no statistically 
significant difference between the data at different gestations.
In the "at risk" group, the pattern of response was similar but the difference 
between the postnatal platelet cyclic AMP response to forskolin and results during 
pregnancy was not statistically significant.
When the two groups of subjects were compared, there was a significant 
reduction in the platelet cyclic AMP response to forskolin in early pregnancy in 
subjects at risk of pre-eclampsia. Although forskolin-stimulated platelet cyclic AMP 
levels appeared lower postnatally in this group compared with healthy women, this 
difference just failed to reach statistical significance.
Arachidonic Acid and Platelet Cyclic AMP.
In the healthy patients, arachidonic acid alone led to a slight rise in platelet 
cyclic AMP above basal levels. This was markedly enhanced in the presence of the 
thromboxane synthetase inhibitor dazmegrel. Following incubation of PRP with AA 
alone platelet cyclic AMP levels tended to be lower in early and mid pregnancy 
compared with late pregnancy and non pregnant data (Figure 5.15). This trend, 
however, did not reach statistical significance. In the presence of the thromboxane 
synthetase inhibitor, the pattern of results was similar, but in this case the 
difference between early pregnancy and 36 week and non pregnant data reached 
significance (Figure 5.16). It is noteworthy that these data differ from the platelet 
cyclic AMP responses to individual prostaglandins and to forskolin in the similarity 
of the late pregnancy response to non pregnant data.
In women at risk of pre-eclampsia there was a trend during pregnancy 
towards a reduction in platelet cyclic AMP levels in the presence of AA alone and 
AA and dazmegrel together compared with postnatal data, but statistical analysis
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FIGURE 5 .1 5 .
The graph show s platelet cyclic A M P  levels in the  presence of 1m M  
arachidonic acid throughout the study period. There w as no statistically  
significant d ifference betw een  results a t d iffe ren t phases o f the study in either 
HP (a )  or RP (O ) .  The Friedman A N O V A  p value for HP w as 0 .0 8 6 8 ,  and for 
RP w as 0 .2 9 8 8 .  Note , how ever th a t a tendency tow ards  a rise in cyclic A M P  
levels occurred in late pregnancy in HP, at w hich tim e p latelet cyclic A M P  
levels w ere  significantly low er in RP ( * * ,  p =  0 .0 3 2 8 ) .
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FIGURE 5.16.
The figure shows platelet cyclic AMP levels in the presence of arachidonic acid 
together w ith the thromboxane synthetase inhibitor dazmegrel. In HPU) platelet 
cyclic AMP levels were significantly lower in very early and mid pregnancy compared 
with non pregnant data. There was a significant late pregnancy rise in the cyclic AMP 
response. The overall p value for Friedman ANOVA was 0.0452, w ith p < 0.05 for 
comparison of non pregnant with 5 and 24 week data and comparison of 5 week and 
36 week data (*). In RP (O )  the late pregnancy rise in cyclic AMP responses under 
these conditions did not occur, and the difference between HP and RP was 
statistically significant at this time point (p = 0.0328, ##).
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F I G U R E  5.17.
The figure show s platelet cyclic A M P  accum ulation in the presence o f 5ng/m l 
iloprost together w ith  1m M  A A . The pattern o f results resem bles those in the  
presence of A A  alone and A A  and dazm egrel as show n in Figures 5 .1 5  and 
5 .1 6 . Friedman A N O V A  revealed p =  0 .0 3 8 2  for HP ( a ) ,  w ith  p <  0 .0 5  for 
5 w eek  and 2 4  w eek  data com pared w ith  non pregnant data. In RP (O ),  
Friedman A N O V A  yielded an overall p value of 0 .0 5 0 3 ,  w ith  p <  0 .0 5  for 
com parison of data in early pregnancy and postnatally. Com parison of 
platelets from  HP and RP under these conditions show ed significantly less 
cyclic A M P  accum ulation in those from  RP in early pregnancy ( * * ,  p =  
0 .0 1 8 8 ) .
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in both cases revealed no significant difference between study time points. It is 
noteworthy, however, that the late pregnancy increase in cyclic AMP in response 
to arachidonic acid and dazmegrel demonstrated by healthy subjects did not occur 
in the "at risk” group. Indeed comparison of the two groups of subjects by two 
way analysis of variance showed that platelet cyclic AMP levels in the presence 
of both AA alone and AA and dazmegrel together were significantly lower in late 
pregnancy in subjects at risk of pre-eclampsia compared with healthy subjects. 
There was no difference between groups in results in early and mid pregnancy and 
when subjects were not pregnant.
Influence of Arachidonic Acid on Platelet Cyclic AMP Response to Iloprost.
In the healthy primigravidae, platelet cyclic AMP responses to iloprost and 
AA together were significantly reduced at 5 and 24 weeks gestation compared 
with non pregnant data. There was, however a significant rise in the platelet cyclic 
AMP levels in the presence of AA and iloprost at 36 weeks compared with those 
at 5 weeks gestation, mirroring the pattern of results with AA alone and AA and 
dazmegrel (Figure 5.17).
In women at risk of pre-eclampsia there was a reduction in the cyclic AMP 
response to iloprost and AA during pregnancy compared with results in the same 
patients postnatally, reaching statistical significance in the early second trimester. 
In this group of subjects there was no increase in cyclic AMP in the presence of 
iloprost and AA in late pregnancy. Comparison of the two subject groups revealed 
that platelets from subjects at risk of pre-eclampsia produced significantly less 
cyclic AMP in response to the combination of AA and iloprost in early pregnancy 
and there was a similar trend in late pregnancy and non pregnant data which just 
failed to reach statistical significance.
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3.8 Platelet Behaviour in Relation to Cyclic AMP Studied Longitudinally in 
a Primiaravida who Developed the HELLP Syndrome.
Case History.
The patient was a 28 year old primigravida who had no past medical 
history of note and was a regular blood donor. She volunteered for the study when 
she was planning pregnancy. At the pre-conceptional visit her blood pressure was 
125/79. Seven weeks following the pre-conceptional study day, she reported that 
her menstrual period was seven days late. A sensitive pregnancy test confirmed 
pregnancy, which was estimated at 5 weeks gestation by dates, and she donated 
blood for platelet studies. Her blood pressure was 136/79. She booked at the 
antenatal clinic of another local hospital at 15 weeks gestation by dates, and 
gestation was confirmed by ultrasound scan. She donated blood for the study at 
12, 24, and 36 weeks gestation. At all of these visits and all antenatal clinic visits 
she was well, with a normal blood pressure, negative urinalysis, and adequate 
fetal growth by both clinical and/or ultrasound assessment.
At 38 weeks gestation she was admitted under the care of her consultant 
obstetrician to her local hospital following an antenatal clinic visit because of the 
"incidental finding" of thrombocytopenia on a routine full blood count (Hb 
11.7g/dl, WBC 5.24 x 109/l, platelets 49 x 109/l). All previous platelet counts 
were within the normal range. Examination of the peripheral blood film showed 
that red cell morphology was normochromic normocytic, and the 
thrombocytopenia was confirmed. Prothrombin time, activated partial 
thromboplastin time, and thrombin clotting times were normal. The blood pressure 
at the time of admission was 150/86 and urinalysis was negative for protein. A 
bone marrow aspirate was carried out, which showed plentiful megakaryocytes, 
indicating that the thrombocytopenia was due to peripheral platelet consumption,
221
and a provisional diagnosis of autoimmune thrombocytopenia was made. The 
patient was treated for three days with high dose intravenous immunoglobulin. 
Over this period, diastolic blood pressures of 90 mmHg ( a rise of 24 mmHg 
compared with the diastolic pressure at 12 weeks) were recorded on several 
occasions. Serum urea and electrolytes were normal, but the urate was raised at 
393umol/i and liver function tests showed a raised ALT at 339IU/I, with a slight 
elevation of bilirubin at 40umol/l.
On the third day following admission, proteinuria was recorded on dipstick 
testing, but was not quantified. The platelet count fell to 27 x 109/l, and 
haemoglobin (Hb) dropped to 10.5g/dl. A reticulocyte count was not done and 
there was no record of the blood film having been examined for schistocytes at 
this stage. Clotting times remained normal, but plasma fibrinogen levels and serum 
FDP were not measured. Later the same day the patient complained of epigastric 
pain, and diastolic blood pressure was recorded as 100. Brisk reflexes and clonus 
were documented in the case record. The cardiotocograph was noted to be 
unreactive with marked prolonged decelerations. A decision was made to perform 
an emergency Caesarean section for "fetal distress and ITP”. During the procedure 
the estimated blood loss was 1 litre and the patient was transfused with 4  units 
of blood and 6 units of platelets. A live male baby weighing 3.8kg was delivered 
with Apgar scores of 9 at 1 minute and 10 at 5 minutes. Following delivery, the 
blood pressure fell within 24 hours, and there was a rapid resolution of the 
thrombocytopenia, the platelet count having reached 231 x 109/l by the second 
postnatal day. The postoperative Hb was 8.5g/dl. Liver function tests gradually 
improved, the ALT reaching a normal value one week following delivery. Mother 
and baby were both well at the 6 week postnatal visit.
The diagnosis of the HELLP syndrome was made postnatally by the
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PLATELET RELEASE IN  RESPONSE TO ImM AA
IN A PATIENT WHO DEVELOPED THE HELLP SYNDROME
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F I G U R E  5.18.
The graph show s % release 14C -5H T  plotted against gestation in the patient
w ith  the HELLP syndrom e (__ ♦ ___). For com parison, results in the healthy
pregnant group studied longitudinally are show n ( - a - ) ,  together w ith  those  
in the group at risk of pre-eclam psia ( - O - ) .
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The figure show s platelet sensitivity to iloprost for the  patient( ♦ — ), as
m easured by threshold concentration of the inhibitor resulting in com plete  
inhibition of arachidonic acid induced 5H T  release. Results in HP ( - a •••) and RP 
( -O •••) are show n for com parison. A lthough the results for the patient did not 
differ from  those in healthy pregnancy at gestational tim e points, it is 
no tew o rth y  th a t p latelet sensitivity to  iloprost rem ained fairly constant over 
the w hole study period.
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consultant obstetrician in charge of the case. There is no doubt that the patient 
had low platelets, elevated liver enzymes, and features of pre-eclampsia. The 
blood pressure was never markedly elevated, but the increment in diastolic 
pressure met the criteria for PIH and serum urate was elevated. Proteinuria 
developed as a late feature. From the clinical features documented in the case 
record, it is apparent that the patient had impending eclampsia just prior to 
delivery. The evidence for microangiopathic haemolysis is less convincing as red 
cell morphology was reputedly normal when thrombocytopenia was first identified, 
but evidence of haemolysis was never specifically sought, and the perioperative 
drop in haemoglobin was greater than expected taking account of estimated blood 
loss and transfusion.
Platelet Studies.
Blood was taken for platelet studies pre-conceptionally, at 5, 12, 24, and 
36 weeks gestation, and at 4 days and 6 weeks postnatally. Unfortunately there 
was no opportunity to study the patient at the time when she developed the 
features of the HELLP syndrome as she was admitted to another hospital and the 
diagnosis was made in retrospect.
Arachidonic Acid Induced Platelet Behaviour.
The % 14C-5HT release in PRP from the patient is shown in Figure 5.18. 
There was a slight increase in dense granule release in late pregnancy which had 
returned to pre-conceptional levels by the 6th postnatal week.
Sensitivity to Cyclic AMP Manipulators.
Iloprost thresholds for the patient, compared with those in healthy pregnant 
women and those at risk of pre-eclampsia, are illustrated in Figure 5.19. Threshold 
concentrations of each of the other inhibitors leading to complete abolition of the 
release reaction in the patient's PRP are shown on Table 5.13. Although the
226
CYCLIC AMP RESPONSE TO 50ng/m l ILOPROST + AH-P719
IN A PATIENT WHO DEVELOPED THE HELLP SYNDROME
CD
CD
*TD
CD
I
m
CD
C
o
• r —I
CO
c_
CD
d
CD
CD
CL
ZE 3.8  -
C_)
I
3.0-
pre-pregnancy 6 12 18 24 30 36 postnatal
g es ta t io n  (weeks)
F I G U R E  5.20
The figure illustrates platelet cyclic A M P  levels in the presence o f iloprost and 
the phosphodiesterase inhibitor for the patient w ho developed the HELLP
syndrom e (__ ♦ ___). Results for HP (- a - )  and RP ( - O - )  are again show n for
com parison. It is noteable th a t results for the patient closely correspond to  
those for the group of patients at risk o f pre-eclam psia.
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CYCLIC AMP RESPONSE TO 5/tg/m l PGD2 + AH-P719
IN A PATIENT WHO DEVELOPED THE HELLP SYNDROME
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The figure illustrates platelet cyclic A M P  levels in the presence o f PG D2 and 
the phosphodiesterase inhibitor for the patient w ho  developed the  HELLP
syndrom e (__ ♦ ___ ). Results for HP ( - a - )  and RP ( - O - )  are again show n for
com parison.
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CYCLIC AMP RESPONSE TO FORSKOLIN
IN A PATIENT WHO DEVELOPED THE HELLP SYNDROME
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FIG U R E 5 .2 2
The figure illustrates platelet cyclic A M P  levels in the presence of forskolin and 
the phosphodiesterase inhibitor for the patient w ho  developed the HELLP 
syndrom e (— ♦ — ). Results for HP ( - a •••) and RP ( -0 - )  are again show n for 
com parison.
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degree of sensitivity of the patient's platelets to the inhibitors did not clearly differ 
from values obtained in healthy pregnancy, it is noteworthy in each case that 
there was little change in sensitivity as pregnancy progressed and results in the 
pre-conceptional and postnatal phases tended to lie closer to those in the "at risk" 
group in the case of iloprost and forskolin. Furthermore the patient was a complete 
non responder to dazmegrel pre-conceptionally, at all gestational time points and 
at 4 days postnatally. At 6 weeks postnatally she was a partial responder. 
Serum Thromboxane Bn
Thromboxane B2 levels in the patient's serum changed little over the period 
of the study and were similar to those recorded in healthy pregnancy. The results 
are shown in Table 5.13.
Platelet Cyclic AMP Levels.
Basal platelet cyclic AMP levels and those in the presence of 
AH-P719 alone did not change throughout the study period. Examples of platelet 
cyclic AMP responses to iloprost, PGD2 and forskolin are shown in Figures 5.20- 
5.22. The data shown demonstrate the typical pattern obtained in the patient's 
PRP with all concentrations of these agents with or without the PDE inhibitor. It 
is noteworthy that the results in the subject who developed the HELLP syndrome, 
more closely resemble those of the "at risk” group than the healthy pregnant 
group, but in late pregnancy, just prior to the onset of clinical signs and 
symptoms, this trend partially reversed, especially in the case of PGD2 and 
forskolin. Platelet cyclic AMP accumulation in PRP from the patient in the presence 
of arachidonic acid in combination with ajdazmegrel, and bjiloprost is shown in 
Figure 5.23 and 5.24. Again, the pattern for the patient resembled that shown by 
the women at risk of pre-eclampsia, and in particular, the patient showed no late 
pregnancy rise in the cyclic AMP response under these conditions, as
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CYCLIC AMP RESPONSE TO DAZMEGREL AND AA
IN A PATIENT WHO DEVELOPED THE HELLP SYNDROME
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The graph show s platelet cyclic A M P  accum ulation in the presence of 
dazm egrel 5 0 0 //M  and 1m M  A A  in the patient w ith  the HELLP syndrom e  
(— ♦ — ), together w ith  results in HP ( - a - )  and RP ( - O •••). Note th a t platelets  
from  the patient, as for RP show ed no late pregnancy rise in cyclic A M P  under 
these conditions.
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CYCLIC AMP RESPONSE TO AA AND ILOPROST
IN A PATIENT WHO DEVELOPED THE HELLP SYNDROME
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The graph show s platelet cyclic A M P  accum ulation in the presence of A A
1m M  and 5ng/m l iloprost in the patient w ith  the HELLP syndrom e (__ ♦ ___),
together w ith  results in HP (..-a - )  and RP ( - O - ) .  Note th a t platelets from  the  
patient, as for RP show ed no late pregnancy rise in cyclic A M P  under these  
conditions.
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demonstrated by healthy primigravidae. It is notable that, when studied 4  days 
postnatally, the patient's cyclic AMP responses to all adenylate cyclase 
stimulators were much lower than at any other time during the study. The 
significance of this is uncertain as no other subjects were studied at this time. 
Furthermore, the patient had received a platelet transfusion at delivery.
4.DISCUSSI0N.
This study has confirmed the findings of the cross sectional studies 
reported in Chapters 3 and 4 by showing that, during healthy pregnancy, platelets 
are less sensitive to the inhibitory effects of a wide range of agents which act via 
cyclic AMP. This was again associated with a reduction in cyclic AMP production 
during pregnancy in PRP in response to all adenylate cyclase stimulators tested, 
compared with results in PRP from the same women when they were not 
pregnant. As before there was no change in cyclic AMP levels under conditions 
of basal adenylate cyclase activity, whether or not phosphodiesterase was 
inhibited. Changes in cyclic AMP responses were observed with a wide range of 
adenylate cyclase stimulators including forskolin which can act directly upon the 
adenylate cyclase enzyme.200,201 These data, taken together with the results of the 
cross sectional study, suggest that a reduction in adenylate cyclase activity occurs 
during pregnancy.
The longitudinal data showed that reduction in efficacy of cyclic AMP 
manipulators as inhibitors of platelet behaviour became gradually more marked as 
pregnancy progressed, reaching a maximum at 36 weeks gestation. The pattern 
of cyclic AMP responses with gestation was somewhat different, with reduction 
in stimulated cyclic AMP levels becoming apparent in the very earliest weeks of 
pregnancy, and subsequently remaining reduced throughout the gestational period.
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In healthy pregnant women changes in platelet sensitivity to cyclic AMP 
manipulators and cyclic AMP responses reversed postnatally. It would, however, 
be difficult to ascertain the timing of this as, although all women were studied 
after the sixth postnatal week, the exact timing of postnatal samples varied widely 
for practical reasons.
The differing time courses of changes in platelet cyclic AMP responses 
compared with changes in the efficacy of the adenylate cyclase stimulators as 
inhibitors of platelet behaviour, suggest that factors other than absolute amounts 
of cyclic AMP play a role in determining inhibitor efficacy. The extent of 
thromboxane production would not seem to be implicated, as serum thromboxane 
B2 levels did not vary throughout the study. As proposed in the discussion of the 
cross sectional data, the hypothesis could be put forward that an increase in 
sensitivity to the pro-aggregatory effects of thromboxane, or to other arachidonic 
acid metabolites could contribute to the reduction in efficacy of the inhibitors as 
pregnancy progressed. The platelet cyclic AMP results in the presence of 
arachidonic acid are also noteworthy in this respect. The pattern of results in the 
healthy pregnant group in the presence of AA alone, or in combination with 
dazmegrel or iloprost was different compared with those when adenylate cyclase 
stimulators were tested in the absence of AA. Healthy pregnant patients showed 
a significant late pregnancy rise in platelet cyclic AMP levels when AA alone, AA 
and dazmegrel and AA and iloprost were investigated. The interpretation of the 
biochemical mechanisms responsible for these observations can only remain 
speculative, but it is pertinent that the late pregnancy increase in cyclic AMP in 
the presence of AA in healthy pregnancy occurred at a time when the majority of 
patients showed a "non responder" status with dazmegrel and when platelets 
were least sensitive to inhibition of their AA induced behaviour by adenylate
234
cyclase stimulators in general. It is possible that in late pregnancy cyclic AMP 
itself is less effective as an inhibitor of platelet behaviour, and these observations 
again raise the possibility that factors such as sensitivity to pro-aggregatory 
prostanoids contribute to the determination of efficacy of cyclic AMP manipulators 
as inhibitors of platelet behaviour including dazmegrel responder status.
In contrast with the data from the cross sectional study, the longitudinal 
study has revealed interesting differences between healthy pregnant women and 
those with a previous history of pre-eclampsia. In women with high risk 
pregnancies, stimulated cyclic AMP levels during pregnancy were consistently 
lower than those in healthy pregnant women and platelets were also less sensitive 
to inhibition of the release reaction by all adenylate cyclase stimulators. The late 
pregnancy rise in platelet cyclic AMP accumulation in the presence of arachidonic 
acid was not noted in high risk pregnancies, suggesting that a mechanism 
potentially capable of limiting the pro-aggregatory platelet response to arachidonic 
acid metabolites, which was present at 36 weeks in healthy pregnancy, appeared 
to be absent in high risk pregnancies. Furthermore, the primigravid patient who 
developed the HELLP syndrome,355 who was recruited independently from the high 
risk women, showed platelet cyclic AMP responses which were similar under most 
experimental conditions to those women recruited to the "at risk” study. Although 
the numbers of subjects in each study group were small, the consistency of 
results in the gestational period together with the results for the patient with the 
HELLP syndrome suggest that the differences between healthy women and those 
at risk of pre-eclampsia are genuine, at least during the gestational period. The 
difference between groups of women in parameters such as blood pressure, serum 
urate and pattern of platelet count during pregnancy also give credence to the 
observed alterations in platelet behaviour in relation to cyclic AMP. The
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interpretation of the data in the non pregnant phase must be approached more 
cautiously, as all the "at risk" subjects were studied postnatally, and no pre- 
conceptional data were available for this group. Nevertheless, the timing of 
postnatal sampling did not differ significantly between the two subject groups. 
The possibility that a longer time is required for pregnancy associated changes in 
platelet cyclic AMP to reverse postnatally in high risk women cannot, however, 
be excluded. The hypothesis could therefore be put forward that, at least during 
pregnancy, there is a reduction in the responsiveness of the platelet adenylate 
cyclase system in some women, over and above that which occurs in healthy 
pregnancy, which is associated with a risk of pre-eclampsia. It is possible that this 
difference also exists when such subjects are not pregnant.
The differences in platelet responses between the two groups during 
pregnancy cannot be explained by the effects of pre-eclampsia upon platelet 
behaviour as none of the women recruited into the high risk group developed 
clinically overt pre-eclampsia during the pregnancy studied. As the cross-sectional 
study showed that platelet parameters in pre-eclamptic women did not differ 
significantly from those in healthy primigravidae, it is even possible that the onset 
of pathological changes in blood vessels which occur when pre-eclampsia is 
clinically detectable could alter platelet behaviour and biochemistry in a way which 
would make differences between healthy women and those at risk of the disease 
more difficult to detect when platelets were studied in vitro. Although caution 
must be applied to the interpretation of data from one subject, this hypothesis is 
supported by the results presented for the patient with the HELLP syndrome 
whose platelet sensitivity to inhibitors acting via cyclic AMP changed little over 
the gestational period. Furthermore, with the exception of responses in the 
presence of arachidonic acid, platelet cyclic AMP accumulation in this patient,
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although more closely resembling the pattern of responses in the at risk group in 
early and mid pregnancy, was less easily distinguishable from that in healthy 
primigravidae at 36 weeks gestation. One possible explanation for these 
observations is that platelet consumption in vivo in pre-eclampsia291'293'353,400 
leaves only a subpopulation of platelets available for in vitro study. Reduction in 
placental production of vasodilatory prostaglandins in pre-eclampsia1 e0'298,310’397'399 
may also alter the profile of platelet sensitivity to inhibitory prostaglandins and 
platelet cyclic AMP accumulation in response to these agents, potentially masking 
any intrinsic differences in such parameters in women at risk of the disease. The 
lack of change in efficacy of prostaglandins as inhibitors of platelet behaviour as 
pregnancy progressed in the patient with the HELLP syndrome would lend support 
to the lack of a factor in pre-eclampsia which is responsible for physiological 
alterations in platelet behaviour in normal pregnancy. This raises the question of 
whether the changes in platelet responses to inhibitory prostaglandins observed 
during healthy pregnancy could result from heterologous desensitisation of platelet 
adenylate cyclase as a result of exposure to prostaglandins synthesised by the 
placenta. If this were the case, reduced placental synthesis of prostaglandins may 
result in desensitisation being less marked when pre-eclampsia develops.
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CHAPTER 6.
EXAMINATION OF THE MECHANISM OF CHANGES IN 
STIMULATED PLATELET CYCLIC AMP 
DURING HEALTHY PREGNANCY.
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CHAPTER 6.
EXAMINATION OF THE MECHANISM OF CHANGES IN 
STIMULATED PLATELET CYCLIC AMP DURING HEALTHY PREGNANCY.
1.INTRODUCTION.
The studies reported in Chapters 4 and 5 showed that platelet cyclic AMP 
accumulation following stimulation of adenylate cyclase was lower in healthy 
pregnant women compared with non pregnant women. This was the case not only 
when adenylate cyclase was stimulated by agents acting through specific 
membrane receptors linked to the stimulatory G protein G,, but also when the 
enzyme was stimulated in a non receptor-dependent manner200,201 with the 
diterpene forskolin. No change was demonstrated in platelet cyclic AMP levels in 
pregnant women under conditions of basal adenylate cyclase activity. 
Furthermore, the reduction in stimulated cyclic AMP was more marked when 
phosphodiesterase was inhibited with AH-P719. Theoretically, reduction in cyclic 
AMP accumulation could result either from reduced activity of adenylate cyclase 
or from increased activity of phosphodiesterase. If increased metabolism of cyclic 
AMP via phosphodiesterase occurred in platelets during pregnancy, then the 
presence of a phosphodiesterase inhibitor would be expected to reduce rather than 
enhance differences in cyclic AMP accumulation between pregnant and non 
pregnant subjects. These observations therefore suggest that a change in 
phosphodiesterase activity is unlikely to explain the pregnancy associated 
reduction in stimulated platelet cyclic AMP levels. The situation is, however, 
complicated by the presence of three isoforms of phosphodiesterase in 
platelets,209,210 some of which are cyclic AMP specific, whilst others are cyclic
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GMP specific, and others can hydrolyse both cyclic AMP and cyclic GMP. At the 
concentrations used in the studies reported in Chapters 4 and 5, AH-P719 is 
thought to be a specific inhibitor of the type III phosphodiesterase which 
preferentially hydrolyses cyclic AMP (personal communication in writing from Dr 
Hans Weisenberger, Karl Thomae GmbH, subsidiary of Boehringer Ingelheim and 
reference 249). Although AH-P719 is purported not to affect cyclic GMP levels, 
its effects on all of the PDE isoforms have not been fully documented, and it is 
therefore possible that metabolism of cyclic AMP was occurring even in the 
presence of AH-P719.
If changes in adenylate cyclase activity do, however, account for 
reductions in stimulated platelet cyclic AMP levels during pregnancy, then it is 
worthwhile considering the possible underlying mechanisms. As cyclic AMP levels 
were lower in platelets from pregnant subjects in response to agents acting via 
different receptors and in response to forskolin, it is unlikely that down regulation 
of prostaglandin receptors could account for the observations. Forskolin is capable 
of stimulating the catalytic subunit of adenylate cyclase directly but its effects on 
cyclic AMP accumulation may be modulated by the G proteins.201,442 Recent 
studies have suggested that control of adenylate cyclase activity by Q may 
involve a dual mechanism.441 All G proteins have a heterotrimeric structure with 
alpha, beta, and gamma subunits.443,122 There is evidence that ligand stimulated 
adenylate cyclase activity can be reduced by activity of the dissociated alpha 
subunit of Gj (GJ when it binds GTP, whereas the beta-gamma subunit (G^) 
inhibits basal adenylate cyclase activity.441 Forskolin stimulated adenylate cyclase 
activity can be inhibited both by G* and by G^ .441 A putative mechanism which 
could explain the observations on platelet cyclic AMP during pregnancy is 
therefore an increase in G* activity. Whilst the study of adenylate cyclase activity
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in platelet membranes together with studies of G protein activity in membranes 
treated with cholera or pertussis toxin443 would offer a direct approach to the 
investigation of the mechanism of changes in cyclic AMP accumulation in platelets 
from pregnant women, such techniques also have inherent disadvantages. The 
necessity to prepare washed platelets and the subsequent manipulation involved 
in isolating the membranes may result in the loss of subpopulations of platelets 
during preparation, which may be all the more important when it could be 
anticipated that platelets from pregnant women may be more subject to activation 
during handling. Furthermore, most published techniques for measuring adenylate 
cyclase activity employ 32P labelled ATP438, and the use of this isotope has 
numerous laboratory safety implications. It was therefore decided to use an 
indirect approach in the first instance to further investigate the possible 
mechanisms of reduction in platelet cyclic AMP levels during pregnancy.
Three studies have been carried out to address the questions of 
phosphodiesterase activity and Gj mediated control of adenylate cyclase activity 
in platelets from healthy pregnant women. The first study involved the comparison 
of the time course of changes in platelet cyclic AMP following stimulation of 
adenylate cyclase with PGE,, which acts at the prostacyclin receptor.195,190 It has 
been shown that following exposure to most prostaglandins, platelet cyclic AMP 
levels rise to a peak and then fall off to reach a plateau.202 It is felt that this 
reduction in cyclic AMP results partly from metabolism of the cyclic nucleotide, 
and partly as a result of activation of Gj, following binding of the prostaglandin to 
receptors distinct from those linked to stimulation of adenylate cyclase.202 The 
affinity and time course of binding to Gj linked receptors differs for each 
prostaglandin. Binding of PGE1 to the latter type of receptor occurs later than its 
binding to receptors linked to G,.202 Comparison of the time course of the platelet
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cyclic AMP response to prostaglandins in pregnant and non pregnant women may 
give insight as to whether a difference exists in the ability of platelets to initially 
generate cyclic AMP in response to stimulation or whether differences occur in 
the subsequent rate of fall off of cyclic AMP as a result of differences in 
metabolism or differences in G{ activation.
The second set of experiments were carried out with the aim of 
establishing whether significant cyclic AMP metabolism occurred in the presence 
of the PDE inhibitor AH-P719, and whether this differed in pregnant and non 
pregnant women. Studies in cells other than platelets have shown that cyclic 
AMP levels, when raised by receptor mediated stimulation of adenylate cyclase, 
fall rapidly following removal of the agonist, even in the presence of a 
phosphodiesterase inhibitor.444
The third study was conducted to further investigate the effects on platelet 
cyclic A M P of activation of G{. PGE2 has been shown to have dual effects on both 
platelet behaviour87'90 and platelet cyclic A M P levels. High concentrations of PGE2 
can raise cyclic A M P  by stimulating adenylate cyclase, possibly via the PGI2 
receptor.88,89,203 By contrast, exposure of platelets to low concentrations of PGE2 
leads to a reduction in cyclic A M P levels, only if these have previously been raised 
by stimulation of adenylate cyclase via another receptor dependent 
mechanism.88,89,203 The latter effect is thought to occur by activation of Gj.89 PGE2 
could therefore provide a suitable tool for the investigation of Q mediated events. 
Furthermore, the examination of the effect on platelet cyclic A M P  levels of PGE2 
is of physiological relevance as PGE2 is the major prostaglandin synthesised by the 
microvascular endothelium,183,164 and PGE2 synthesis also takes place in the 
placenta.288,300
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2.METH0DS.
2.1 Time Course of Platelet Cyclic AMP Response to PGE,
Eleven healthy non pregnant women and nine healthy third trimester 
primigravidae donated blood for the study. Previously described criteria for subject 
selection were strictly followed. All subjects were normotensive and gave no 
history of relevant drug ingestion. PRP was prepared from citrated blood, the 
platelet count adjusted to 250 x 109/l and labelled with 3H-adenine. Aliquots of 
PRP (450ul) were then incubated with 25ul of saline at 37°C and stirred at 
1,000rpm for 2 minutes. 25ul PGE1 (30uM) or saline (for measurement of basal 
cyclic AMP) was then added and the reaction stopped with 2ml 15% TCA at 
times varying between 7 seconds and 12 minutes. Assay of cyclic AMP was 
completed as documented in Chapter 2. A graph of % conversion 3H-adenine to 
3H-cyclic AMP against time was drawn for each subject. These graphs showed a 
typical peak and plateau pattern (Figure 6.1). When log time was plotted against 
percentage of peak cyclic AMP for time points following the peak response, a 
sigmoid curve was obtained. An example is shown in Figure 6.2. Points 
subsequent to the peak for each subject were therefore fitted to a sigmoid curve 
using computerised non linear regression analysis ("Graphpad Inplot", Graphpad 
Software Inc, San Diego) and values for the downward slope of each graph were 
generated. Comparison of the slopes for each subject group was carried out using 
the Mann-Whitney U test. Overall comparison of cyclic AMP levels in response to 
PGEj in pregnant and non pregnant women was carried out using two way 
analysis with repeated measures, supplemented with unpaired t tests, as data at 
each time point were shown to be normally distributed using the Kolmogorov- 
Smirnov cumulative distribution test.
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Sigmoid curve (log scale)
A = bottom, B = top, C = log(EC50), D = 'Hill' Slope
Final Results. Sum of Squares = 9.185E-06 (df = 2) 
Goodness-of-fit assessed using actual distances; R squared = 1.000.
Parameter Value Approx. SE %Error(CV)
A 72 .63993  1.524E-03 < 0 .1 %
B 100 (Constant)
C .04959364  4.209E-04 0 .8%
D -11 .32642  .09570017  0.8%
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FIGURE 6 .2
The figure show s platelet cA M P  levels, at tim e points fo llow ing the peak  
achieved in response to 3 0 //M  PGEV expressed as a % o f this peak level, and 
plotted against the log10 of the tim e in m inutes fo llow ing addition of P G E ,. The  
curve fitting data using the Hill equation are show n below  the graph. The top  
of the curve w as a lw ays fixed at 1 0 0 %  'D ' represents the slope and this 
value w as used in each subject as a measure o f the rate o f reduction in cyclic 
A M P  fo llow ing peak levels. In the exam ple the value of 1 for R squared 
represents a perfect fit of the data to  the Hill equation. For all subjects R 
squared w as >  0 .9 .
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METABOLISM OF PLATELET CYCLIC AMP 
IN THE PRESENCE OF AH-P719
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FIGURE 6 .3
The figure show s data from  a single experim ent. The phosphodiesterase  
inhibitor A H -P 7 1 9  had been added to PRP 4  minutes before tim e 0  on the  
graph, fo llow ed by 0 .1  m M  adenosine 2 m inutes before tim e 0 . Adenosine  
deam inase 1 .2 U /m l (or saline in control tubes) w as added at tim e 0 , and 
platelet cyclic A M P  levels w ere  measured at the intervals show n.
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2.2 Investigation of Phosphodiesterase Activity in Platelets in the Presence 
of AH-P719.
As reduction in cyclic AMP levels following interaction of a ligand with a 
receptor linked to adenylate cyclase is often not purely dependent on 
phosphodiesterase activity, but also on activation of Gj,202 it was necessary to 
design an experiment in which platelet adenylate cyclase could be activated, in the 
presence of AH-P719, by a ligand which could subsequently be easily removed. 
Any reduction in cyclic AMP levels with time could only result from metabolism 
of cyclic AMP. Adenosine is known to raise cyclic AMP levels in platelets by 
stimulating adenylate cyclase,184 and can also be removed by the addition of the 
enzyme, adenosine deaminase.444,445 An experiment was therefore set up as 
follows: 440ul aliquots of 3H-adenine labelled PRP were incubated at 37°C with 
20ul of AH-P719 (100uM) for 2 minutes. 20ul of a solution of adenosine (0.1 mM) 
was then added to each tube and incubation continued for a further 2 minutes, at 
which time either 20ul adenosine deaminase (1.2u/ml) or 20ul of saline was 
added. The reaction was then "stopped" by the addition of 2ml 15% 
trichloroacetic acid, at time points varying between 15 seconds and 8 minutes 
following the addition of the adenosine deaminase (ADA). The assay of cyclic 
AMP was then completed by column chromatography as described previously. A 
graph was then drawn of % conversion 3H-adenine to 3H-cyclic AMP against time 
for ADA treated and control platelets. Results of a pilot experiment is shown in 
Figure 6.3. It is clear that ongoing metabolism of cyclic AMP was taking place in 
the presence of AH-P719, and it was therefore necessary to repeat the above 
experiment in a series of healthy third trimester pregnant women with non 
pregnant women as controls. 10 non pregnant women and 11 healthy 
primigravidae donated blood for such studies. Criteria for subject selection
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CYCLIC AMP LEVELS ON STIMULATION WITH 
VARYING CONCENTRATIONS OF PGE2
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FIGURE 6 .4 .
The figure show s data from  a single experim ent. The concentration-response  
relationship for the e ffec t on platelet cyclic A M P  levels o f PGE2 ( □ )  is show n. 
The experim ent w as also carried out in the presence of A H -P 7 1 9  ( ♦ ) .
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previously set out in detail were strictly adhered to.
Graphs were constructed for each subject of % conversion 3H-adenine to 
3H-cyclic AMP against time. As can be seen in Fig 6.3 cyclic AMP levels were 
fairly constant in control tubes, but in tubes where adenosine was removed, there 
was an initial rapid reduction in cyclic AMP levels, which then fell more slowly 
after 1 minute, reaching a plateau by 3 minutes. The slope of the initial rapid 
reduction in cyclic AMP was calculated for each subject by linear regression 
analysis using a computer program devised by Dr A Kelman, University of 
Glasgow. The slopes were then compared for pregnant and non pregnant subjects, 
using a Mann Whitney-U test. Cyclic AMP accumulation in control tubes, to which 
saline was added in place of ADA, was compared for each subject group using the 
Mann Whitney~U test. This gave an indication of the "steady state" response to 
adenosine in the presence of the PDE inhibitor.
2.3 investigation of the Effect Upon Stimulated Platelet Cyclic AMP Levels 
of PGE2.
It was necessary to define a concentration of PGE2 which could 
reproducibly activate Gt, whilst itself having a minimal effect on G,. An experiment 
was conducted in which platelet cyclic AMP levels in response to a range of 
concentrations of PGE2 were measured, by the method previously described, using 
blood from a healthy non pregnant female volunteer. PRP was pre-incubated for 
2 minutes at 37°C, before adding PGE2 and incubation was continued for 6 
minutes thereafter. A dose response curve was constructed, as shown in Figure 
6.4. Cyclic AMP levels remained similar to basal levels, until the concentration of 
PGE2 was raised above 10*5M when a significant rise was noted. At 
concentrations above 10‘7M, however, PGE2 synergised with the PDE inhibitor AH- 
P719. The concentration response curve in the presence of AH-P719 100//M is
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also shown in Figure 6.4. Experiments were then carried out in PRP from healthy 
non pregnant female donors to examine the effect on iloprost stimulated cyclic 
AMP of 10'8M, 10'7M, and 10 ®M PGE2, as at these concentrations, PGE2 had no 
appreciable effect itself upon platelet cyclic AMP. The concentration of iloprost 
was fixed at 5ng/ml, and PRP was exposed to iloprost for 2 minutes at 37°C 
before adding PGE2. Saline only was added to PRP for measurement of basal cyclic 
AMP levels, and controls for each assay consisted of tubes to which PGE2 alone 
was added to PRP, and those to which iloprost alone was added. The final volume 
in each tube was constant at 500ul. The total incubation time was again 8 
minutes, when the reaction was stopped with 15% TCA. Table 6.1 shows the 
results of these pilot experiments. It was apparent that 10'8M PGE2 caused very 
little reduction in iloprost stimulated cyclic AMP, whilst with 10‘7M PGE2 caused 
a substantial decrease. The latter concentration was therefore chosen as 
appropriate for use for further investigation of PGE2 mediated activation of G(.
Healthy non pregnant women who were not on an oral contraceptive and 
healthy third trimester pregnant women were recruited as described previously. 
Blood from 12 pregnant and 12 non pregnant subjects was used to study the 
effects on cyclic AMP of PGE2 in the absence of a phosphodiesterase inhibitor and 
a further 18 primigravidae and 18 non pregnant women donated blood for the 
investigation of the effect of PGE2 in the presence of AH-P719. On the day of 
study, blood pressure was measured for each subject, and blood was withdrawn 
for platelet studies and for measurement of full blood count.
Citrated PRP was prepared and the platelet count adjusted to 250 x 109/l. 
After incubation with 3H-adenine, PRP was incubated in aliquots with PGE2 alone, 
iloprost alone or with both prostaglandins, in the presence or absence of AH-P719. 
Measurements of basal platelet cyclic AMP were also made in each experiment.
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TIME COURSE OF PLATELET CAMP ACCUMULATION
IN RESPONSE TO PGE*
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FIGURE 6.5
The graph show s the tim e course of the platelet cyclic A M P  response to 30/yM  
PGE, in a group of 11 non pregnant (O ) and 9 third trim ester pregnant ( ♦ )  
subjects. M ean and S .E .M . for the group is show n for each tim e point. 
A N O V A  revealed a highly significant d ifference betw een  the tw o  subject 
groups (p =  0 .0 0 1 3 ) .  Unpaired t tests revealed a significant reduction in 
cA M P  in pregnant subjects at 7 seconds (p =  0 .0 3 7 )  and at 3 0  seconds (p 
=  0 .0 4 6 ) .
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PLATELET CYCLIC AMP RESPONSE TO ADENOSINE
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FIGURE 6 .6
M ean and S .E .M . platelet cyclic A M P  levels in response to 0 .1  m M  adenosine 
and 100/yM  A H -P 7 1 9  are show n. Data are from  a group o f 11 non pregnant 
w om en and a group of 10  third trim ester prim igravidae. The cyclic A M P  
m easurem ents illustrated w ere  made follow ing incubation of PRP for 2 
m inutes w ith  the PDE inhibitor, fo llow ed by incubation for a further 2 minutes 
15 seconds w ith  adenosine. No adenosine deam inase w as added to the PRP 
in w hich these m easurem ents w ere m ade. S ignificantly less cyclic A M P  was  
generated in PRP from  pregnant w om en under these conditions  
(p =  0 .0 0 7 4 , M ann-W hitney  U test).
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An example of the protocol is shown in Appendix 5. The cyclic AMP assay was 
completed by column chromatography on platelet extracts as previously described. 
The Mann-Whitney U test was used for the comparison of cyclic AMP levels in the 
two subject groups in response to each agent.
3.RESULTS.
3.1 Time Course of Platelet Cyclic AMP Response to PGEV
Figure 6.5 illustrates the time course of platelet cyclic AMP responses to 
PGE1 in pregnant and non pregnant women. It was apparent that cyclic AMP levels 
were lower in pregnant subjects, particularly at early time points. Analysis of 
variance revealed a highly significant difference between the two groups of 
subjects (p=0.0013) and between time points (p=0.0001). Individual 
comparisons showed that platelets from pregnant women generated significantly 
less cyclic AMP at 7 seconds (p = 0.037) and 30 seconds (p = 0.046) and the 
difference just failed to reach significance at 15 seconds (p=0.069). Analysis of 
the gradients of the downward slopes following the peak cyclic AMP response 
revealed no difference between groups of subjects. The means (and standard 
errors) of the gradients of the downward slopes following the peak cyclic AMP 
responses were -14.02 (±  3.86) for non pregnant subjects and -13.75 (±2.80) 
for pregnant subjects (p = 0.9045).
3.2 Platelet Cyclic AMP Response to Adenosine.
The baseline cyclic AMP response to adenosine was significantly lower in 
pregnant compared with non pregnant women. The data are illustrated in Figure 
6 .6.
3.3 Rate of Metabolism of Cyclic AMP in the Presence of AH-P719.
The rate of metabolism of cyclic AMP in platelets, following removal of
254
METABOLISM OF CYCLIC AMP:
COMPARISON OF PREGNANT AND NON PREGNANT SUBJECTS
 J___________ I
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FIGURE 6 .7 .
The graph show s mean and S .E .M . of cyclic A M P  levels plotted against tim e  
in PRP from  11 non pregnant ( 0 )  and 10  healthy pregnant w om en ( ♦  ). PRP 
had been incubated w ith  A H -P 7 1 9  for 4  m inutes and w ith  adenosine (0 .1  m M )
before tim e 0  on the graph. A t tim e 0  adenosine deam inase (__ ) or saline as a
control (...) w as added, and cyclic A M P  m easured at the intervals illustrated  
thereafter. Analysis o f the dow nw ard  slopes of the curves yielded values of 
- 3 .8 6  _±_ 0 .1 8 5  in the pregnant group and -5 .0 2 3  +  0 . 3 2 1  jn the non pregnant 
group. The M ann-W hitney  U test revealed th a t the decrease in the rate of 
m etabolism  of cyclic A M P  in pregnant subjects w as significant (p =  0 .0 0 5 7 ) .
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FIGURE 6 .8 .
The figure shows basal levels of cyclic A M P  and those in the presence of 
10 7M  PGE2 in 12  pregnant and 12 non pregnant w om en . M eans and S .E .M .s  
are illustrated. There w as no difference in results betw een  subject groups.
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CYCLIC AMP RESPONSE TO ILOPROST AND PGE2
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FIGURE 6 .9
The figure show s mean _+ S .E .M . cyclic A M P  levels in 12  third trim ester 
pregnant and 12 non pregnant subjects in the presence of iloprost 5ng/m l 
alone and in the presence of both iloprost 5ng/m l and PGE2 1 0 '7M . There w as  
a strong trend tow ards reduced cyclic A M P  levels in pregnant subjects in the  
presence of iloprost alone, w hich just failed to reach statistical significance (p 
=  0 .0 7 2 7 ) .  In both groups of subjects, PGE2 decreased the cyclic A M P  
response to  iloprost, and under these conditions, cyclic A M P  levels w ere  
significantly low er in pregnant com pared w ith  non pregnant w om en (*  p =
0 .0 2 0 6 ) .
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adenosine with ADA, in the presence of AH-P719, is shown for both groups of 
subjects in Figure 6.7. The gradient of the downward slope of the graph obtained 
when platelet cyclic AMP was plotted against time was significantly lower in 
pregnant compared with non pregnant subjects.
3.4 Effect on Platelet Cyclic AMP of PGE3.
Basal levels of cyclic AMP were similar in platelets from non pregnant and 
pregnant subjects. 10 '7M PGE2 alone produced a very small increase in platelet 
cyclic AMP levels but, again, there was no difference between subject groups. The 
data are shown in Figure 6 .8 . Iloprost (5ng/ml) substantially raised platelet cyclic 
AMP levels and there was a strong trend towards a reduced cyclic AMP response 
in platelets from pregnant subjects, which just failed to reach statistical 
significance (Figure 6.9). The addition of PGE2 (10‘7M) significantly reduced the 
platelet cyclic AMP response to 5ng/ml iloprost and under these conditions, cyclic 
AMP levels were significantly lower in platelets from pregnant compared with non 
pregnant women (Figure 6.9). The extent of reduction, however, was similar in 
both subject groups.
There was no difference in platelet cyclic AMP levels between pregnant and 
non pregnant women when the phosphodiesterase inhibitor AH-P719 was present 
alone. When PGE2 (10'7M) was present together with AH-P719, platelet cyclic 
AMP levels were higher than when AH-P719 alone was added, but results were 
again similar in both groups of subjects (Figure 6.10). Platelet cyclic AMP levels 
were significantly reduced in pregnant compared with non pregnant women in 
response to the combination of 50ng/ml iloprost and AH-P719, but there was no 
difference between subject groups when platelets were exposed to 5ng/ml iloprost 
together with the phosphodiesterase inhibitor (Figure 6.11). The addition of 10*7M 
PGE2 reduced the cyclic AMP response to both 5 and 50ng/ml iloprost in both
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FIGURE 6 .1 0
The bar graph show s cyclic A M P  levels in the presence of 100/yM  A H -P 7 1 9  
alone and together w ith  10  7M PGE2. M eans _+_ S .E .M .s  o f 18 observations in 
each group are show n in each case. There w as no d ifference betw een  
pregnant and non pregnant w om en in cyclic A M P  levels under these  
conditions (p =  0 .2 1 5 0  for A H -P 7 1 9  data, and 0 .1 1 3 0  for A H -P 7 1 9  +  PGE2)
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CYCLIC AMP LEVELS IN THE PRESENCE OF
ILOPROST, AH-P719, AND PGE2
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FIGURE 6 .1 1
The bar graph show s platelet cyclic A M P  levels in the presence of 10 0 //M  AH- 
P 7 1 9 , together w ith  iloprost and com binations of iloprost and PGE2 1 0 '7M . 
M eans and S .E .M .s  of 18 observations are show n in each case. Platelets from  
pregnant w om en accum ulated significantly less cyclic A M P  in the presence of 
50n g /m l iloprost ( *  p =  0 .0 3 1 2 ) .  PGE2 again reduced the cyclic A M P  
response to iloprost in both groups of subjects, and p latelet cyclic A M P  levels 
rem ained significantly low er in the pregnant group in response to the  
com bination of iloprost 50ng /m l and PGE2 (*  p =  0 .0 0 8 5 ) .
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FIGURE 6 .1 2
The graph show s the % reduction in cyclic A M P  levels in response to iloprost 
50n g /m l, in the presence of the phosphodiesterase inhibitor, resulting from  the  
addition of PGE2 1 0 '7M to the incubation m ixture. These data w ere  derived  
from  the data illustrated in Figure 6 .1 1 . M eans and S .E .M .s  of 18  
observations are again show n for each subject group. It is clear th a t there was  
no difference betw een  pregnant and non pregnant subjects in the exten t of 
the PGE2 e ffec t (p =  0 .4 8 3 9 ) .
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groups, and platelet cyclic AMP levels were significantly lower in pregnant 
compared with non pregnant women in the presence of the combination of 
50ng/ml iloprost, 100uM AH-P719, and 10*7M PGE2. There was, however no 
difference between the two groups of subjects in the percentage reduction in 
cyclic AMP induced by PGE2 (Figure 6.12).
4.DISCUSSI0N
Studies of the time course of platelet cyclic AMP responses to PGE1 
showed that a peak and plateau type response, as described by previous 
investigators,202 was observed in both pregnant and non pregnant women. 
Platelets from pregnant women produced less cyclic AMP in response to this 
prostaglandin at very early time points following exposure. After the response had 
reached a peak, however, the difference between pregnant and non pregnant 
subjects was less marked and there was no difference in the rate of fall off of 
cyclic AMP levels from peak. These data support a reduction in adenylate cyclase 
activity rather than an increase in phosphodiesterase activity during pregnancy and 
suggest that changes in PGE1 induced stimulation of G{ do not occur in pregnant 
women.
Time course studies following removal of adenosine, in the presence of the 
phosphodiesterase inhibitor AH-P719, showed that AH-P719 permits ongoing 
metabolism of cyclic AMP. In platelets from pregnant women cyclic AMP was 
metabolised at a slower rate under these conditions than in non pregnant women. 
Increased metabolism of cyclic AMP could not, therefore, account for the 
reduction in cyclic AMP accumulation in platelets from pregnant subjects under the 
conditions of the experiments described in preceding chapters. These data would 
again support the hypothesis that a change in the ability of the platelet adenylate
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cyclase enzyme to respond to stimulation occurs during healthy pregnancy. 
Furthermore, this study has shown that this holds true when adenylate cyclase is 
stimulated with adenosine, which acts through a receptor distinct from any of the 
prostaglandin receptors, probably an A2 adenosine receptor.184-446
When the effects on platelet cyclic AMP of low levels of PGE2 were 
investigated, this prostaglandin had only a small effect upon platelet cyclic AMP, 
but produced a substantial reduction in cyclic AMP levels when already raised by 
another adenylate cyclase stimulator. This effect occurred in both non pregnant 
and pregnant subjects and provided a tool for the investigation of control of 
platelet adenylate cyclase by hormone stimulated G{.89 The results confirmed the 
findings of previous studies reported in Chapters 4 and 5 by showing a reduced 
platelet cyclic AMP response to iloprost during pregnancy, both in the presence 
and absence of PGE2. There was no difference, however, in the extent of the 
reduction in the iloprost response induced by PGE2 in pregnant compared with non 
pregnant women. Consequently, it is unlikely that any change in G* activity occurs 
in platelets during pregnancy. The similarity of basal platelet cyclic AMP levels in 
pregnant and non pregnant subjects tends to rule out a pregnancy related change 
in Gp, subunit activity.441
In conclusion, the results of studies presented in this Chapter lend support 
to the hypothesis that, during pregnancy there is a reduction in activity of the 
catalytic portion of platelet adenylate cyclase enzyme but changes in the 
regulation of adenylate cyclase by G, cannot be ruled out.
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CHAPTER 7.
PLATELET SENSITIVITY TO THE ENDOPEROXIDE ANALOGUE 
U46619 DURING HEALTHY PREGNANCY.
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CHAPTER 7.
PLATELET SENSITIVITY TO THE ENDOPEROXIDE ANALOGUE U46619 
DURING HEALTHY PREGNANCY.
1. INTRODUCTION
During healthy pregnancy there is considerable evidence of platelet 
activation in vivo and there are also well documented changes in platelet reactivity 
in vitro. This has been discussed at length in the general introductory chapter but 
it is appropriate here to review some aspects of platelet behaviour in vitro during 
pregnancy. Increased platelet aggregation in PRP or in whole blood has been 
demonstrated by other investigators using arachidonic acid,321,322'327 adp,295,305,320, 
and adrenaline320,327 as agonists. Furthermore, the cross sectional study reported 
in Chapter 3 showed that platelet dense granule release in response to 1 mM AA, 
was slightly but significantly increased in healthy third trimester pregnant women 
compared with non pregnant controls. Platelet responses to all of these agonists 
are at least partially dependent on thromboxane A2 production. This raises the 
question of whether increased platelet thromboxane production occurs during 
pregnancy or whether platelet sensitivity to thromboxane is enhanced. Whilst 
there is sound evidence that platelet derived thromboxane metabolites are present 
in urine in increased amounts during pregnancy,309 data on platelet thromboxane 
production in vitro are conflicting,292,327,329 and measurement of in vivo 
thromboxane production cannot determine whether alterations in the activity of 
the platelet thromboxane pathway are the primary cause of the observed changes 
in platelet behaviour.
Both cross-sectional and longitudinal data on serum thromboxane B2
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presented in preceding chapters suggest that platelet thromboxane production in 
vitro, at least under conditions of spontaneous clotting of whole blood, does not 
change during healthy pregnancy. These results were generated in pregnant 
subjects who simultaneously demonstrated increased arachidonic acid induced 
platelet behaviour, and amongst whom the majority were non responders to the 
thromboxane synthetase inhibitor dazmegrel. In studies outwith the context of 
pregnancy it has been shown that platelets from subjects who are non responders 
to thromboxane synthetase inhibitors show increased sensitivity to the pro- 
aggregatory effects of PGE2 and of the endoperoxide analogue U46619,253,254 
which acts at the same receptor as thromboxane.447
When all of these observations are taken together, the hypothesis could be 
put forward that platelets from pregnant women may be more sensitive to 
thromboxane. As thromboxane A2 is extremely unstable,35 in practice this 
hypothesis must be tested using the endoperoxide analogue U46619 as an agonist 
to induce platelet activation.
2.METHODS.
2.1 Study Design.
The studies conducted were of cross sectional design comparing healthy third 
trimester primigravidae with healthy non pregnant women who were not on an 
oral contraceptive. The criteria for subject selection were as outlined in Chapter
2. No subject had ingested any drug within two weeks of donating blood except 
iron and vitamin supplements. Four separate studies were conducted as follows 
and subjects were distinct for each : 1) platelet aggregation in response to 
U46619 in PRP was studied and the effect of the thromboxane receptor 
antagonist ICI 192605448*450 in vitro was tested 2) U46619 induced platelet
266
aggregation in whole blood was investigated in the absence and presence of ICI 
192605; 3) U46619 induced platelet aggregation in whole blood treated with 
aspirin was investigated; 4) platelet thromboxane production in PRP stimulated 
with arachidonic acid was measured.
On the day of study subjects were placed in the supine position, and after 
5 minutes rest blood pressure was measured and venepuncture performed as 
described in Chapter 2. Blood was taken into 3.13% trisodium citrate dihydrate 
(9 parts blood to 1 part anticoagulant) for platelet studies, and into EDTA for 
measurement of the full blood count.
2.2 Laboratory Methods.
Platelet aggregation studies in PRP were conducted by preparing PRP with 
an adjusted platelet count of 250 x 109/l as described previously. Platelet 
aggregation was then induced in a PAP-4 Biodata four channel aggregometer using 
the method of Born as detailed in Chapter 2. Experimental tubes containing 180ul 
of PRP and 20iA of saline or the thromboxane antagonist ICI 192605 (final 
concentration 10'8M or 10'7M) were placed in the aggregometer wells and stirred 
and incubated for 2 minutes before inducing platelet aggregation with 20//I 
U46619 (0.1uM-200uM). Aggregation was allowed to proceed for 6 minutes, at 
which time percentage aggregation was noted. Graphs of concentration of 
U46619 against % aggregation were then constructed and the EC50 of the agonist 
calculated.
Platelet aggregation in whole blood was measured by the counting method 
described in Chapter 2, following incubation of citrated blood at 37°C for 30 
minutes. For whole blood experiments, aliquots of 460//I of whole blood were 
added to polystyrene tubes containing a metal stir bar and 20//I of saline or ICI 
192605 (final concentration 10*7M or 10 eM) and incubated at 37°C whilst stirring
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for 2 minutes. 20//I U46619 (final concentration 0.3//M or 3//M) or saline was then 
added and aggregation allowed to proceed for 8 minutes. 15//I subsamples of 
blood for subsequent platelet counting were taken from each tube and placed in 
30//I of fixative at 0,0.25, 0.5, 0.75, 1, 2, 4, and 8 minutes after addition of the 
agonist.
In those studies in whole blood in which the effect of aspirin was 
investigated, duplicate samples of citrated whole blood containing 0.56mM aspirin 
or saline as a control, were incubated at 37°C for 30 minutes. Platelet aggregation 
in response to 1 mM arachidonic acid was shown to be completely abolished by 
treating with aspirin in this way. Triplicate 480ul aliquots of aspirin treated and of 
control blood were then pre-incubated and stirred in the water bath for 2 minutes, 
when 20ul U46619 (0.3//M or 3//M) or saline was added to each tube and 
aggregation allowed to proceed for 8 minutes. 15ul subsamples of blood were 
removed and placed in fixative at the times detailed above and used for later 
platelet counting.
For all experiments in whole blood, percentage aggregation was calculated 
as detailed in Chapter 2, and graphs of percentage aggregation against time were 
constructed.
Platelet thromboxane production in response to 1mM AA was measured by 
pre-incubating 500ul adjusted PRP in siliconised glass tubes in the aggregometer 
wells for 2 minutes whilst stirring at 1,000rpm. Aggregation was then induced 
with 50ul 1 mM AA and the reaction allowed to proceed for 4 minutes at which 
time 200ul of PRP was removed and immediately placed in a plastic Eppendorf 
tube containing 200ul ice cold absolute alcohol. The tubes were then thoroughly 
vortex mixed and immediately placed at -70°C. Radioimmunoassay for 
thromboxane B2 was then performed within 3 months as described in Chapter 2.
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U46619 INDUCED PLATELET AGGREGATION IN PRP
1 0 ( h
C
o•H
-M
CD
CJ)
CD
C_
CJ)
CJ)
CD
NON PREGNANT40-
20-
""T------------ '------------- 1 —------ »------------- 1
-7  -6  -5
lo g 10 [U46619]M
FIGURE 7 .1 .
The figure show s data from  10  non pregnant and 10  healthy third trim ester 
pregnant w om en . The concentration response curves for U 4 6 6 1 9  induced 
aggregation in PRP are illustrated. M eans and S .E .M s  for each group of 
subjects are illustrated. The curve is shifted to the left in pregnant com pared  
w ith  non pregnant subjects.
269
CJ)i
CD
CD
C_J
C
o
CJ
EC50 OF U46619 
FOR PLATELET AGGREGATION IN  PRP
NON PREGNANT PREGNANT
FIGURE 7 .2
The bar graph illustrates means +  S .E .M .s  of EC50 values for U 4 6 6 1 9 induced 
platelet aggregation in PRP. The data w ere derived from  those illustrated in 
Figure 7 .1 . There w as a significant reduction in EC50 for U 4 6 6 1 9  in pregnant 
subjects (*  p =  0 .0 5 ) .
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2.3 Data Analysis.
For the experiments in PRP, EC50 values for U46619 induced aggregation
were compared in pregnant and non pregnant subjects using a Mann Whitney-U
test. The dissociation constant (K,,) values for the thromboxane antagonist ICI
192605 were estimated for each subject using the equation:
Kj = Concentration of antagonist
[EC50U46619(2)/EC50U46619(1 )]-1
where EC50(1) was in the absence of the antagonist and ECS0(2) was in the
presence of the antagonist.
Kd values for pregnant and non pregnant subjects were then compared using the 
Mann Whitney-U test. Statistical significance was defined as p<0.05. For all 
experiments in whole blood, percentage aggregation for each time point was 
compared using the Mann Whitney-U test and statistical significance was defined 
as p < 0.01 as repeated tests were performed on data from the same subjects. 
Thromboxane B2 radioimmunoassay data were analyzed using the Mann-Whitney 
U test.
3 .RESULTS.
3.1 Platelet Aggregation in Response to U46619 in PRP.
In the absence of the thromboxane antagonist, EC50 values for U46619 for platelet 
aggregation in PRP were significantly lower in pregnant than in non pregnant 
women. Figure 7.1 illustrates the concentration response curves for U46619 
induced aggregation in PRP, and Figure 7.2 illustrates the EC50 values for U46619. 
In the presence of 10'8M ICI 192605, there was a small and highly variable shift 
in the U46619 dose response curve, and there was no statistically significant 
difference in the EC50 values for U46619 for pregnant (0.97.±0.34//M) and non
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U46619 INDUCED PLATELET AGGREGATION IN PRP 
IN THE PRESENCE OF IC I192605 10“ 7M
60-CZ
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■56 4
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F I G U R E  7.3.
The figure illustrates the concentration response curve for U 4 6 6 1 9  induced 
platelet aggregation in PRP in the presence of the throm boxane antagonist ICI 
1 9 2 6 0 5  (1 0 ‘7M ). M eans and S .E .M .s  of 10  observations are show n for each  
data point. The concentration-response curve w as again shifted to  the left for 
the  pregnant subjects.
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EC50 for U46619 IN PRESENCE OF
ICI 192605 10-7M
CO
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FIGURE 7 .4 .
The bar graph show s means and S .E .M .s  o f ECso values for U 4 6 6 1 9  induced 
platelet aggregation in PRP. The data are derived from  those illustrated in 
Figure 7 .3 . There w as a significant reduction in the E C ^  for U 4 6 6 1 9  in 
pregnant subjects (*  p = 0 .0 1 ) .
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pregnant subjects (1.68jf 0.42//M). When the thromboxane antagonist was 
present at a concentration of 10'7M, there was an approximate 10 fold shift to the 
right in the U46619 dose response curve, and there was again a significant 
reduction in EC50 values in pregnant compared with non pregnant subjects. The 
data are illustrated in Figures 7.3 and 7.4. In the presence of ICI 192605, the 
extent of platelet aggregation in response to high concentrations of U46619 
appeared to decrease. The effect was less marked in pregnant subjects. Estimation 
of the Kd values for ICI 192605 for each subject showed a mean value of 
10.19jt.2.78nM for non pregnant subjects and 13.85j±2.54nM for pregnant 
subjects (p = 0.15).
3.2 Platelet Aggregation in Whole Blood in Response to 1)46619
In the presence of saline alone, a degree of "spontaneous" platelet 
aggregation was noted in both pregnant and non pregnant subjects. This was 
maximal at 8 minutes in both subject groups, and whilst there was a tendency for 
spontaneous aggregation to be more marked in pregnant subjects, this did not 
reach statistical significance. The data are shown in Figure 7.5.
When platelet aggregation was induced with 0.3uM U46619, the pattern 
of response in pregnant subjects differed from that in the non pregnant group. In 
the majority of non pregnant women, rapid but submaximal platelet aggregation 
took place which was partially reversible by 1 minute, and this was followed by 
a slow increase in aggregation from 2 to 8 minutes. By contrast, in pregnant 
women, the general pattern of response was rapid maximal aggregation which 
was sustained thereafter. The data are shown on Figure 7.6. The increase in 
platelet aggregation in response to 0.3uM U46619 in the pregnant group was 
statistically significant at all time points except 8 minutes.
When 3uM U46619 was used as the agonist, a maximal platelet
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SPONTANEOUS AGGREGATION
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FIGURE 7 .5 .
The figure show s the exten t o f "spontaneous" platelet aggregation in w hole  
blood plotted against tim e. Each data point represents m ean _+ S .E .M . o f 14  
observations for the non pregnant group ( • ) ,  and 15 observations for the  
pregnant group ( a ) .  There w as a slight trend to w ard s  increased spontaneous  
aggregation in pregnant subjects but this w as not statistically significant.
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AGGREGATION INDUCED BY 0.3jiM U46619
100 -
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FIG URE 7 .6 .
The figure shows % platelet aggregation in whole blood plotted against time 
for pregnant ( a )  and non pregnant ( • )  subjects using 0.3/yM U 4 6619  as the 
agonist. Means and standard errors of data from 15 pregnant and 14 non 
pregnant subjects are shown. There was a significant increase in platelet 
aggregation in response to 0 .3u M  U 4 6619  in the pregnant group at all time 
points except at 8 minutes when the effects of " spontaneous " platelet 
aggregation enhanced the response to U 4 6 6 1 9 in the non pregnant group. (8 
minute time point not shown).
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AGGREGATION INDUCED BY 3jiM U46619
PREGNANT
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FIGURE 7.7.
The figure shows % platelet aggregation in whole blood plotted against time 
in response to 3//M  U 46619. Means _+ S.E.M.s o f data from  14 non pregnant 
( • )  and 15 pregnant ( a ) subjects are shown. Statistical analysis revealed no 
difference between subject groups.
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aggregation response was obtained in all subjects and there was no difference 
between pregnant and non pregnant groups (Figure 7.7). The statistical analysis 
of data relating to U46619 induced platelet aggregation in whole blood is shown 
in Table 7.1.
3.3 Effect of the Thromboxane Antagonist on U46619 Induced Platelet 
Aggregation in Whole Blood.
In the presence of 10'7M ICI 192605, platelet aggregation in response to 
0.3uM U46619 was inhibited in both subject groups, but the extent of 
aggregation was still significantly greater in the pregnant group at all time points 
except 0.25 minutes and 8 minutes. The results are shown in Figure 7.8. 10*7M 
ICI 192605 had only very minor inhibitory effects upon platelet aggregation 
induced by 3uM U46619 in both non pregnant and pregnant subjects and there 
was little difference between groups in this respect as shown in Table 7.2.
In the presence of 10'6M U46619, platelet aggregation in response to 
0.3uM U46619 was reduced to levels similar to "spontaneous" aggregation, and 
there was no difference between subject groups in the extent of aggregation under 
these conditions. The data are shown in Table 7.2. 10*®M ICI 192605 also 
significantly inhibited platelet aggregation induced by 3uM U46619. In non 
pregnant subjects, a pattern similar to "spontaneous" aggregation was obtained 
under these conditions, but in pregnant subjects, aggregation was greater at early 
time points than in the presence of saline alone. In the pregnant group the extent 
of aggregation was significantly greater than in non pregnant women at all time 
points except 0.25 and 8 minutes (Figure 7.9). The statistical analysis relating to 
U46619 induced platelet aggregation in whole blood in the presence of the 
thromboxane antagonist is summarised in Table 7.2.
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AGGREGATION INDUCED BY 0.3/iM U46619: 
EFFECT OF A THROMBOXANE ANTAGONIST
100
8 0 -
C
o
CONTROLr—I
CDcn
CDc_cn
cn
CD
ICI 192605
time (mins)
F I G U R E  7.8.
The graph show s the e ffec t of the throm boxane antagonist ICI 1 9 2 6 0 5  (10* 
7M ) on p latelet aggregation in w hole blood induced by 0 .3 u M  U 4 6 6 1 9. M eans  
and standard errors of data from  15 pregnant ( a )  and 14  non pregnant 
subjects (O ) are show n. Control data in the absence of the throm boxane  
antagonist are illustrated w ith  filled symbols ( a  =  pregnant, •  =  non 
pregnant).
The throm boxane antagonist inhibited U 4 6 6 1 9  induced platelet aggregation  
in both subject groups, but platelet aggregation occurred to a significantly  
greater ex ten t at all tim e points except 0 .2 5  and 8 minutes in pregnant 
subjects in the presence of ICI 1 9 2 6 0 5 .
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AGGREGATION INDUCED BY 3mM U46619: 
EFFECT OF A THROMBOXANE ANTAGONIST
CONTROL100 -
c=
o
r - i
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ICI 192605
) ^ ________I________  I-------------   I------------- .------------- L
0 1 2  3 4
tim e (mins)
FIGURE 7.9.
The effects  o f 1 0 6M ICI 1 9 2 6 0 5  on platelet aggregation in w hole  blood 
induced by 3u M  U 4 6 6 1 9  are show n. M eans and standard errors o f data from  
15 pregnant ( a )  and 14  non pregnant (O ) subjects are illustrated. Filled 
sym bols ( a  =  pregnant, •  =  non pregnant) are used for control data in the  
absence of the throm boxane antagonist.
The throm boxane antagonist inhibited platelet aggregation in both subject 
groups. A lthough there w as no difference betw een  groups in the exten t of 
platelet aggregation in response to 3u M  U 4 6 6 1 9 in control tubes, aggregation  
occurred to a significantly greater exten t in blood from  pregnant subjects at 
all tim e points except 0 .2 5  and 8 minutes in the presence of the throm boxane  
antagonist.
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SPONTANEOUS PLATELET AGGREGATION 
IN THE PRESENCE OF ASPIRIN
dO
•rl
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time (mins)
FIGURE 7.10.
The figure show s the extent o f "spontaneous" platelet aggregation in w hole  
blood pre-incubated w ith  aspirin (0 .5 6 m M ). M ean s_±_S .E .M .so f data from  11 
pregnant and 10  non pregnant subjects are illustrated. A lthough there w as a 
slight trend in aspirin treated platelets to increased spontaneous platelet 
aggregation in pregnant subjects, this only reached statistical significance at 
one tim e point (1 m inute). For clarity spontaneous aggregation in control blood 
is not illustrated here.
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3.4 Platelet Aggregation in Whole Blood in the Presence of Aspirin.
Aspirin slightly inhibited "spontaneous” platelet aggregation in both groups 
of subjects. "Spontaneous” aggregation was slightly but significantly greater in 
pregnant compared with non pregnant subjects, at the 45 second, 1 minute, and 
2 minute time points in control blood, but the increase only reached significance 
at 1 minute in aspirin treated blood (Figure 7.10).
Aspirin did not inhibit, and in fact, rather surprisingly, in non pregnant 
subjects, significantly enhanced platelet aggregation induced by 0.3uM U46619. 
A significant increase in platelet aggregation in response to 0.3uM U46619 was 
present in control and aspirin treated blood from pregnant compared with non 
pregnant subjects at all time points except 8 minutes. The results are shown in 
Figure 7.11 and the statistics are documented in Table 7.3.
3.5 Platelet Thromboxane Production in Platelet Rich Plasma Stimulated 
with Arachidonic Acid.
Platelet thromboxane B2 production in PRP stimulated with 1 mM AA is 
shown in Figure 7.12. There was no statistically significant difference between 
pregnant and non pregnant subjects.
DISCUSSION.
These studies have shown that platelet aggregation in response to the 
endoperoxide analogue U46619, which acts at the thromboxane receptor,40,447 is 
enhanced in healthy pregnant women. The effect appeared more marked in whole 
blood than in PRP but was statistically significant under both conditions. It is 
possible that the loss of some active platelets during the preparation of PRP made 
the effect more obvious in whole blood but differing experimental design in the 
two studies may also have contributed. The choice of a concentration of U46619
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AGGREGATION INDUCED BY 0.3/iM U46619: 
EFFECT OF ASPIRIN
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FIGURE 7 .1 1 .
The e ffe c t o f aspirin on platelet aggregation in w hole blood in response to  
0 .3 u M  U 4 6 6 1 9  is show n. M eans and standard errors of data from  11 
pregnant and 10  non pregnant subjects are illustrated. Control data are 
indicated by filled symbols ( a , •  ) and data in the presence of aspirin by open  
sym bols ( a ,  O ).
Aspirin did not inhibit, and in fact, in non pregnant subjects, significantly  
enhanced U 4 6 6 1 9  induced platelet aggregation (p <  0 .0 1  at all tim e points, 
W ilcoxon m atched pairs test). A significant increase in platelet aggregation in 
response to 0 .3 u M  U 4 6 6 1 9  w as present in control and aspirin treated blood 
from  pregnant subjects at all tim e points except 8 m inutes. (8 m inute data not 
show n.
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The bar graph show s mean and S .E .M . o f throm boxane B2 production in PRP 
stim ulated w ith  1 m M  A A  in 13 healthy third trim ester pregnant and 13 non 
pregnant subjects. Statistical analysis revealed no d ifference betw een  subject 
groups.
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near to the EC50 in whole blood experiments would tend to bring out the 
differences between the two subject groups.
The enhanced aggregation response to U46619 in pregnant women is 
unlikely to be due to non specific effects such as changes in haematocrit and 
plasma fibrinogen, as there were only minimal differences in spontaneous platelet 
aggregation in whole blood in pregnant compared with non pregnant subjects, and 
these differences were reduced when thromboxane synthesis was inhibited by 
aspirin.
In both PRP and in whole blood, an enhanced platelet response to U46619 
was still detectable in the presence of ICI 192605, an antagonist at the 
thromboxane receptor.448*450 Differences in EC50 values for U46619 in pregnant 
and non pregnant subjects in the presence of ICI 192605 in PRP cannot be 
explained by differing receptor affinity of the antagonist as the estimated values 
for ICI 192605 were similar for both subject groups. Furthermore, the specificity 
of the effects of U46619 in pregnancy are supported by the abolition of 
differences between subject groups in the presence of an excess of the 
thromboxane antagonist relative to U46619 in whole blood. The reason is unclear 
for the unusual shape of the concentration response curve for U46619 in PRP in 
the presence of the thromboxane antagonist. A non competitive component to the 
antagonism by ICI 192605 should be considered but the shape of the curve was 
not typical of such an effect, and previous studies have suggested that this agent 
is a competitive antagonist at the thromboxane/endoperoxide receptor.448'449 It is 
possible that thromboxane receptor blockade unmasked an inhibitory effect of very 
high concentrations of U46619, possibly mediated by binding of the endoperoxide 
analogue to another prostaglandin receptor. It is interesting in this respect that 
the decrease in aggregation in response to high concentrations of U46619 when
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the antagonist was present, was less marked in pregnant subjects.
In whole blood treated with aspirin, at concentrations shown to abolish 
aggregation dependent upon platelet thromboxane synthesis, platelet sensitivity 
to U46619 remained enhanced in pregnant women. Endogenous thromboxane A2 
production does not therefore contribute to the enhanced platelet response to 
U46619 during pregnancy. In addition, no enhancement of platelet thromboxane 
synthesis in PRP in response to arachidonic acid was detectable in pregnant 
subjects, thus casting doubt upon the importance of the amount of thromboxane 
synthesised as a determinant of increased platelet sensitivity to weak agonists and 
to arachidonic acid in vitro during pregnancy.
It is of interest that platelets in aspirin treated blood from non pregnant 
subjects were more sensitive to U46619 than control platelets. It is possible that 
production of inhibitory prostanoids from white cells in whole blood440 was 
inhibited by aspirin, resulting in an increased platelet response to U46619. This 
must, however, remain speculative, as experiments were not carried out in aspirin 
treated PRP, nor was prostaglandin production measured. The corollary is that 
enhanced platelet responses to 0.3uM U46619 in whole blood during pregnancy 
cannot result from reduced responses to inhibitory prostanoids synthesised by 
white cells and platelets.
These data taken together suggest that platelets from pregnant women 
either possess greater numbers of thromboxane/endoperoxide receptors than those 
from non pregnant women, or that occupancy of fewer thromboxane receptors is 
required to elicit aggregation as a result of tighter stimulus response coupling. 
Consequently, enhanced platelet sensitivity to thromboxane A2 may make a major 
contribution towards increased platelet reactivity during pregnancy to agonists 
whose mechanism of action has a thromboxane dependent component. As platelet
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thromboxane B2 production in arachidonic acid stimulated PRP and indeed serum 
thromboxane B2 levels (reported in Chapters 3 and 5) were similar in pregnant and 
non pregnant women, sensitivity to thromboxane during pregnancy is probably a 
more important determinant of platelet reactivity to thromboxane dependent 
agonists in vitro than the extent of thromboxane synthesis. It is also possible that 
enhanced reactivity towards thromboxane contributes to platelet activation in vivo 
during pregnancy. It has been suggested that the pro-aggregatory effects of PGE2 
at low concentrations may be mediated by the endoperoxide receptor.89 If this 
were confirmed, the results of the studies presented here would imply that platelet 
activation in vivo may also be promoted during pregnancy by PGE2 synthesised by 
the placenta.298
There is recent evidence that two distinct thromboxane/endoperoxide 
binding sites exist on human platelets, one of which mediates calcium influx 
across the cell membrane leading to platelet shape change, and the other of which 
is linked to platelet aggregation and secretion via the activation of phospholipase 
£ 85.451 |t has a|so been pr0p0Secj that activation of phospholipase C by 
thromboxane and endoperoxides is mediated by a G protein distinct from Gp,132 the 
putative GTP binding protein involved in linking polyphosphoinositol hydrolysis 
with platelet activation responses to thrombin, PAF and vasopressin.122 Platelet 
shape change and cytosolic calcium were not measured in these studies, so 
changes in this aspect of response to thromboxane during pregnancy cannot be 
ruled out. It is evident, however, that alterations at or beyond the thromboxane 
receptor mediating aggregation and phospholipase C activation do occur in 
platelets from healthy pregnant women, but further studies would be required to 
determine whether this results from increased receptor numbers, changes at G 
protein level or alterations in phospholipase C itself.
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It is interesting to note that both protein kinase C activation85,452,453 and G 
protein mediated effects85,454 have been implicated in the regulation of 
thromboxane induced platelet activation, including the desensitisation of this 
response.85,454 Previous reports have suggested that prior exposure of platelets to 
thromboxane agonists results in a rapid desensitisation phenomenon mediated by 
reduction in receptor numbers455 and uncoupling between the receptor and the G 
protein.85,454 As it is established that thromboxane production is increased in vivo 
during pregnancy,298,309 other mechanisms must come into play which prevent 
desensitisation from taking place and paradoxically permit enhancement of platelet 
responses to thromboxane. Protein kinase C activation could possibly play such 
a role.85,452,453 Oxidation or reduction of sulphydryl/disulphide groups on the 
thromboxane receptor has been shown to cause, respectively, up- and down- 
regulation of the thromboxane/endoperoxide receptor in human platelet 
membranes.458 It has been proposed that exposure of platelets to locally generated 
oxidants may increase platelet thromboxane receptor numbers in patients with 
acute myocardial infarction,85,457 but it would be difficult to envisage that such 
mechanisms could contribute to platelet sensitivity to thromboxane during healthy 
pregnancy.
CHAPTER 8.
GENERAL DISCUSSION.
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CHAPTER 8.
GENERAL DISCUSSION.
This thesis has examined the effect on platelet behaviour in healthy 
pregnancy and in pre-eclampsia of prostaglandins which inhibit and those which 
promote platelet activation and has explored some aspects of intracellular 
signalling which mediate the platelet response to these agents.
The results relating to healthy pregnancy are in themselves of considerable 
interest as an understanding of the pathophysiology of disease can only be 
obtained on the basis of sound physiological data. The studies presented have 
demonstrated significant alterations during normal pregnancy in platelet responses 
in vitro to a variety of prostaglandins which play a role in regulating platelet 
behaviour in vivo. Platelets from healthy pregnant women have been shown to be 
less sensitive to inhibition of their behaviour by iloprost, the stable prostacyclin 
analogue, and by PGD2, compared with those from non pregnant young women. 
This was associated with a reduction in platelet cyclic AMP accumulation in 
response to these agents and other adenylate cyclase stimulators. On the other 
hand, during pregnancy, platelets were more sensitive in vitro to the pro- 
aggregatory effects of the endoperoxide analogue U46619, which acts at the 
thromboxane A2/PGH2 receptor.40,447
Reduced cyclic AMP accumulation in response to inhibitory prostanoids 
occurred very early in the first trimester and was sustained throughout gestation. 
The time course of alterations in sensitivity to pro-aggregatory prostanoids with 
respect to gestation was not investigated in these studies, but other authors have 
described enhanced platelet reactivity to agonists dependent on thromboxane for 
their action from 16 to 24 weeks gestation onwards.322,327
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The possible mechanisms underlying the observations on platelet responses 
to inhibitory prostaglandins merit further discussion. The results of the studies 
presented in this thesis leave little doubt that reduction in platelet cyclic AMP 
accumulation during pregnancy at least contributes to loss of platelet sensitivity 
to prostanoids such as prostacyclin. Indirect evidence has been presented in 
favour of a change occurring during pregnancy in the ability of the platelet 
adenylate cyclase enzyme to respond to stimulation, perhaps residing in alteration 
of the catalyst or its regulatory G proteins. This evidence comes firstly from the 
demonstrated reduction during healthy pregnancy in platelet cyclic AMP responses 
to a wide range of adenylate cyclase stimulators including forskolin (Chapters 4 
and 5), excluding changes in receptors as a likely underlying mechanism. 
Secondly,increased platelet cyclic AMP metabolism in pregnancy has been 
excluded under the experimental conditions used (Chapter 6). Furthermore, 
reduced platelet cyclic AMP responses to PGE, during pregnancy were observed 
at very early time points following exposure of platelets to this agent, suggesting 
an alteration in the generation of cyclic AMP.
Some caution must be exercised in interpreting the data regarding forskolin, 
as this agent has been shown to have a number of pharmacological effects other 
than stimulation of adenylate cyclase, for example it modulates potassium 
channels in some tissues and it inhibits the glucose transporter in many cell types 
including platelets.458 There is no evidence, however, that any of these other 
actions are likely to affect cyclic AMP levels. It therefore seems reasonable, in the 
context of the rest of the data presented here, to conclude that the difference in 
cyclic AMP accumulation in platelets from pregnant women in the presence of 
forskolin is likely to result from a reduction in adenylate cyclase activity. Although 
the action of forskolin on adenylate cyclase does not require the stimulatory G
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protein, the diterpene has been shown to interact in a complex manner with 
adenylate cyclase, and its actions may be modulated by G, and Gj.201,442 
Involvement of G proteins in the pregnancy associated reductions in platelet cyclic 
AMP accumulation cannot therefore be ruled out, although the data presented 
suggest that prostaglandin stimulated Gt activity is not altered. Similarity was 
demonstrated in the extent of reduction in stimulated cyclic AMP levels on 
activation of the inhibitory G protein by PGE2 in platelets from pregnant and non 
pregnant women. Assay of adenylate cyclase activity together with studies of G 
proteins in platelet membranes may clarify the exact nature of the changes in 
platelet adenylate cyclase during pregnancy.
It is interesting to speculate on how changes in adenylate cyclase in 
platelets may be brought about in pregnancy. The synthesis of steroid hormones, 
principally oestrogen and progesterone, rise markedly during pregnancy,459 and 
these may have effects on platelets. Steroid hormones have classically been 
thought to influence cellular function by entering the nucleus and exerting effects 
on protein synthesis.450 As platelets are anucleate, an effect at megakaryocyte 
level would be required to explain any steroid mediated effect on platelet 
behaviour. It is possible to speculate that steroid hormones could for example 
program changes in the synthesis of adenylate cyclase or the stimulatory G protein 
by megakaryocytes. It is interesting to note that gonadal steroids have been 
shown to influence the adenylate cyclase system in a variety of tissues from other 
species. In particular, oestradiol has been shown to reduce cyclic AMP 
accumulation in CNS preparations from experimental animals.451
Another possible mechanism by which pregnancy may bring about changes 
in the platelet cyclic AMP accumulation is by exposure of platelets to vasodilatory 
prostaglandins synthesised by the placenta,150,298'308'310 resulting in heterologous
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desensitisation of adenylate cyclase. Desensitisation of platelet responses to 
inhibitory prostaglandins has been previously reported following both in vitro and 
in vivo exposure. Initial reports of desensitisation of platelet cyclic AMP 
accumulation in response to PGI2 and PGD2 in vitro suggested that this was 
agonist specific.198 As a result of evaluation of infusion of PGI2 as a therapeutic 
agent in conditions such as peripheral vascular disease, it became apparent that 
rebound platelet hyperactivity and desensitisation of platelet responses to PGI2 in 
terms of inhibition of platelet behaviour and cyclic AMP accumulation occurred 
following prolonged exposure to PGI2 in vivo.283'284,482,483 Whilst most investigators 
examined only desensitisation to PGI2 itself, some reported heterologous 
desensitisation with respect to PGD2 following infusion of PGI2 or PGE,, but these 
reports did not include measurement of cyclic AMP.482,464 One study designed to 
investigate the effects of intravenous PGI2 infusion in rabbits showed that platelets 
were also refractory to the antiaggregatory effects of adenosine as well as 
prostaglandins, and it was proposed that impairment of the platelet adenylate 
cyclase regulatory subunit may be the underlying mechanism.485 Since then, a 
large amount of data regarding both homologous and heterologous desensitisation 
of adenylate cyclase in many cell types has accumulated and has been 
reviewed.488 Most studies involve cells other than platelets, although some have 
examined the mechanism of homologous and heterologous desensitisation of 
platelet adenylate cyclase following prolonged in vitro exposure of platelets to 
iloprost.487*489 Homologous desensitisation was associated with reduced 3H-iloprost 
binding to platelets,487,488 but heterologous desensitisation, leading to reduced 
platelet membrane adenylate cyclase activity following stimulation with the 
adenosine analogue 5-N-ethylcarboxyaminoadenosine (NECA) also occurred.489 
Some evidence was presented that this may be due to loss or modification of the
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a subunit of G,.489 This hypothesis is supported by work in other tissues which has 
implicated modification of both G, and Gj in heterologous desensitisation of 
adenylate cyclase, but modification of the catalyst itself has not been entirely 
excluded in these systems.486 Interestingly, a recent publication showed that in the 
S49 lymphoma cell line, a simultaneous increase in G* and decrease in G„ 
expression resulted from prolonged stimulation of adenylate cyclase by either 
forskolin or by agonists at the ^ -adrenergic receptor.470 There is evidence from this 
and other studies that cyclic AMP itself or cyclic AMP dependent protein kinase 
may be implicated in heterologous desensitisation.486,470
Although not classifiable as a desensitisation phenomenon, protein kinase 
C has also been implicated in the modulation of adenylate cyclase activity.471,472 
Some reports suggest that activation of protein kinase C prevents agonist induced 
inhibition of adenylate cyclase in platelet membranes by phosphorylation of G|.471 
A more recent report, however suggests that the predominant effect of activation 
of protein kinase C is inhibition of adenylate cyclase.472
The results of the studies presented in this thesis would be in keeping with 
the development during pregnancy of heterologous desensitisation of platelet 
adenylate cyclase, mediated either by reduction or modification of G, or the 
catalytic subunit of adenylate cyclase itself. Evidence of altered activity of Gj has 
not been found. A protein kinase C mediated reduction in adenylate cyclase 
activity could not be excluded.
Irrespective of the underlying biochemical mechanisms, the changes 
demonstrated in vitro in platelet sensitivity to the inhibitory prostaglandins may 
play a role in contributing to platelet activation in vivo during pregnancy. There is 
a great deal of evidence supporting a degree of in vivo platelet activation in 
healthy pregnancy and it has been open to question why this occurs in the context
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of increased production of prostaglandins which inhibit platelet behaviour.473 This 
can clearly be at least partly explained by the blunting of the platelet cyclic AMP 
response to such prostanoids.
The significance of the very early change in platelet cyclic AMP responses 
to prostaglandins during the gestational period also merits discussion. In other 
species, platelet activation has been shown to play a role in implantation, probably 
via mechanisms involving the secretion of growth factors such as PDGF and 
release of adhesion molecules such as fibronectin.474 Furthermore, 5-HT released 
from platelet dense granules is thought to contribute to the maintenance of the 
corpus luteum in mammalian species such as cattle.474 If similar mechanisms were 
involved in the early establishment of human pregnancy, down>regulation of 
platelet inhibitory mechanisms at this time could help to permit any platelet 
activity involved in the early establishment of pregnancy.
Another important determinant during pregnancy of platelet reactivity both 
in vivo and in vitro, however, may be the enhanced platelet aggregatory response 
to thromboxane and endoperoxides as demonstrated in Chapter 7. Whilst it is well 
established that platelet reactivity in vitro is enhanced particularly in response to 
agents with a thromboxane dependent component in their mechanism of 
action,295,305,320'322,327 results of studies investigating platelet thromboxane 
production in vitro have been inconsistent.292,327,329 The data presented in Chapter 
7 suggest that platelet sensitivity to thromboxane during pregnancy may be a 
more important determinant of platelet responses to thromboxane dependent 
agonists in vitro than platelet thromboxane synthesis. It is possible that enhanced 
sensitivity to pro-aggregatory prostanoids also contributes to platelet activation 
in vivo, and increases in excretion of thromboxane metabolites may be a 
secondary phenomenon. Increased platelet reactivity towards endoperoxides may
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also be an important contributing factor to the predominance of non responder 
status to thromboxane synthetase inhibitors in vitro in pregnant women. 
Furthermore, an interplay between effects of pro-aggregatory and inhibitory 
prostanoids is likely to be important in determining platelet responses both in vitro 
and in vivo. Such an interplay could offer an explanation for the later development 
during the gestational period of loss of efficacy of iloprost and PGD2 as inhibitors 
of arachidonic acid induced dense granule release on the background of the cyclic 
AMP response to these agents being reduced from very early pregnancy.
The mechanisms underlying the enhanced platelet responses to pro- 
aggregatory prostanoids have not been investigated in the studies presented in 
this thesis and therefore must remain entirely speculative. Changes at the level of 
receptor, G protein, or phosphoinositol metabolism are each possible. The recent 
recognition of the likely linkage of the thromboxane/endoperoxide receptor to a 
unique G protein132 and reports that protein kinase C activation modulates 
sensitivity to thromboxane may be of relevance.85 It is of particular note that 
increased platelet reactivity to thromboxane/endoperoxides occurs during 
pregnancy when increased thromboxane production has been demonstrated in 
vivo.309 Under such circumstances, current data on regulation of thromboxane 
mediated events, suggest that desensitisation of platelets to thromboxane would 
be expected.85,454,455 Further investigation of the mechanisms regulating platelet 
responses to pro-aggregatory prostanoids in the context of pregnancy would 
therefore be of interest.
This thesis set out not only to examine the physiological changes in platelet 
responses to prostaglandins during pregnancy, but to explore the pathological 
changes relating to pre-eclampsia. Even without invoking a further intrinsic change 
in platelet behaviour in pre-eclampsia, increased platelet activation in vivo is readily
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explicable by the well established changes in the balance of in vivo biosynthesis 
of pro-aggregatory and inhibitory prostanoids158*1®0,298'310 occurring on the 
background of platelets "primed" by the pregnancy associated changes in platelet 
responses to these prostaglandins which have been demonstrated. The studies 
presented here have shown that, in established pre-eclampsia, there was no 
significant alteration, compared with normal pregnancy, either in platelet 
sensitivity to inhibitory prostanoids or in cyclic AMP accumulation in response to 
these agents. By contrast, pregnant women at risk of pre-eclampsia, who did not 
develop the condition in the index pregnancy, appeared to demonstrate reduced 
platelet sensitivity to inhibitory prostaglandins and reduced stimulated platelet 
cyclic AMP accumulation compared with healthy pregnant women. Furthermore, 
platelet cyclic AMP increments in response to iloprost and PGD2 were reduced in 
women at risk when studied after the 6th postnatal week in comparison with 
results from healthy women at non pregnant time points. Some caution must be 
exercised in interpreting these data, firstly because the number of subjects in the 
longitudinal study was small, and secondly because of the lack of pre-conceptional 
data in the women at risk of pre-eclampsia. Nevertheless, the consistency of the 
pattern of results during pregnancy suggest that genuine differences in platelet 
responses to inhibitory prostaglandins exist between women at risk and healthy 
women during the gestational period. It is quite possible however that differences 
demonstrated postnatally could result from platelet responses taking longer to 
revert to non pregnant patterns in women at risk of pre-eclampsia compared with 
healthy women. A larger study comparing women who have had pre-eclampsia 
with those who have had healthy pregnancies at a time more remote from 
pregnancy, for example 6 months postnatally, may help to resolve the issue of 
whether an intrinsically less responsive platelet adenylate cyclase system is
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associated with pre-eclampsia. Until then, it could not be recommended that 
platelet sensitivity to inhibitory prostaglandins or platelet cyclic AMP responses 
could be used to predict pre-eclampsia.
It is of interest to speculate on the reasons why the findings of the cross- 
sectional and longitudinal studies were in contrast with one another regarding 
women with, or at risk of, pre-eclampsia. Statistical chance is a possible 
explanation as subject numbers were small in the longitudinal study. Secondary 
effects of the disease itself could, however, have influenced results in the cross- 
sectional study. For example, platelet activation in vivo as a result of pre­
eclampsia could have resulted in only a subpopulation of platelets being available 
for study in vitro. Secondly, if prior exposure to inhibitory prostaglandins in vivo 
is important in regulating platelet sensitivity to these agents, reductions in 
prostaglandin synthesis by the vasculature of the placenta and/or damaged 
systemic vascular endothelium secondary to the establishment of pre­
eclampsia180,298,31 °'397'399 could offset any physiological desensitisation of platelet 
adenylate cyclase, thus masking any intrinsic reductions in the activity of the 
system in women at risk of pre-eclampsia. Perhaps platelet insensitivity to 
inhibitory prostanoids constitutes a risk factor for the disease which subsequently 
becomes manifest when placentation is abnormal.390 This is, however, a highly 
speculative hypothesis.
As there is increasing interest in the potential therapeutic role of antiplatelet 
agents in pre-eclampsia, it is worth considering the implications of the data 
resulting from studies presented here for the prophylaxis or treatment of the 
condition with such drugs. Aspirin is the only agent being currently 
evaluated.368,387,388,389 The demonstration of enhanced platelet sensitivity to pro- 
aggregatory prostanoids during pregnancy with reduced sensitivity to inhibitory
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prostaglandins implies that the choice of a dose of aspirin with optimum selectivity 
for suppressing thromboxane production whilst preserving prostacyclin synthesis 
would have more importance in the context of pregnancy than in non obstetric 
practice. As complete selectivity is difficult to achieve with aspirin,245 a good 
argument could be put forward for the evaluation of the combination of a 
thromboxane synthetase inhibitor with a thromboxane receptor blocker. Such 
combinations offer the potential of maintaining prostacyclin synthesis, whilst 
selectively antagonising the effects of thromboxane and possibly enhancing the 
availability of inhibitory prostanoids.257,258 Although a number of thromboxane 
synthetase inhibitors and receptor blockers have undergone investigation in clinical 
trials in non obstetric practice,251 there is no proof as yet of clinical superiority to 
aspirin and caution would be required in the investigation of any relatively new 
agents in the context of pregnancy.
Another possible approach to anti platelet treatment in pre-eclampsia would 
be the use of agents which inhibit platelet behaviour by increasing cyclic AMP. 
The advantage of the use of such agents is their ability to inhibit platelet activation 
irrespective of the pathway by which this has been stimulated. Anecdotal reports 
of the use of prostacyclin in pre-eclampsia,423,424,425 however have yielded 
disappointing results, probably partly because of its use in late stages of the 
disease but also because it was poorly tolerated. The demonstrated reduction in 
sensitivity of platelets to adenylate cyclase stimulators during pregnancy may 
increase the prostacyclin dose requirement for an antiplatelet effect, thus reducing 
efficacy and patient tolerance. Further desensitisation and rebound platelet 
hyperactivity would also represent likely problems.263,284,482,483 Although some loss 
of sensitivity to phosphodiesterase inhibitors was also demonstrated in late 
pregnancy in the present studies, there was no difference in the platelet cyclic
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AMP response to these agents in pregnant women, and so such drugs may 
represent a better means of manipulating cyclic AMP dependent inhibition of 
platelet behaviour in the context of pregnancy. There is also a future potential for 
selectively inhibiting the platelet cyclic AMP phosphodiesterase enzyme whilst 
having no effect on those in cardiac and smooth muscle,209,210 thus offering the 
possibility of inhibition of platelet behaviour without the cardiovascular effects of 
adenylate cyclase stimulators such as prostacyclin. Such drugs, however, are in 
early phases of evaluation. It is unlikely that they will be available for clinical use 
in the near future and caution in their investigation in pregnancy would in any case 
be imperative. It is interesting to note that stimulators of guanylate cyclase such 
as nitric oxide and adenylate cyclase stimulators synergise in terms of their 
inhibitory effects on platelets,182 but preliminary reports suggest that synergism 
of their relaxant effects on smooth muscle does not occur.475 This may offer the 
possibility of using combinations of these agents to limit the adverse 
cardiovascular effects of drugs such as prostacyclin or its analogues whilst 
enhancing antiplatelet effects. The effects on platelets of guanylate cyclase 
stimulators alone and in combination with cyclic AMP manipulators would 
therefore be worthy of study in healthy pregnancy and in PIH.
Finally, in conclusion, this work has shown that study of the stimulus 
response coupling mechanisms which regulate platelet responses to agents such 
as prostaglandins can be fruitful in elucidating the mechanisms underlying 
alterations in platelet behaviour during pregnancy. It is likely that further studies, 
not only of the adenylate cyclase system but also of other platelet signal 
transduction systems would be of value in contributing to a fuller understanding 
both of physiological changes in primary haemostasis during pregnancy and of the 
pathophysiology of pre-eclampsia.
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APPENDIX 1.
CALCULATION OF EXTENT OF PLATELET RELEASE REACTION
The extent of the platelet release reaction was measured using the assay of 14C-5-HT
release described in Chapter 2. % 14C-5-HT was expressed as a percentage of 14C-5-HT
taken up by platelet dense granules. The following formula was used for each
experimental sample:
% Release = sample count - saline count x 100
T' count - saline count
Sample count = dpm in 50ul of the supernatant platelet poor plasma of an experimental 
sample in which the release reaction was induced by an agonist e.g. arachidonic acid in 
the presence or absence of an inhibitor.
Saline count « the dpm in 50ul of the supernatant platelet poor plasma of a sample to 
which saline/sodium carbonate had been added in place of arachidonic acid.
T' count = "Totals" dom x volume of PRP in each sample
total volume of each sample
"Totals" dpm = dpm in 50ul of untreated 14C-5-HT labelled PRP.
All dpm were corrected for background count, measured in vials containing only liquid
scintillant.
343
WORKED EXAMPLE
Consider an experiment where 460ul of 14C -5-HT labelled PRP was incubated with the 
following reagents, and reactions were stopped by the addition of 50ul of aspirin.
Sample No 
1 
2 
3
Pre-addition 
20ul saline 
20ul saline 
20ul iloprost
The following 14C counts were obtained:
Agonist
20ul N aC I/NaC 03 
20ul arachidonate 
20ul arachidonate
Mean Background
Corrected
Background counts: 21 .3 2 0 .4 2 0 .8 5 -
Sample 1 3 5 9 .0 3 5 9 .6 3 5 9 .3 3 38 .45
Sample 2 1 62 9 .0 1 80 1 .8 1 71 5 .4 1694 .55
Sample 3 3 5 9 .4 3 6 0 .2 3 5 9 .8 3 3 8 .9 5
"Totals" 2 9 7 7 .7 3 0 6 5 .7 3 0 2 1 .7 3 0 0 0 .8 5
T' = 3 0 0 0 .8 5  x 460ul 
550ul
= 2 5 0 9 .8
T ' count -saline count = 2 5 0 9 .8  - 3 3 8 .4 5  =- 2 1 7 1 .3 5
% release in sample 2 = 1 69 4 .5 5  - 3 3 8 .4 5  x 100  = 
2 1 7 1 .3 5
6 2 .4 5 %
% release in sample 3 = 3 3 8 .9 5  - 3 3 8 .4 5  x 100 = 0 .0 2 %
2 1 7 1 .3 5
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APPENDIX 2
CALCULATION OF % CONVERSION 3H-ADENINE TO 3H-CYCLIC AMP.
1) Subtract mean background cpm channel 1 (3H) and channel 2 (14C) 
from all samples and "totals” and mean all duplicates.
2) Calculate uptake of 3H-adenine by platelets:
3H-adenine uptake = 100  - f  cpm in "uptake tubes" x 10* x 1001
lepm in 3H "totals" tubes I
* multiply by 10 to correct for counting 50ul of plasma in uptake samples.
3) Correct 3H "totals" for uptake:
Uptake corrected 3H totals = cpm in 3H "totals" x % uptake
4) Correct sample counts for crossover:
(i) crossover of 14C to channel 1 =
channel 1 cpm crossover control x 100
channel 1 cpm + channel 2 cpm crossover control
(ii) adjust channel 1 and channel 2 counts in samples for crossover:
True 14C count = 100 x actual channel 2 cpm
100 - % crossover
14C counts in channel 1 = true 14C count - actual channel 2 cpm
True 3H count = actual channel 1 count - 14C counts in channel 1.
5) Calculate cyclic AMP recovery in each sample:
% recovery =  true 14C count in sample x 100  
cpm in 14C "totals"
6) Correct 3H counts for recovery of cyclic AMP:
recovery corrected 3H cpm = true 3H cpm x 100
% recovery
7) Calculate % conversion 3H-adenine to 3H-cyclic AMP:
recovery corrected 3H com in sample x 100  
uptake corrected 3H "totals"
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WORKED EXAMPLE OF CALCULATION OF PLATELET CYCLIC AMP
RESULTS
Consider an assay with the following data output from the scintillation counter. The 
procedure outlined above has been applied to calculate % conversion 3H-adenine to 3H- 
cyclic AMP.
Test Data:
Backgrounds 
14C totals
14C crossover controls
3H totals
3H uptake
Sample 1 
Sample 2
1) Background corrected counts: 
14C totals
14C crossover controls
3H totals
3H uptake
Sample 1 
Sample 2
100  - [12165.1  x 
1870859 .18
10 x100J
Channel 1
26.1
2 3 .8
2 6 4 .0 7
2 7 3 .1 6
3 5 6 9 .7 5  
3201 .91  
8 58288 .51
8 8 3 4 7 9 .7 5
1 24 85 .5
1 1 8 9 4 .6
3 8 3 .6  
2 9 9 8 .2
Channel 1
2 3 9 .1 2
248.21
3 5 4 4 .8  
3 1 7 6 .9 6  
8 5 8 2 6 3 .5 6
8 8 3 4 5 4 .8  
1 2 4 60 .5 5
1 1 8 6 9 .6 5
3 5 8 .6 5  
2 9 7 3 .2 5
2) Uptake of 3H-adenine by platelets =
= 100 - 13 .97  
= 8 6 .0 3 %
3) Uptake corrected 3H totals = 8 7 0 8 5 9 .1 8  x 8 6 .0 3
100
Channel 2
13.2
10 .4
5 3 5 .1 8
5 5 5 .0 9
7 7 4 0 .5 6
6 9 9 6 .1 6
3 8 7 .3
2 8 2 .6
Channel 2
5 2 3 .3 8
5 4 3 .2 9
7 7 2 8 .7 6
6 9 8 4 .3 6
3 7 5 .5
2 7 0 .8
= 749200.15
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4) (i) crossover of 14C to channel 1 =
3 3 6 Q 9 8  x 100
7 3 5 6 .5 6  + 3 3 6 0 .8 8
= 3 1 .3 6 %
(ii) true 14C count sample 1 =  100 x 3 7 5 .5  =  5 4 7 .0 6
6 8 .6 4
sample 2 =  100 x 2 7 0 .8  = 3 9 4 .5 2
6 8 .6 4
14C counts in channel 1, sample 1 = 5 4 7 .0 6  - 3 7 5 .5  = 1 71 .56
sample 2 =  3 9 4 .5 2  - 2 7 0 .8  = 1 23 .72  
true 3H counts, sample 1 = 3 5 8 .6 5  - 1 7 1 .5 6  =  1 87 .09
sample 2 =  2 9 7 3 .2 5  - 1 2 3 .7 2  = 2 8 4 9 .5 3
5) Cyclic AMP recovery =
sample 1, 5 4 7 .0 6  x 100 =  7 0 .4 %
5 3 3 .3 4  + 2 4 3 .6 7
sample 2, 3 9 4 .5 2  x 100  = 5 0 .7 7 %
5 3 3 .3 4  + 2 4 3 .6 7
6) recovery corrected 3H counts =
sample 1, 1 87 .09  x 100 = 2 6 5 .7 5
70 .4
sample 2, 2 8 4 9 .5 3  x 100 =  5 6 1 2 .6 3  
50 .77
7) % conversion 3H-adenine to 3H-cyclic AMP =
sample 1, 2 6 5 .7 5  x 100  = 0 .0 3 5 5  %
7 4 9 2 0 0 .1 5
sample 2, 5 6 1 2 .6 3  x 100 = 0 .7 4 9 1 %
7 4 9 2 0 0 .1 5
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A P P E N D IX  3
C A L C U L A T IO N  OF P LA TELET A G G R E G A T IO N  IN  W H O L E  B LO O D
1) Mean all duplicate platelet counts
2) Subtract mean count at time x after addition of agonist from mean count at time 0 
(equivalent to platelet count before the addition of the agonist)
3) Divide the difference in time x and time 0 counts by the time 0  count and express as 
a percentage.
A worked example based on the following raw data is shown overleaf.
Times Saline 0 .3u M  U 46619
0  minutes 170 178
176 182
15 seconds 164 78
169 75
3 0  seconds 160 4 6
166 4 3
4 5  seconds 168 38
161 36
1 minute 172 4 2
167 41
2  minutes 158 35
164 34
4  minutes 152 18
158 20
6 minutes 135 10
140 13
348
Time Saline 0 .3uM  U 46 61 9
Mean
count
Count V t , %  agg Mean
count
Count V t , % agg
0  min 173 180
15 sec 166 7 4 .0 76 104 57 .5
3 0  sec 163 10 5 .8 4 4 136 75 .3
4 5  sec 164 9 5 .2 37 143 7 9 .4
1 min 169 4 2 .3 41 139 7 6 .9
2  min 161 12 6 .9 34 146 8 0 .8
4  min 155 18 1 0 .4 19 161 8 9 .4
6 min 137 36 2 0 .8 11 169 93 .6
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Pre-additions to Tubes.
Tubes 1 & 2 50ul
Tubes 3 & 4 40ul
Tubes 5 & 6 20ul
Tubes 7 & 8 20ui
Tubes 9 & 10 20ul
Tubes 11 & 12 20ul
Tubes 13 & 14 ro o c
All concentrations stated are final concentrations.
For the measurement of the effect on platelet cyclic AM P of PGE2 in the absence of AH- 
P719, a very similar but more simple protocol was used. In this case, the assay consisted 
of only 8 tubes. The timing of additions was as for the first 8 tubes in the protocol on the 
foregoing page. Pre-additions were as follows:
Tubes 1 & 2 
Tubes 3 & 4 
Tubes 5 & 6 
Tubes 7 & 8
50ul saline
25ul iloprost (5ng/ml) 
25ul saline
25ul iloprost (5ng/ml)
25ul of drug solutions were then added during the timed protocol. Saline was added to 
Tubes 3 and 4 at 2 .5  and 2 .7 5  minutes respectively, and PGE2 to tubes 5-8 at the times 
shown on the protocol on the previous page.
353
PUBLICATIONS
The following is a current list of publications which have resulted from the work 
presented in this thesis:
Full Papers.
Platelets in Normal and Hypertensive Pregnancy : A Review E.H. Horn. 
Platelets, 2 : 183 -195 , 1991.
A cross sectional study of platelet cyclic AMP in normal and hypertensive 
pregnancy. E.H. Horn, J. Cooper, E.Hardy, S.Heptinstall, P.C. Rubin. 
Clinical Science, 80: 5 49 -5 5 8 , 1991.
Abstracts.
Preliminary studies on the effects of cyclic AMP manipulators in vitro in 
pregnancy. Horn EH, Heptinstall S, and Rubin PC. Platelets, 1: 51, 1990.
Platelet adenylate cyclase activity in normal and hypertensive pregnancy. 
Horn EH, Cooper J, Hardy E, Heptinstall S, Rubin PC. British Journal of 
Haematology, 76, Suppl 1: 32, 1990.
Platelet Sensitivity to the Endoperoxide Analogue U 46619  during 
Pregnancy. E.H. Horn, J. Cooper, E. Hardy, S. Heptinstall, P.C. Rubin. 
British Journal of Haematology, 77 , Suppl 1: 79 , 1991.
U 46619  Induced Platelet Aggregation in Whole Blood During Pregnancy. 
E.H. Horn, J Cooper, E Hardy, S Heptinstall, P.C. Rubin. Thrombosis and 
Haemostasis, 65 (6): 1229 , 1991.
A Longitudinal Study of Platelet Cyclic AMP in Healthy Primigravidae and 
in Pregnant Women at Risk of Pre-eclampsia. E.H. Horn, J Cooper, E Hardy, 
S Heptinstall, P.C. Rubin. British Journal of Haematology 80 (Supplement 
1): 10, 1992.
GLASGOW
UNIVERSITY
LIBRARY
354
